<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Adderall - Wikipedia, the free encyclopedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>window.RLQ = window.RLQ || []; window.RLQ.push( function () {
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Adderall","wgTitle":"Adderall","wgCurRevisionId":702211477,"wgRevisionId":702211477,"wgArticleId":649100,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Good articles","Use dmy dates from March 2014","Drugs that are a combination of chemicals","Infobox drug articles with contradicting parameter input","Articles without UNII source","Articles containing potentially dated statements from May 2014","All articles containing potentially dated statements","Articles containing potentially dated statements from December 2013","Adderall","Amphetamine","Combination drugs","Drugs acting on the cardiovascular system","Drugs acting on the nervous system","Euphoriants","Norepinephrine-dopamine releasing agents","Phenethylamines","Stimulants","Substituted amphetamines","TAAR1 agonists","Treatment and management of attention deficit hyperactivity disorder","VMAT inhibitors"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Adderall","wgRelevantArticleId":649100,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wikilove-recipient":"","wikilove-anon":0,"wgGatherShouldShowTutorial":true,"wgGatherEnableSample":0,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/e/e7/D-Amphetamine-3D-balls.png/100px-D-Amphetamine-3D-balls.png","wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgULSAcceptLanguageList":["en-us","en"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgCentralAuthMobileDomain":false,"wgWikibaseItemId":"Q935761","wgVisualEditorToolbarScrollOffset":0}); /* @nomin */mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});mw.loader.implement("user.tokens",function ( $, jQuery ) {
mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"}); /* @nomin */ ;

});mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","ext.centralauth.centralautologin","ext.gadget.WatchlistBase","ext.gadget.WatchlistGreenIndicators","mmv.head","ext.visualEditor.desktopArticleTarget.init","ext.uls.init","ext.uls.interface","ext.quicksurveys.init","mw.MediaWikiPlayer.loader","mw.PopUpMediaTransform","ext.centralNotice.bannerController","skins.vector.js"]);
} );</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistBase%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.tmh.thumbnail.styles%7Cext.uls.nojs%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.raggett%2CsectionAnchor%7Cmediawiki.skinning.interface%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector" />
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="generator" content="MediaWiki 1.27.0-wmf.11" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Adderall" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Adderall&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Adderall&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Adderall" />
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.27.0-wmf.11/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Adderall skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
<div id="mw-indicator-good-star" class="mw-indicator"><a href="/wiki/Wikipedia:Good_articles" title="This is a good article. Click here for more information."><img alt="This is a good article. Click here for more information." src="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/19px-Symbol_support_vote.svg.png" width="19" height="20" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/29px-Symbol_support_vote.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/39px-Symbol_support_vote.svg.png 2x" data-file-width="180" data-file-height="185" /></a></div>
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Adderall</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="hatnote">For other mixtures including the racemic compound, see <a href="/wiki/Amphetamine" title="Amphetamine">amphetamine</a>.</div>
<table class="infobox" style="width:22em;border-spacing:2px;">
<caption>Adderall</caption>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Racemic_amphetamine_2.svg" class="image" title="an image of the amphetamine skeletal formula"><img alt="an image of the amphetamine skeletal formula" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/67/Racemic_amphetamine_2.svg/220px-Racemic_amphetamine_2.svg.png" width="220" height="100" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/67/Racemic_amphetamine_2.svg/330px-Racemic_amphetamine_2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/67/Racemic_amphetamine_2.svg/440px-Racemic_amphetamine_2.svg.png 2x" data-file-width="206" data-file-height="94" /></a></td>
</tr>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:D-Amphetamine-3D-balls.png" class="image" title="a 3d image of the dextroamphetamine compound found in Adderall"><img alt="a 3d image of the dextroamphetamine compound found in Adderall" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e7/D-Amphetamine-3D-balls.png/220px-D-Amphetamine-3D-balls.png" width="220" height="203" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e7/D-Amphetamine-3D-balls.png/330px-D-Amphetamine-3D-balls.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e7/D-Amphetamine-3D-balls.png/440px-D-Amphetamine-3D-balls.png 2x" data-file-width="2000" data-file-height="1849" /></a></td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Combination of</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Amphetamine_aspartate_monohydrate" title="Amphetamine aspartate monohydrate" class="mw-redirect">amphetamine aspartate monohydrate</a></th>
<td>(25%) <a href="/wiki/Stimulant" title="Stimulant">stimulant</a></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Amphetamine_sulfate" title="Amphetamine sulfate" class="mw-redirect">amphetamine sulfate</a></th>
<td>(25%) stimulant</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Dextroamphetamine_saccharate" title="Dextroamphetamine saccharate" class="mw-redirect">dextroamphetamine saccharate</a></th>
<td>(25%) stimulant</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Dextroamphetamine_sulfate" title="Dextroamphetamine sulfate" class="mw-redirect">dextroamphetamine sulfate</a></th>
<td>(25%) stimulant</td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Clinical data</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th>
<td>Adderall, Adderall XR</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugs.com/monograph/Adderall.html">monograph</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601234.html">a601234</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Licence data</a></th>
<td><a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration" class="mw-redirect">US&#160;FDA</a>:<span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Adderall&amp;SearchType=BasicSearch">link</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy<br />
category</a></th>
<td>
<div class="plainlist">
<ul>
<li><small><abbr title="United States">US</abbr>:</small> <a href="/wiki/Pregnancy_category#United_States" title="Pregnancy category">C</a> (Risk not ruled out)</li>
</ul>
<ul>
<li class="mw-empty-li"></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th>
<td>
<div class="plainlist">
<ul>
<li><small><abbr title="Australia">AU</abbr>:</small> <a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Drugs_and_Poisons#Schedule_8_Controlled_Drug" title="Standard for the Uniform Scheduling of Drugs and Poisons" class="mw-redirect">S8</a> (Controlled)</li>
<li><small><abbr title="Canada">CA</abbr></small>: <a href="/wiki/Controlled_Drugs_and_Substances_Act#Schedule_I" title="Controlled Drugs and Substances Act">Schedule I</a></li>
<li><small><abbr title="Germany">DE</abbr></small>: <a href="/wiki/Drugs_controlled_by_the_German_Bet%C3%A4ubungsmittelgesetz" title="Drugs controlled by the German Betäubungsmittelgesetz">Anlage III</a></li>
<li><small><abbr title="New Zealand">NZ</abbr></small>: <a href="/wiki/Misuse_of_Drugs_Act_1975#Class_B" title="Misuse of Drugs Act 1975">Class B</a></li>
<li><small><abbr title="United Kingdom">UK</abbr>:</small> <a href="/wiki/Drugs_controlled_by_the_UK_Misuse_of_Drugs_Act#Class_B_drugs" title="Drugs controlled by the UK Misuse of Drugs Act">Class B</a></li>
<li><small><abbr title="United States">US</abbr>:</small> <a href="/wiki/Controlled_Substances_Act#Schedule_II_drugs" title="Controlled Substances Act">Schedule II</a></li>
<li><small><abbr title="United Nations">UN</abbr>:</small> <a href="/wiki/Convention_on_Psychotropic_Substances#Schedule_II" title="Convention on Psychotropic Substances">Psychotropic Schedule&#160;II</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Substance_dependence" title="Substance dependence">Dependence<br />
liability</a></th>
<td><a href="/wiki/Physical_dependence" title="Physical dependence">Physical</a>: none<br />
<a href="/wiki/Psychological_dependence" title="Psychological dependence">Psychological</a>: moderate</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Addiction" title="Addiction">Addiction<br />
liability</a></th>
<td>Moderate</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of<br />
administration</a></th>
<td><a href="/wiki/Mouth" title="Mouth">Oral</a>, <a href="/wiki/Insufflation_(medicine)" title="Insufflation (medicine)">insufflation</a>, <a href="/wiki/Suppository" title="Suppository">rectal</a>, <a href="/wiki/Sublingual" title="Sublingual" class="mw-redirect">sublingual</a></td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Identifiers</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=300-62-9">300-62-9</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup> <a class="external text" href="//tools.wmflabs.org/magnustools/cas.php?language=en&amp;cas=51-64-9&amp;title=">51-64-9</a></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th>
<td><a href="/wiki/ATC_code_N06" title="ATC code N06">N06</a><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.whocc.no/atc_ddd_index/?code=N06BA02">BA02</a></span> <a href="/wiki/ATC_code_N06" title="ATC code N06">N06</a><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.whocc.no/atc_ddd_index/?code=N06BA01">BA01</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/PubChem" title="PubChem">PubChem</a></th>
<td>CID <span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="//pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007">3007</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/IUPHAR/BPS" title="IUPHAR/BPS" class="mw-redirect">IUPHAR/BPS</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4804">4804</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182">DB00182</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.chemspider.com/Chemical-Structure.13852819.html">13852819</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.kegg.jp/entry/D03740">D03740</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/ChEBI" title="ChEBI">ChEBI</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2679">CHEBI:2679</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL405">CHEMBL405</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd"><span style="font-weight:normal;">&#160;&#160;<span class="reflink plainlinks nourlexpansion"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Special:ComparePages&amp;rev1=578643702&amp;page2=Adderall">(verify)</a></span></span></th>
</tr>
</table>
<p><b>Adderall</b><sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span>[</span>note 1<span>]</span></a></sup> is a <a href="/wiki/Combination_drug" title="Combination drug">combination drug</a> containing <a href="/wiki/Salt_(chemistry)" title="Salt (chemistry)">salts</a> of the two <a href="/wiki/Enantiomer" title="Enantiomer">enantiomers</a> of <a href="/wiki/Amphetamine" title="Amphetamine">amphetamine</a>, a <a href="/wiki/Stimulant" title="Stimulant">psychostimulant</a> of the <a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">phenethylamine</a> <a href="/wiki/Chemical_classification" title="Chemical classification">class</a>. Adderall is prescribed in the treatment of <a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">attention deficit hyperactivity disorder</a> (ADHD) and <a href="/wiki/Narcolepsy" title="Narcolepsy">narcolepsy</a>. It is also used as an athletic performance and <a href="/wiki/Nootropic" title="Nootropic">cognitive enhancer</a>, and recreationally as an <a href="/wiki/Aphrodisiac" title="Aphrodisiac">aphrodisiac</a> and <a href="/wiki/Euphoriant" title="Euphoriant" class="mw-redirect">euphoriant</a>. By salt content, the active ingredients of Adderall are 75%&#160;<a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a> salts (the <a href="/wiki/Dextrorotary" title="Dextrorotary" class="mw-redirect">dextrorotary</a> or "right-handed" enantiomer) and 25%&#160;<a href="/wiki/Levoamphetamine" title="Levoamphetamine">levoamphetamine</a> salts (the <a href="/wiki/Levorotary" title="Levorotary" class="mw-redirect">levorotary</a> or "left-handed" enantiomer).<sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span>[</span>note 2<span>]</span></a></sup><sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>sources 1<span>]</span></a></sup></p>
<p>Adderall increases the activity of the <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitters</a> <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> and <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> in the brain, which results from its interactions with <a href="/wiki/TAAR1" title="TAAR1">trace amine associated receptor 1</a> (TAAR1) and <a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">vesicular monoamine transporter 2</a> (VMAT2). Adderall shares many chemical and pharmacological properties with the human <a href="/wiki/Trace_amine" title="Trace amine">trace amine</a> neurotransmitters, especially <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamine</a> and <span class="nowrap"><a href="/wiki/N-methylphenethylamine" title="N-methylphenethylamine" class="mw-redirect"><i>N</i>-methylphenethylamine</a></span>, the latter being an <a href="/wiki/Isomer" title="Isomer">isomer</a> of amphetamine that is produced within the human body.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>sources 2<span>]</span></a></sup></p>
<p>Adderall is generally well-tolerated and effective in treating the symptoms of ADHD. The most common side effects are cardiovascular, such as <a href="/wiki/Arrythmia" title="Arrythmia" class="mw-redirect">irregular heartbeat</a> (usually manifesting as <a href="/wiki/Tachycardia" title="Tachycardia">tachycardia</a>, i.e. a fast heartbeat), and psychological, such as euphoria or anxiety. Much larger doses of Adderall are likely to impair cognitive function and induce rapid muscle breakdown (<a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">rhabdomyolysis</a>). <a href="/wiki/Addiction" title="Addiction">Drug addiction</a> is a serious risk of Adderall abuse, but only rarely arises from medical use. Very high doses can result in a <a href="/wiki/Stimulant_psychosis#Amphetamines" title="Stimulant psychosis">psychosis</a> (e.g., delusions and paranoia) which rarely occurs at therapeutic doses even during long-term use. Recreational doses are generally much larger than prescribed therapeutic doses, and carry a far greater risk of serious side effects.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>sources 3<span>]</span></a></sup></p>
<div class="toclimit-3">
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Uses"><span class="tocnumber">1</span> <span class="toctext">Uses</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Medical"><span class="tocnumber">1.1</span> <span class="toctext">Medical</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Performance-enhancing"><span class="tocnumber">1.2</span> <span class="toctext">Performance-enhancing</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Recreational"><span class="tocnumber">1.3</span> <span class="toctext">Recreational</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-5"><a href="#Contraindications"><span class="tocnumber">2</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Side_effects"><span class="tocnumber">3</span> <span class="toctext">Side effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Physical"><span class="tocnumber">3.1</span> <span class="toctext">Physical</span></a></li>
<li class="toclevel-2"><a href="#Psychological"><span class="tocnumber">3.2</span> <span class="toctext">Psychological</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Overdose"><span class="tocnumber">4</span> <span class="toctext">Overdose</span></a>
<ul>
<li class="toclevel-2"><a href="#Addiction"><span class="tocnumber">4.1</span> <span class="toctext">Addiction</span></a>
<ul>
<li class="toclevel-3"><a href="#Biomolecular_mechanisms"><span class="tocnumber">4.1.1</span> <span class="toctext">Biomolecular mechanisms</span></a></li>
<li class="toclevel-3"><a href="#Pharmacological_treatments"><span class="tocnumber">4.1.2</span> <span class="toctext">Pharmacological treatments</span></a></li>
<li class="toclevel-3"><a href="#Behavioral_treatments"><span class="tocnumber">4.1.3</span> <span class="toctext">Behavioral treatments</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Dependence_and_withdrawal"><span class="tocnumber">4.2</span> <span class="toctext">Dependence and withdrawal</span></a></li>
<li class="toclevel-2"><a href="#Toxicity_and_psychosis"><span class="tocnumber">4.3</span> <span class="toctext">Toxicity and psychosis</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#Interactions"><span class="tocnumber">5</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Pharmacology"><span class="tocnumber">6</span> <span class="toctext">Pharmacology</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#Mechanism_of_action"><span class="tocnumber">6.1</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Pharmacokinetics"><span class="tocnumber">6.2</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Related_endogenous_compounds"><span class="tocnumber">6.3</span> <span class="toctext">Related endogenous compounds</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-13"><a href="#History.2C_society.2C_and_culture"><span class="tocnumber">7</span> <span class="toctext">History, society, and culture</span></a>
<ul>
<li class="toclevel-2 tocsection-14"><a href="#Commercial_formulation"><span class="tocnumber">7.1</span> <span class="toctext">Commercial formulation</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Comparison_to_other_formulations"><span class="tocnumber">7.2</span> <span class="toctext">Comparison to other formulations</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Past_formulations"><span class="tocnumber">7.3</span> <span class="toctext">Past formulations</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Legal_status"><span class="tocnumber">7.4</span> <span class="toctext">Legal status</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-18"><a href="#See_also"><span class="tocnumber">8</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-19"><a href="#Notes"><span class="tocnumber">9</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#Reference_notes"><span class="tocnumber">10</span> <span class="toctext">Reference notes</span></a></li>
<li class="toclevel-1 tocsection-21"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
</ul>
</div>
</div>
<div style="clear:right;"></div>
<h2><span class="mw-headline" id="Uses">Uses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=1" title="Edit section: Uses">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="wikitable" style="float: right; margin-left:15px; text-align:center">
<caption>US Prevalence of drugs in 2013<sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span>[</span>17<span>]</span></a></sup></caption>
<tr>
<th>Grade level</th>
<th>Amphetamine</th>
<th>Adderall</th>
</tr>
<tr>
<td>8th-graders</td>
<td>2.60%</td>
<td>1.80%</td>
</tr>
<tr>
<td>10th-graders</td>
<td>5.90%</td>
<td>4.40%</td>
</tr>
<tr>
<td>12th-graders</td>
<td>7.90%</td>
<td>7.40%</td>
</tr>
</table>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Amph_salts.jpg" class="image"><img alt="Adderall tablets" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/Amph_salts.jpg/220px-Amph_salts.jpg" width="220" height="147" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/Amph_salts.jpg/330px-Amph_salts.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/0e/Amph_salts.jpg/440px-Amph_salts.jpg 2x" data-file-width="2644" data-file-height="1770" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Amph_salts.jpg" class="internal" title="Enlarge"></a></div>
A group of 20&#160;mg Adderall tablets, some broken in half, with a lengthwise-folded US dollar bill along the bottom for size comparison</div>
</div>
</div>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Adderall_20mg_capsules.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Adderall_20mg_capsules.JPG/220px-Adderall_20mg_capsules.JPG" width="220" height="233" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Adderall_20mg_capsules.JPG/330px-Adderall_20mg_capsules.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Adderall_20mg_capsules.JPG/440px-Adderall_20mg_capsules.JPG 2x" data-file-width="1281" data-file-height="1357" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Adderall_20mg_capsules.JPG" class="internal" title="Enlarge"></a></div>
A pair of 20&#160;mg Adderall XR capsules with a US penny to illustrate size</div>
</div>
</div>
<h3><span class="mw-headline" id="Medical">Medical</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=2" title="Edit section: Medical">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">Part of this section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>Adderall is used to treat <a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">attention deficit hyperactivity disorder</a> (ADHD) and <a href="/wiki/Narcolepsy" title="Narcolepsy">narcolepsy</a> (a sleep disorder).<sup id="cite_ref-Amph_Uses_1-2" class="reference"><a href="#cite_note-Amph_Uses-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Adderall_IR_23-0" class="reference"><a href="#cite_note-Adderall_IR-23"><span>[</span>18<span>]</span></a></sup> Long-term amphetamine exposure in some animal species is known to produce abnormal <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">dopamine system</a> development or nerve damage,<sup id="cite_ref-pmid22392347_24-0" class="reference"><a href="#cite_note-pmid22392347-24"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-AbuseAndAbnormalities_25-0" class="reference"><a href="#cite_note-AbuseAndAbnormalities-25"><span>[</span>20<span>]</span></a></sup> but, in humans with ADHD, pharmaceutical amphetamines appear to improve brain development and nerve growth.<sup id="cite_ref-Neuroplasticity_1_26-0" class="reference"><a href="#cite_note-Neuroplasticity_1-26"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_2_27-0" class="reference"><a href="#cite_note-Neuroplasticity_2-27"><span>[</span>22<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_3_28-0" class="reference"><a href="#cite_note-Neuroplasticity_3-28"><span>[</span>23<span>]</span></a></sup> Reviews of <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> (MRI) studies suggest that long-term treatment with amphetamine decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function in several parts of the brain, such as the right <a href="/wiki/Caudate_nucleus" title="Caudate nucleus">caudate nucleus</a> of the <a href="/wiki/Basal_ganglia" title="Basal ganglia">basal ganglia</a>.<sup id="cite_ref-Neuroplasticity_1_26-1" class="reference"><a href="#cite_note-Neuroplasticity_1-26"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_2_27-1" class="reference"><a href="#cite_note-Neuroplasticity_2-27"><span>[</span>22<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_3_28-1" class="reference"><a href="#cite_note-Neuroplasticity_3-28"><span>[</span>23<span>]</span></a></sup></p>
<p>Reviews of clinical stimulant research have established the safety and effectiveness of long-term amphetamine use for ADHD.<sup id="cite_ref-Millichap_29-0" class="reference"><a href="#cite_note-Millichap-29"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Long-term_2015_30-0" class="reference"><a href="#cite_note-Long-term_2015-30"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Long-Term_Outcomes_Medications_31-0" class="reference"><a href="#cite_note-Long-Term_Outcomes_Medications-31"><span>[</span>26<span>]</span></a></sup> Controlled trials spanning two years have demonstrated treatment effectiveness and safety.<sup id="cite_ref-Millichap_29-1" class="reference"><a href="#cite_note-Millichap-29"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Long-Term_Outcomes_Medications_31-1" class="reference"><a href="#cite_note-Long-Term_Outcomes_Medications-31"><span>[</span>26<span>]</span></a></sup> One review highlighted a nine-month <a href="/wiki/Randomized_controlled_trial" title="Randomized controlled trial">randomized controlled trial</a> in children with ADHD that found an average increase of&#160;4.5 <a href="/wiki/Intelligence_quotient" title="Intelligence quotient">IQ</a> points, continued increases in attention, and continued decreases in disruptive behaviors and hyperactivity.<sup id="cite_ref-Millichap_29-2" class="reference"><a href="#cite_note-Millichap-29"><span>[</span>24<span>]</span></a></sup></p>
<p>Current models of ADHD suggest that it is associated with functional impairments in some of the brain's <a href="/wiki/Neurotransmitter_systems" title="Neurotransmitter systems" class="mw-redirect">neurotransmitter systems</a>;<sup id="cite_ref-Malenka_2009_03_8-1" class="reference"><a href="#cite_note-Malenka_2009_03-8"><span>[</span>5<span>]</span></a></sup> these functional impairments involve impaired <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> neurotransmission in the <a href="/wiki/Mesocorticolimbic_projection" title="Mesocorticolimbic projection" class="mw-redirect">mesocorticolimbic projection</a> and <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> neurotransmission in the <a href="/wiki/Locus_coeruleus" title="Locus coeruleus">locus coeruleus</a> and <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a>.<sup id="cite_ref-Malenka_2009_03_8-2" class="reference"><a href="#cite_note-Malenka_2009_03-8"><span>[</span>5<span>]</span></a></sup> Psychostimulants like <a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a> and amphetamine are effective in treating ADHD because they increase neurotransmitter activity in these systems.<sup id="cite_ref-Malenka_2009_15-1" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_03_8-3" class="reference"><a href="#cite_note-Malenka_2009_03-8"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-cognition_enhancers_32-0" class="reference"><a href="#cite_note-cognition_enhancers-32"><span>[</span>27<span>]</span></a></sup> Approximately&#160;80% of those who use these stimulants see improvements in ADHD symptoms.<sup id="cite_ref-Long-term_36_33-0" class="reference"><a href="#cite_note-Long-term_36-33"><span>[</span>28<span>]</span></a></sup> Children with ADHD who use stimulant medications generally have better relationships with peers and family members, perform better in school, are less distractible and impulsive, and have longer attention spans.<sup id="cite_ref-Millichap_3_34-0" class="reference"><a href="#cite_note-Millichap_3-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-ADHD_35-0" class="reference"><a href="#cite_note-ADHD-35"><span>[</span>30<span>]</span></a></sup> The <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration" class="mw-redirect">Cochrane Collaboration</a>'s review<sup id="cite_ref-37" class="reference"><a href="#cite_note-37"><span>[</span>note 3<span>]</span></a></sup> on the treatment of adult ADHD with pharmaceutical amphetamines stated that while these drugs improve short-term symptoms, they have higher discontinuation rates than non-stimulant medications due to their adverse <a href="/wiki/Side_effect" title="Side effect">side effects</a>.<sup id="cite_ref-Cochrane_Amphetamines_ADHD_38-0" class="reference"><a href="#cite_note-Cochrane_Amphetamines_ADHD-38"><span>[</span>32<span>]</span></a></sup> A Cochrane Collaboration review on the treatment of ADHD in children with <a href="/wiki/Tic_disorder" title="Tic disorder">tic disorders</a> such as <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a> indicated that stimulants in general do not make <a href="/wiki/Tic" title="Tic">tics</a> worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>33<span>]</span></a></sup></p>
<p>Adderall is available as immediate release tablets or extended-release capsules.<sup id="cite_ref-Adderall_IR_23-1" class="reference"><a href="#cite_note-Adderall_IR-23"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-Adderall_XR_all_pages_40-0" class="reference"><a href="#cite_note-Adderall_XR_all_pages-40"><span>[</span>34<span>]</span></a></sup> The extended release capsule is generally used in the morning.<sup id="cite_ref-MMX-PMH_41-0" class="reference"><a href="#cite_note-MMX-PMH-41"><span>[</span>35<span>]</span></a></sup> The extended release formulation available under the brand Adderall XR is designed to provide therapeutic effect and plasma concentrations identical to taking two doses 4&#160;hours apart.<sup id="cite_ref-Adderall_XR_all_pages_40-1" class="reference"><a href="#cite_note-Adderall_XR_all_pages-40"><span>[</span>34<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Performance-enhancing">Performance-enhancing</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=3" title="Edit section: Performance-enhancing">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">Part of this section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>In 2015, a <a href="/wiki/Systematic_review" title="Systematic review">systematic review</a> and a <a href="/wiki/Meta-analysis" title="Meta-analysis">meta-analysis</a> of high quality <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a> found that, when used at low (therapeutic) doses, amphetamine produces modest, unambiguous improvements in cognition, including <a href="/wiki/Working_memory" title="Working memory">working memory</a>, <a href="/wiki/Episodic_memory" title="Episodic memory">episodic memory</a>, and <a href="/wiki/Inhibitory_control_test" title="Inhibitory control test">inhibitory control</a>, in normal healthy adults;<sup id="cite_ref-Unambiguous_PFC_D1_A2_42-0" class="reference"><a href="#cite_note-Unambiguous_PFC_D1_A2-42"><span>[</span>36<span>]</span></a></sup><sup id="cite_ref-Cognitive_and_motivational_effects_43-0" class="reference"><a href="#cite_note-Cognitive_and_motivational_effects-43"><span>[</span>37<span>]</span></a></sup> the cognition-enhancing effects of amphetamine are known to occur through its <a href="/wiki/Indirect_agonist" title="Indirect agonist">indirect activation</a> of both <a href="/wiki/Dopamine_receptor_D1" title="Dopamine receptor D1">dopamine receptor D<sub>1</sub></a> and <a href="/wiki/Alpha-2_adrenergic_receptor" title="Alpha-2 adrenergic receptor">adrenoceptor A<sub>2</sub></a> in the <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a>.<sup id="cite_ref-Unambiguous_PFC_D1_A2_42-1" class="reference"><a href="#cite_note-Unambiguous_PFC_D1_A2-42"><span>[</span>36<span>]</span></a></sup> Therapeutic doses of amphetamine also enhance cortical network efficiency, an effect which mediates improvements in working memory in all individuals.<sup id="cite_ref-Malenka_2009_15-2" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-pmid11337538_44-0" class="reference"><a href="#cite_note-pmid11337538-44"><span>[</span>38<span>]</span></a></sup> Amphetamine and other ADHD stimulants also improve <a href="/wiki/Incentive_salience" title="Incentive salience">task saliency</a> (motivation to perform a task) and increase <a href="/wiki/Arousal" title="Arousal">arousal</a> (wakefulness), in turn promoting goal-directed behavior.<sup id="cite_ref-Malenka_2009_15-3" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Malenka_NAcc_45-0" class="reference"><a href="#cite_note-Malenka_NAcc-45"><span>[</span>39<span>]</span></a></sup><sup id="cite_ref-Continuum_46-0" class="reference"><a href="#cite_note-Continuum-46"><span>[</span>40<span>]</span></a></sup> Stimulants such as amphetamine can improve performance on difficult and boring tasks and are used by some students as a study and test-taking aid.<sup id="cite_ref-Malenka_2009_15-4" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Continuum_46-1" class="reference"><a href="#cite_note-Continuum-46"><span>[</span>40<span>]</span></a></sup><sup id="cite_ref-Test_taking_aid_47-0" class="reference"><a href="#cite_note-Test_taking_aid-47"><span>[</span>41<span>]</span></a></sup> Based upon studies of self-reported illicit stimulant use, 5–35% of college students use <a href="/wiki/Drug_diversion" title="Drug diversion">diverted</a> ADHD stimulants, which are primarily used for performance enhancement rather than as recreational drugs.<sup id="cite_ref-pmid16999660_48-0" class="reference"><a href="#cite_note-pmid16999660-48"><span>[</span>42<span>]</span></a></sup><sup id="cite_ref-Diversion_prevalence_1_49-0" class="reference"><a href="#cite_note-Diversion_prevalence_1-49"><span>[</span>43<span>]</span></a></sup><sup id="cite_ref-Diversion_prevalence_2_50-0" class="reference"><a href="#cite_note-Diversion_prevalence_2-50"><span>[</span>44<span>]</span></a></sup> However, high amphetamine doses that are above the therapeutic range can interfere with working memory and other aspects of cognitive control.<sup id="cite_ref-Malenka_2009_15-5" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Continuum_46-2" class="reference"><a href="#cite_note-Continuum-46"><span>[</span>40<span>]</span></a></sup></p>
<p>Amphetamine is used by some athletes for its psychological and performance-enhancing effects, such as increased stamina and alertness;<sup id="cite_ref-Ergogenics_51-0" class="reference"><a href="#cite_note-Ergogenics-51"><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-Westfall_19-1" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> however, its use is prohibited at sporting events regulated by collegiate, national, and international anti-doping agencies.<sup id="cite_ref-NCAA_52-0" class="reference"><a href="#cite_note-NCAA-52"><span>[</span>46<span>]</span></a></sup><sup id="cite_ref-WADA_.26_AD_regulation_53-0" class="reference"><a href="#cite_note-WADA_.26_AD_regulation-53"><span>[</span>47<span>]</span></a></sup> In healthy people at oral therapeutic doses, amphetamine has been shown to increase physical strength, acceleration, stamina, and endurance, while reducing <a href="/wiki/Reaction_time" title="Reaction time" class="mw-redirect">reaction time</a>.<sup id="cite_ref-Ergogenics_51-1" class="reference"><a href="#cite_note-Ergogenics-51"><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_54-0" class="reference"><a href="#cite_note-Ergogenics2-54"><span>[</span>48<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_55-0" class="reference"><a href="#cite_note-Roelands_2013-55"><span>[</span>49<span>]</span></a></sup> Amphetamine improves stamina, endurance, and reaction time primarily through <a href="/wiki/Reuptake_inhibitor" title="Reuptake inhibitor">reuptake inhibition</a> and <a href="/wiki/Releasing_agent" title="Releasing agent" class="mw-redirect">effluxion</a> of dopamine in the central nervous system.<sup id="cite_ref-Ergogenics2_54-1" class="reference"><a href="#cite_note-Ergogenics2-54"><span>[</span>48<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_55-1" class="reference"><a href="#cite_note-Roelands_2013-55"><span>[</span>49<span>]</span></a></sup><sup id="cite_ref-Amph-DA_reaction_time_56-0" class="reference"><a href="#cite_note-Amph-DA_reaction_time-56"><span>[</span>50<span>]</span></a></sup> At therapeutic doses, the adverse effects of amphetamine do not impede athletic performance;<sup id="cite_ref-Ergogenics_51-2" class="reference"><a href="#cite_note-Ergogenics-51"><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_54-2" class="reference"><a href="#cite_note-Ergogenics2-54"><span>[</span>48<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_55-2" class="reference"><a href="#cite_note-Roelands_2013-55"><span>[</span>49<span>]</span></a></sup> however, at much higher doses, amphetamine can induce effects that severely impair performance, such as <a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">rapid muscle breakdown</a> and <a href="/wiki/Hyperthermia" title="Hyperthermia">elevated body temperature</a>.<sup id="cite_ref-FDA_Abuse_.26_OD_13-1" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-1" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_54-3" class="reference"><a href="#cite_note-Ergogenics2-54"><span>[</span>48<span>]</span></a></sup></p>
<p>Adderall has been banned in the <a href="/wiki/National_Football_League" title="National Football League">National Football League</a> (NFL), <a href="/wiki/Major_League_Baseball" title="Major League Baseball">Major League Baseball</a> (MLB), <a href="/wiki/National_Basketball_Association" title="National Basketball Association">National Basketball Association</a> (NBA), and the National Collegiate Athletics Association (NCAA).<sup id="cite_ref-Leon_57-0" class="reference"><a href="#cite_note-Leon-57"><span>[</span>51<span>]</span></a></sup> In leagues such as the NFL, there is a very rigorous process required to obtain an exemption to this rule even when the athlete has been medically prescribed the drug by their physician.<sup id="cite_ref-Leon_57-1" class="reference"><a href="#cite_note-Leon-57"><span>[</span>51<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Recreational">Recreational</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=4" title="Edit section: Recreational">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">See also: <a href="/wiki/History_and_culture_of_substituted_amphetamines" title="History and culture of substituted amphetamines">History and culture of substituted amphetamines</a></div>
<p>Adderall is considered to have a high potential for misuse as a <a href="/wiki/Recreational_drug_use" title="Recreational drug use">recreational drug</a>.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span>[</span>52<span>]</span></a></sup><sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>53<span>]</span></a></sup> Adderall tablets can be crushed and snorted, or dissolved in water and injected.<sup id="cite_ref-NIDA_60-0" class="reference"><a href="#cite_note-NIDA-60"><span>[</span>54<span>]</span></a></sup> Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels.<sup id="cite_ref-NIDA_60-1" class="reference"><a href="#cite_note-NIDA-60"><span>[</span>54<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Contraindications">Contraindications</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=5" title="Edit section: Contraindications">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote">This section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>According to the <a href="/wiki/International_Programme_on_Chemical_Safety" title="International Programme on Chemical Safety">International Programme on Chemical Safety</a> (IPCS) and <a href="/wiki/United_States_Food_and_Drug_Administration" title="United States Food and Drug Administration" class="mw-redirect">United States Food and Drug Administration</a> (USFDA),<sup id="cite_ref-62" class="reference"><a href="#cite_note-62"><span>[</span>note 4<span>]</span></a></sup> amphetamine is <a href="/wiki/Contraindicated" title="Contraindicated" class="mw-redirect">contraindicated</a> in people with a history of <a href="/wiki/Drug_abuse" title="Drug abuse" class="mw-redirect">drug abuse</a>,<sup id="cite_ref-63" class="reference"><a href="#cite_note-63"><span>[</span>note 5<span>]</span></a></sup> <a href="/wiki/Heart_disease" title="Heart disease" class="mw-redirect">heart disease</a>, severe <a href="/wiki/Irritability" title="Irritability">agitation</a>, or severe anxiety.<sup id="cite_ref-FDA_Contra_Warnings_64-0" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-International_65-0" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> It is also contraindicated in people currently experiencing <a href="/wiki/Arteriosclerosis" title="Arteriosclerosis">arteriosclerosis</a> (hardening of the arteries), <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a> (increased eye pressure), <a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">hyperthyroidism</a> (excessive production of thyroid hormone), or moderate to severe <a href="/wiki/Hypertension" title="Hypertension">hypertension</a>.<sup id="cite_ref-FDA_Contra_Warnings_64-1" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-International_65-1" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup><sup id="cite_ref-Dexedrine_FDA_66-0" class="reference"><a href="#cite_note-Dexedrine_FDA-66"><span>[</span>58<span>]</span></a></sup> People who have experienced <a href="/wiki/Hypersensitivity" title="Hypersensitivity">allergic reactions</a> to other stimulants in the past or who are taking <a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">monoamine oxidase inhibitors</a> (MAOIs) are advised not to take amphetamine,<sup id="cite_ref-FDA_Contra_Warnings_64-2" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-International_65-2" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> although safe concurrent use of amphetamine and monoamine oxidase inhibitors has been documented.<sup id="cite_ref-Review_MAOI-amph_67-0" class="reference"><a href="#cite_note-Review_MAOI-amph-67"><span>[</span>59<span>]</span></a></sup><sup id="cite_ref-Primary_MAOI-amph_68-0" class="reference"><a href="#cite_note-Primary_MAOI-amph-68"><span>[</span>60<span>]</span></a></sup> These agencies also state that anyone with <a href="/wiki/Anorexia_nervosa" title="Anorexia nervosa">anorexia nervosa</a>, <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a>, depression, hypertension, liver or kidney problems, <a href="/wiki/Mania" title="Mania">mania</a>, <a href="/wiki/Psychosis" title="Psychosis">psychosis</a>, <a href="/wiki/Raynaud%27s_phenomenon" title="Raynaud's phenomenon">Raynaud's phenomenon</a>, <a href="/wiki/Seizure" title="Seizure" class="mw-redirect">seizures</a>, <a href="/wiki/Thyroid" title="Thyroid">thyroid</a> problems, <a href="/wiki/Tic" title="Tic">tics</a>, or <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a> should monitor their symptoms while taking amphetamine.<sup id="cite_ref-FDA_Contra_Warnings_64-3" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-International_65-3" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> Evidence from human studies indicates that therapeutic amphetamine use does not cause developmental abnormalities in the fetus or newborns (i.e., it is not a human <a href="/wiki/Teratology" title="Teratology">teratogen</a>), but amphetamine abuse does pose risks to the fetus.<sup id="cite_ref-International_65-4" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> Amphetamine has also been shown to pass into breast milk, so the IPCS and USFDA advise mothers to avoid breastfeeding when using it.<sup id="cite_ref-FDA_Contra_Warnings_64-4" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-International_65-5" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> Due to the potential for reversible growth impairments,<sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>note 6<span>]</span></a></sup> the USFDA advises monitoring the height and weight of children and adolescents prescribed an amphetamine pharmaceutical.<sup id="cite_ref-FDA_Contra_Warnings_64-5" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Side_effects">Side effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=6" title="Edit section: Side effects">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote">Part of this section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>The <a href="/wiki/Side_effects" title="Side effects" class="mw-redirect">side effects</a> of Adderall are many and varied, but the amount of substance consumed is the primary factor in determining the likelihood and severity of side effects.<sup id="cite_ref-FDA_Abuse_.26_OD_13-2" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-2" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Westfall_19-2" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Adderall is currently approved for long-term therapeutic use by the USFDA.<sup id="cite_ref-FDA_Effects_14-3" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup> <a href="/wiki/Recreational_drug_use#Stimulants" title="Recreational drug use">Recreational use</a> of Adderall generally involves far larger doses and is therefore significantly more dangerous, involving a much greater risk of serious side effects.<sup id="cite_ref-Westfall_19-3" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Physical">Physical</span></h3>
<p>At normal therapeutic doses, the physical side effects of amphetamine vary widely by age and from person to person.<sup id="cite_ref-FDA_Effects_14-4" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup> <a href="/wiki/Cardiovascular" title="Cardiovascular" class="mw-redirect">Cardiovascular</a> side effects can include <a href="/wiki/Hypertension" title="Hypertension">hypertension</a> or <a href="/wiki/Hypotension" title="Hypotension">hypotension</a> from a <a href="/wiki/Vasovagal_response" title="Vasovagal response">vasovagal response</a>, <a href="/wiki/Raynaud%27s_phenomenon" title="Raynaud's phenomenon">Raynaud's phenomenon</a> (reduced blood flow to extremities), and <a href="/wiki/Tachycardia" title="Tachycardia">tachycardia</a> (increased heart rate).<sup id="cite_ref-FDA_Effects_14-5" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Westfall_19-4" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-pmid18295156_69-2" class="reference"><a href="#cite_note-pmid18295156-69"><span>[</span>61<span>]</span></a></sup> Sexual side effects in males may include <a href="/wiki/Erectile_dysfunction" title="Erectile dysfunction">erectile dysfunction</a>, frequent erections, or <a href="/wiki/Priapism" title="Priapism">prolonged erections</a>.<sup id="cite_ref-FDA_Effects_14-6" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup> Abdominal side effects may include abdominal pain, loss of appetite, nausea, and weight loss.<sup id="cite_ref-FDA_Effects_14-7" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Dyanavel_71-0" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup> Other potential side effects include acne, blurred vision, <a href="/wiki/Xerostomia" title="Xerostomia">dry mouth</a>, <a href="/wiki/Bruxism" title="Bruxism">excessive grinding of the teeth</a>, nosebleed, profuse sweating, <a href="/wiki/Rhinitis_medicamentosa" title="Rhinitis medicamentosa">rhinitis medicamentosa</a> (drug-induced nasal congestion), reduced <a href="/wiki/Seizure_threshold" title="Seizure threshold">seizure threshold</a>, and <a href="/wiki/Tics" title="Tics" class="mw-redirect">tics</a> (a type of movement disorder).<sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>sources 4<span>]</span></a></sup> Dangerous physical side effects are rare at typical pharmaceutical doses.<sup id="cite_ref-Westfall_19-6" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup></p>
<p>Amphetamine stimulates the <a href="/wiki/Respiratory_center" title="Respiratory center">medullary respiratory centers</a>, producing faster and deeper breaths.<sup id="cite_ref-Westfall_19-7" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident.<sup id="cite_ref-Westfall_19-8" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Amphetamine also induces <a href="/wiki/Muscle_contraction" title="Muscle contraction">contraction</a> in the urinary <a href="/wiki/Detrusor_muscle" title="Detrusor muscle" class="mw-redirect">bladder sphincter</a>, the muscle which controls urination, which can result in difficulty urinating. This effect can be useful in treating <a href="/wiki/Enuresis" title="Enuresis">bed wetting</a> and <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">loss of bladder control</a>.<sup id="cite_ref-Westfall_19-9" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> The effects of amphetamine on the gastrointestinal tract are unpredictable.<sup id="cite_ref-Westfall_19-10" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> If intestinal activity is high, amphetamine may reduce <a href="/wiki/Gastrointestinal_motility" title="Gastrointestinal motility" class="mw-redirect">gastrointestinal motility</a> (the rate at which content moves through the digestive system);<sup id="cite_ref-Westfall_19-11" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> however, amphetamine may increase motility when the <a href="/wiki/Smooth_muscle_tissue" title="Smooth muscle tissue">smooth muscle</a> of the tract is relaxed.<sup id="cite_ref-Westfall_19-12" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Amphetamine also has a slight <a href="/wiki/Analgesic" title="Analgesic">analgesic</a> effect and can enhance the pain relieving effects of <a href="/wiki/Opioid" title="Opioid">opioids</a>.<sup id="cite_ref-Westfall_19-13" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup></p>
<p>USFDA-commissioned studies from 2011 indicate that in children, young adults, and adults there is no association between serious adverse cardiovascular events (<a href="/wiki/Sudden_cardiac_death" title="Sudden cardiac death">sudden death</a>, <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">heart attack</a>, and <a href="/wiki/Stroke" title="Stroke">stroke</a>) and the medical use of amphetamine or other ADHD stimulants.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78"><span>[</span>sources 5<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Psychological">Psychological</span></h3>
<p>Common psychological effects of therapeutic doses can include increased <a href="/wiki/Alertness" title="Alertness">alertness</a>, apprehension, <a href="/wiki/Concentration" title="Concentration">concentration</a>, decreased sense of fatigue, mood swings (<a href="/wiki/Euphoria" title="Euphoria">elated mood</a> followed by mildly <a href="/wiki/Dysphoria" title="Dysphoria">depressed mood</a>), increased initiative, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a> or <a href="/wiki/Wakefulness" title="Wakefulness">wakefulness</a>, <a href="/wiki/Self-confidence" title="Self-confidence">self-confidence</a>, and sociability.<sup id="cite_ref-FDA_Effects_14-9" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Westfall_19-14" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Less common side effects include <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, change in <a href="/wiki/Libido" title="Libido">libido</a>, <a href="/wiki/Grandiosity" title="Grandiosity">grandiosity</a>, <a href="/wiki/Irritability" title="Irritability">irritability</a>, repetitive or <a href="/wiki/Fixation_(psychology)" title="Fixation (psychology)">obsessive</a> behaviors, and restlessness;<sup id="cite_ref-80" class="reference"><a href="#cite_note-80"><span>[</span>sources 6<span>]</span></a></sup> these effects depend on the user's personality and current mental state.<sup id="cite_ref-Westfall_19-16" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> <a href="/wiki/Amphetamine_psychosis" title="Amphetamine psychosis" class="mw-redirect">Amphetamine psychosis</a> (e.g., delusions and paranoia) can occur in heavy users.<sup id="cite_ref-FDA_Abuse_.26_OD_13-3" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-11" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Cochrane_16-1" class="reference"><a href="#cite_note-Cochrane-16"><span>[</span>12<span>]</span></a></sup> Although very rare, this psychosis can also occur at therapeutic doses during long-term therapy.<sup id="cite_ref-FDA_Abuse_.26_OD_13-4" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-12" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Stimulant_Misuse_17-1" class="reference"><a href="#cite_note-Stimulant_Misuse-17"><span>[</span>13<span>]</span></a></sup> According to the USFDA, "there is no systematic evidence" that stimulants produce aggressive behavior or hostility.<sup id="cite_ref-FDA_Effects_14-13" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup></p>
<p>Amphetamine has also been shown to produce a <a href="/wiki/Conditioned_place_preference" title="Conditioned place preference">conditioned place preference</a> in humans taking therapeutic doses,<sup id="cite_ref-Cochrane_Amphetamines_ADHD_38-1" class="reference"><a href="#cite_note-Cochrane_Amphetamines_ADHD-38"><span>[</span>32<span>]</span></a></sup><sup id="cite_ref-Human_CPP_81-0" class="reference"><a href="#cite_note-Human_CPP-81"><span>[</span>69<span>]</span></a></sup> meaning that individuals acquire a preference for spending time in places where they have previously used amphetamine.<sup id="cite_ref-Human_CPP_81-1" class="reference"><a href="#cite_note-Human_CPP-81"><span>[</span>69<span>]</span></a></sup><sup id="cite_ref-Addiction_glossary_82-0" class="reference"><a href="#cite_note-Addiction_glossary-82"><span>[</span>70<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Overdose">Overdose</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=7" title="Edit section: Overdose">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote">This section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>An amphetamine overdose can lead to many different symptoms, but is rarely fatal with appropriate care.<sup id="cite_ref-International_65-6" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup><sup id="cite_ref-Amphetamine_toxidrome_83-0" class="reference"><a href="#cite_note-Amphetamine_toxidrome-83"><span>[</span>71<span>]</span></a></sup> The severity of overdose symptoms increases with dosage and decreases with <a href="/wiki/Drug_tolerance" title="Drug tolerance">drug tolerance</a> to amphetamine.<sup id="cite_ref-Westfall_19-17" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-International_65-7" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> Tolerant individuals have been known to take as much as 5&#160;grams of amphetamine in a day, which is roughly 100&#160;times the maximum daily therapeutic dose.<sup id="cite_ref-International_65-8" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup> Symptoms of a moderate and extremely large overdose are listed below; fatal amphetamine poisoning usually also involves convulsions and <a href="/wiki/Coma" title="Coma">coma</a>.<sup id="cite_ref-FDA_Abuse_.26_OD_13-5" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-Westfall_19-18" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> In 2013, overdose on amphetamine, methamphetamine, and other compounds implicated in an "<a href="/wiki/ICD-10_Chapter_V:_Mental_and_behavioural_disorders#.28F10.E2.80.93F19.29_Mental_and_behavioural_disorders_due_to_psychoactive_substance_use" title="ICD-10 Chapter V: Mental and behavioural disorders">amphetamine use disorder</a>" resulted in an estimated 3,788&#160;deaths worldwide (3,425–4,145&#160;deaths, <a href="/wiki/95%25_confidence_interval" title="95% confidence interval" class="mw-redirect">95%&#160;confidence</a>).<sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>note 7<span>]</span></a></sup><sup id="cite_ref-GDB2013_85-0" class="reference"><a href="#cite_note-GDB2013-85"><span>[</span>72<span>]</span></a></sup></p>
<p>Pathological overactivation of the <a href="/wiki/Mesolimbic_pathway" title="Mesolimbic pathway">mesolimbic pathway</a>, a <a href="/wiki/Dopamine_pathway" title="Dopamine pathway" class="mw-redirect">dopamine pathway</a> that connects the <a href="/wiki/Ventral_tegmental_area" title="Ventral tegmental area">ventral tegmental area</a> to the <a href="/wiki/Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a>, plays a central role in amphetamine addiction.<sup id="cite_ref-Amphetamine_KEGG_.E2.80.93_.CE.94FosB_86-0" class="reference"><a href="#cite_note-Amphetamine_KEGG_.E2.80.93_.CE.94FosB-86"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Magnesium_87-0" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup> Individuals who frequently overdose on amphetamine during recreational use have a high risk of developing an amphetamine addiction, since repeated overdoses gradually increase the level of <a href="/wiki/Accumbal" title="Accumbal" class="mw-redirect">accumbal</a> <a href="/wiki/%CE%94FosB" title="ΔFosB" class="mw-redirect">ΔFosB</a>, a "molecular switch" and "master control protein" for addiction.<sup id="cite_ref-What_the_.CE.94FosB.3F_88-0" class="reference"><a href="#cite_note-What_the_.CE.94FosB.3F-88"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Cellular_basis_89-0" class="reference"><a href="#cite_note-Cellular_basis-89"><span>[</span>76<span>]</span></a></sup><sup id="cite_ref-Nestler1_90-0" class="reference"><a href="#cite_note-Nestler1-90"><span>[</span>77<span>]</span></a></sup> Once nucleus accumbens ΔFosB is sufficiently overexpressed, it begins to increase the severity of addictive behavior (i.e., compulsive drug-seeking) with further increases in its expression.<sup id="cite_ref-What_the_.CE.94FosB.3F_88-1" class="reference"><a href="#cite_note-What_the_.CE.94FosB.3F-88"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Natural_and_drug_addictions_91-0" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup> While there are currently no effective drugs for treating amphetamine addiction, regularly engaging in sustained aerobic exercise appears to reduce the risk of developing such an addiction.<sup id="cite_ref-Running_vs_addiction_92-0" class="reference"><a href="#cite_note-Running_vs_addiction-92"><span>[</span>79<span>]</span></a></sup> Sustained aerobic exercise on a regular basis also appears to be an effective treatment for amphetamine addiction;<sup id="cite_ref-Natural_and_drug_addictions_91-1" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Running_vs_addiction_92-1" class="reference"><a href="#cite_note-Running_vs_addiction-92"><span>[</span>79<span>]</span></a></sup><sup id="cite_ref-Exercise_Rev_3_93-0" class="reference"><a href="#cite_note-Exercise_Rev_3-93"><span>[</span>80<span>]</span></a></sup> exercise therapy improves <a href="//en.wiktionary.org/wiki/clinical" class="extiw" title="wikt:clinical">clinical</a> treatment outcomes and may be used as a <a href="/wiki/Combination_therapy" title="Combination therapy">combination therapy</a> with <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">cognitive behavioral therapy</a>, which is currently the best clinical treatment available.<sup id="cite_ref-Running_vs_addiction_92-2" class="reference"><a href="#cite_note-Running_vs_addiction-92"><span>[</span>79<span>]</span></a></sup><sup id="cite_ref-Exercise_Rev_3_93-1" class="reference"><a href="#cite_note-Exercise_Rev_3-93"><span>[</span>80<span>]</span></a></sup><sup id="cite_ref-Nestler_CBT_94-0" class="reference"><a href="#cite_note-Nestler_CBT-94"><span>[</span>81<span>]</span></a></sup></p>
<table class="wikitable unsortable center" style="margin: 1em auto;">
<caption>Overdose symptoms by system</caption>
<tr>
<th scope="col" style="text-align:center">System</th>
<th scope="col" style="width: 40%;">Minor or moderate overdose<sup id="cite_ref-FDA_Abuse_.26_OD_13-6" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-Westfall_19-19" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-International_65-9" class="reference"><a href="#cite_note-International-65"><span>[</span>57<span>]</span></a></sup></th>
<th scope="col" style="width: 50%;">Severe overdose<sup id="cite_ref-97" class="reference"><a href="#cite_note-97"><span>[</span>sources 7<span>]</span></a></sup></th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Cardiovascular_system" title="Cardiovascular system" class="mw-redirect">Cardiovascular</a></th>
<td>
<ul>
<li><a href="/wiki/Cardiac_dysrhythmia" title="Cardiac dysrhythmia" class="mw-redirect">Abnormal heartbeat</a></li>
<li><a href="/wiki/Hypertension" title="Hypertension">High</a> or <a href="/wiki/Hypotension" title="Hypotension">low blood pressure</a></li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Cardiogenic_shock" title="Cardiogenic shock">Cardiogenic shock</a> (heart not pumping enough blood)</li>
<li><a href="/wiki/Cerebral_hemorrhage" title="Cerebral hemorrhage">Cerebral hemorrhage</a> (bleeding in the brain)</li>
<li><a href="/wiki/Circulatory_collapse" title="Circulatory collapse">Circulatory collapse</a> (partial or complete failure of the circulatory system)</li>
</ul>
</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Central_nervous_system" title="Central nervous system">Central nervous<br />
system</a></th>
<td>
<ul>
<li>Confusion</li>
<li><a href="/wiki/Hyperreflexia" title="Hyperreflexia">Abnormally fast reflexes</a></li>
<li>Severe agitation</li>
<li><a href="/wiki/Tremor" title="Tremor">Tremor</a> (involuntary muscle twitching)</li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Stimulant_psychosis#Substituted_amphetamines" title="Stimulant psychosis">Acute amphetamine psychosis</a> (e.g., delusions and paranoia)</li>
<li><a href="/wiki/Stereotypy" title="Stereotypy">Compulsive and repetitive movement</a></li>
<li><a href="/wiki/Serotonin_syndrome" title="Serotonin syndrome">Serotonin syndrome</a> (excessive serotonergic nerve activity)</li>
<li><a href="/wiki/Sympathomimetic_toxidrome" title="Sympathomimetic toxidrome" class="mw-redirect">Sympathomimetic toxidrome</a> (excessive adrenergic nerve activity)</li>
</ul>
</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Musculoskeletal_system" title="Musculoskeletal system" class="mw-redirect">Musculoskeletal</a></th>
<td>
<ul>
<li><a href="/wiki/Myalgia" title="Myalgia">Muscle pain</a></li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">Rhabdomyolysis</a> (rapid muscle breakdown)</li>
</ul>
</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Respiratory_system" title="Respiratory system">Respiratory</a></th>
<td>
<ul>
<li>Rapid breathing</li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Pulmonary_edema" title="Pulmonary edema">Pulmonary edema</a> (fluid accumulation in the lungs)</li>
<li><a href="/wiki/Pulmonary_hypertension" title="Pulmonary hypertension">Pulmonary hypertension</a> (high blood pressure in the arteries of the lung)</li>
<li><a href="/wiki/Respiratory_alkalosis" title="Respiratory alkalosis">Respiratory alkalosis</a> (reduced blood <a href="/wiki/Carbon_dioxide" title="Carbon dioxide">CO<sub>2</sub></a>)</li>
</ul>
</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Urogenital_system" title="Urogenital system" class="mw-redirect">Urinary</a></th>
<td>
<ul>
<li><a href="/wiki/Dysuria" title="Dysuria">Painful urination</a></li>
<li><a href="/wiki/Urinary_retention" title="Urinary retention">Urinary retention</a> (inability to urinate)</li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Anuria" title="Anuria">No urine production</a></li>
<li><a href="/wiki/Kidney_failure" title="Kidney failure" class="mw-redirect">Kidney failure</a></li>
</ul>
</td>
</tr>
<tr>
<th scope="row">Other</th>
<td>
<ul>
<li><a href="/wiki/Hyperthermia" title="Hyperthermia">Elevated body temperature</a></li>
<li><a href="/wiki/Mydriasis" title="Mydriasis">Mydriasis</a> (dilated pupils)</li>
</ul>
</td>
<td>
<ul>
<li><a href="/wiki/Hyperkalemia" title="Hyperkalemia">Elevated</a> or <a href="/wiki/Hypokalemia" title="Hypokalemia">low blood potassium</a></li>
<li><a href="/wiki/Hyperpyrexia" title="Hyperpyrexia" class="mw-redirect">Hyperpyrexia</a> (extremely elevated body temperature)</li>
<li><a href="/wiki/Metabolic_acidosis" title="Metabolic acidosis">Metabolic acidosis</a> (excessively acidic bodily fluids)</li>
</ul>
</td>
</tr>
</table>
<h3><span class="mw-headline" id="Addiction">Addiction</span></h3>
<table align="right" border="0" width="350em" cellpadding="2" cellspacing="0" class="toccolours" style="margin-left:0.5em;">
<tr>
<th style="text-align:center;background:#EE9900"><a href="/wiki/Addiction" title="Addiction">Addiction</a> and <a href="/wiki/Substance_dependence" title="Substance dependence">dependence</a> glossary<sup id="cite_ref-Addiction_glossary_82-1" class="reference"><a href="#cite_note-Addiction_glossary-82"><span>[</span>70<span>]</span></a></sup><sup id="cite_ref-Cellular_basis_89-1" class="reference"><a href="#cite_note-Cellular_basis-89"><span>[</span>76<span>]</span></a></sup><sup id="cite_ref-Nestler_Labs_Glossary_98-0" class="reference"><a href="#cite_note-Nestler_Labs_Glossary-98"><span>[</span>84<span>]</span></a></sup></th>
</tr>
<tr>
<td>• <b><a href="/wiki/Addiction" title="Addiction">addiction</a></b> – a state characterized by compulsive engagement in rewarding stimuli despite adverse consequences</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Addictive_behavior" title="Addictive behavior">addictive behavior</a></b> – a behavior that is both rewarding and reinforcing</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Addictive_drug" title="Addictive drug" class="mw-redirect">addictive drug</a></b> – a drug that is both rewarding and reinforcing</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Substance_dependence" title="Substance dependence">dependence</a></b> – an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake)</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Reverse_tolerance" title="Reverse tolerance">drug sensitization</a></b> or <b>reverse tolerance</b> – the escalating effect of a drug resulting from repeated administration at a given dose</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a></b> – dependence that involves persistent physical–somatic withdrawal symptoms (e.g., fatigue and <a href="/wiki/Delirium_tremens" title="Delirium tremens">delirium tremens</a>)</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Psychological_dependence" title="Psychological dependence">psychological dependence</a></b> – dependence that involves emotional–motivational withdrawal symptoms (e.g., <a href="/wiki/Dysphoria" title="Dysphoria">dysphoria</a> and <a href="/wiki/Anhedonia" title="Anhedonia">anhedonia</a>)</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Reinforcement" title="Reinforcement">reinforcing</a> stimuli</b> – stimuli that increase the probability of repeating behaviors paired with them</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Reward_system" title="Reward system">rewarding</a> stimuli</b> – stimuli that the brain interprets as intrinsically positive or as something to be approached</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Sensitization" title="Sensitization">sensitization</a></b> – an amplified response to a stimulus resulting from repeated exposure to it</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Drug_tolerance" title="Drug tolerance">tolerance</a></b> – the diminishing effect of a drug resulting from repeated administration at a given dose</td>
</tr>
<tr>
<td>• <b><a href="/wiki/Drug_withdrawal" title="Drug withdrawal">withdrawal</a></b> – symptoms that occur after chronic use of a drug is reduced abruptly or stopped</td>
</tr>
<tr>
<td style="text-align:right;"><small class="editlink noprint plainlinksneverexpand">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Addiction_glossary&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Addiction_glossary&amp;action=history">history</a>)</small></td>
</tr>
</table>
<p><a href="/wiki/Addiction" title="Addiction">Addiction</a> is a serious risk with heavy recreational amphetamine use but is unlikely to arise from typical medical use at therapeutic doses.<sup id="cite_ref-Westfall_19-21" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Addiction_risk_99-0" class="reference"><a href="#cite_note-Addiction_risk-99"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-EncycOfPsychopharm_18-1" class="reference"><a href="#cite_note-EncycOfPsychopharm-18"><span>[</span>14<span>]</span></a></sup> <a href="/wiki/Drug_tolerance" title="Drug tolerance">Drug tolerance</a> develops rapidly in amphetamine abuse (i.e., a recreational amphetamine overdose), so periods of extended use require increasingly larger doses of the drug in order to achieve the same effect.<sup id="cite_ref-100" class="reference"><a href="#cite_note-100"><span>[</span>86<span>]</span></a></sup><sup id="cite_ref-101" class="reference"><a href="#cite_note-101"><span>[</span>87<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Biomolecular_mechanisms">Biomolecular mechanisms</span></h4>
<p>Current models of addiction from chronic drug use involve alterations in <a href="/wiki/Gene_expression" title="Gene expression">gene expression</a> in certain parts of the brain, particularly the <a href="/wiki/Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a>.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_102-0" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-102"><span>[</span>88<span>]</span></a></sup><sup id="cite_ref-Nestler_103-0" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup><sup id="cite_ref-Addiction_genetics_104-0" class="reference"><a href="#cite_note-Addiction_genetics-104"><span>[</span>90<span>]</span></a></sup> The most important <a href="/wiki/Transcription_factor" title="Transcription factor">transcription factors</a><sup id="cite_ref-106" class="reference"><a href="#cite_note-106"><span>[</span>note 8<span>]</span></a></sup> that produce these alterations are <a href="/wiki/%CE%94FosB" title="ΔFosB" class="mw-redirect">ΔFosB</a>, <a href="/wiki/Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate">cAMP</a> response element binding protein (<a href="/wiki/CAMP_response_element_binding_protein" title="CAMP response element binding protein" class="mw-redirect">CREB</a>), and nuclear factor kappa B (<a href="/wiki/NF-%CE%BAB" title="NF-κB">NF-κB</a>).<sup id="cite_ref-Nestler_103-1" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup> ΔFosB plays a crucial role in the development of drug addictions, since its overexpression in <a href="/wiki/D1-type" title="D1-type" class="mw-redirect">D1-type</a> <a href="/wiki/Medium_spiny_neuron" title="Medium spiny neuron">medium spiny neurons</a> in the nucleus accumbens is <a href="/wiki/Necessary_and_sufficient#Definitions" title="Necessary and sufficient" class="mw-redirect">necessary and sufficient</a><sup id="cite_ref-107" class="reference"><a href="#cite_note-107"><span>[</span>note 9<span>]</span></a></sup> for most of the behavioral and neural adaptations that arise from addiction.<sup id="cite_ref-What_the_.CE.94FosB.3F_88-2" class="reference"><a href="#cite_note-What_the_.CE.94FosB.3F-88"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Cellular_basis_89-2" class="reference"><a href="#cite_note-Cellular_basis-89"><span>[</span>76<span>]</span></a></sup><sup id="cite_ref-Nestler_103-2" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup> Once ΔFosB is sufficiently overexpressed, it induces an addictive state that becomes increasingly more severe with further increases in ΔFosB expression.<sup id="cite_ref-What_the_.CE.94FosB.3F_88-3" class="reference"><a href="#cite_note-What_the_.CE.94FosB.3F-88"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Cellular_basis_89-3" class="reference"><a href="#cite_note-Cellular_basis-89"><span>[</span>76<span>]</span></a></sup> It has been implicated in addictions to <a href="/wiki/Alcoholism" title="Alcoholism">alcohol</a>, <a href="/wiki/Cannabinoid" title="Cannabinoid">cannabinoids</a>, <a href="/wiki/Cocaine" title="Cocaine">cocaine</a>, <a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a>, <a href="/wiki/Nicotine" title="Nicotine">nicotine</a>, <a href="/wiki/Opioid" title="Opioid">opioids</a>, <a href="/wiki/Phencyclidine" title="Phencyclidine">phencyclidine</a>, <a href="/wiki/Propofol" title="Propofol">propofol</a>, and <a href="/wiki/Substituted_amphetamines" title="Substituted amphetamines" class="mw-redirect">substituted amphetamines</a>, among others.<sup id="cite_ref-110" class="reference"><a href="#cite_note-110"><span>[</span>sources 8<span>]</span></a></sup></p>
<p><a href="/wiki/%CE%94JunD" title="ΔJunD" class="mw-redirect">ΔJunD</a>, a transcription factor, and <a href="/wiki/EHMT2" title="EHMT2">G9a</a>, a <a href="/wiki/Histone_methyltransferase" title="Histone methyltransferase">histone methyltransferase</a> enzyme, both directly oppose the induction of ΔFosB in the nucleus accumbens (i.e., they oppose increases in its expression).<sup id="cite_ref-Cellular_basis_89-4" class="reference"><a href="#cite_note-Cellular_basis-89"><span>[</span>76<span>]</span></a></sup><sup id="cite_ref-Nestler_103-4" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup><sup id="cite_ref-Nestler_2014_epigenetics_111-0" class="reference"><a href="#cite_note-Nestler_2014_epigenetics-111"><span>[</span>94<span>]</span></a></sup> Sufficiently overexpressing ΔJunD in the nucleus accumbens with <a href="/wiki/Viral_vector" title="Viral vector">viral vectors</a> can completely block many of the neural and behavioral alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB).<sup id="cite_ref-Nestler_103-5" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup> ΔFosB also plays an important role in regulating behavioral responses to <a href="/wiki/Natural_reward" title="Natural reward" class="mw-redirect">natural rewards</a>, such as palatable food, sex, and exercise.<sup id="cite_ref-Natural_and_drug_addictions_91-3" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Nestler_103-6" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup><sup id="cite_ref-.CE.94FosB_reward_112-0" class="reference"><a href="#cite_note-.CE.94FosB_reward-112"><span>[</span>95<span>]</span></a></sup> Since both natural rewards and addictive drugs <a href="/wiki/Inducible_gene" title="Inducible gene" class="mw-redirect">induce expression</a> of ΔFosB (i.e., they cause the brain to produce more of it), chronic acquisition of these rewards can result in a similar pathological state of addiction.<sup id="cite_ref-Natural_and_drug_addictions_91-4" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Nestler_103-7" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup> Consequently, ΔFosB is the most significant factor involved in both amphetamine addiction and amphetamine-induced <a href="/wiki/Sex_addiction" title="Sex addiction" class="mw-redirect">sex addictions</a>, which are compulsive sexual behaviors that result from excessive sexual activity and amphetamine use.<sup id="cite_ref-Natural_and_drug_addictions_91-5" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Amph_and_sex_addiction_113-0" class="reference"><a href="#cite_note-Amph_and_sex_addiction-113"><span>[</span>96<span>]</span></a></sup> These sex addictions are associated with a <a href="/wiki/Dopamine_dysregulation_syndrome" title="Dopamine dysregulation syndrome">dopamine dysregulation syndrome</a> which occurs in some patients taking <a href="/wiki/Dopaminergic#Supplements_and_drugs" title="Dopaminergic">dopaminergic drugs</a>.<sup id="cite_ref-Natural_and_drug_addictions_91-6" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-.CE.94FosB_reward_112-1" class="reference"><a href="#cite_note-.CE.94FosB_reward-112"><span>[</span>95<span>]</span></a></sup><sup id="cite_ref-Amph_and_sex_addiction_113-1" class="reference"><a href="#cite_note-Amph_and_sex_addiction-113"><span>[</span>96<span>]</span></a></sup></p>
<p>The effects of amphetamine on gene regulation are both dose- and route-dependent.<sup id="cite_ref-Addiction_genetics_104-1" class="reference"><a href="#cite_note-Addiction_genetics-104"><span>[</span>90<span>]</span></a></sup> Most of the research on gene regulation and addiction is based upon animal studies with intravenous amphetamine administration at very high doses.<sup id="cite_ref-Addiction_genetics_104-2" class="reference"><a href="#cite_note-Addiction_genetics-104"><span>[</span>90<span>]</span></a></sup> The few studies that have used equivalent (weight-adjusted) human therapeutic doses and oral administration show that these changes, if they occur, are relatively minor.<sup id="cite_ref-Addiction_genetics_104-3" class="reference"><a href="#cite_note-Addiction_genetics-104"><span>[</span>90<span>]</span></a></sup> This suggests that medical use of amphetamine does not significantly affect gene regulation.<sup id="cite_ref-Addiction_genetics_104-4" class="reference"><a href="#cite_note-Addiction_genetics-104"><span>[</span>90<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Pharmacological_treatments">Pharmacological treatments</span></h4>
<p>As of May 2014<sup class="plainlinks noprint asof-tag update" style="display:none;"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Adderall&amp;action=edit">[update]</a></sup>, there is no effective <a href="/wiki/Pharmacotherapy" title="Pharmacotherapy">pharmacotherapy</a> for amphetamine addiction.<sup id="cite_ref-pmid24716825_114-0" class="reference"><a href="#cite_note-pmid24716825-114"><span>[</span>97<span>]</span></a></sup><sup id="cite_ref-Cochrane_2013_treatments_115-0" class="reference"><a href="#cite_note-Cochrane_2013_treatments-115"><span>[</span>98<span>]</span></a></sup><sup id="cite_ref-pmid23039267_116-0" class="reference"><a href="#cite_note-pmid23039267-116"><span>[</span>99<span>]</span></a></sup> Amphetamine addiction is largely mediated through increased activation of <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">dopamine receptors</a> and <span class="nowrap"><a href="//en.wiktionary.org/wiki/colocalize" class="extiw" title="wikt:colocalize">co-localized</a></span> <a href="/wiki/NMDA_receptor" title="NMDA receptor">NMDA receptors</a><sup id="cite_ref-118" class="reference"><a href="#cite_note-118"><span>[</span>note 10<span>]</span></a></sup> in the nucleus accumbens;<sup id="cite_ref-Magnesium_87-1" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup> <a href="/wiki/Magnesium" title="Magnesium">magnesium ions</a> inhibit NMDA receptors by blocking the receptor <a href="/wiki/Calcium_channel" title="Calcium channel">calcium channel</a>.<sup id="cite_ref-Magnesium_87-2" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup><sup id="cite_ref-NHM-NMDA_117-1" class="reference"><a href="#cite_note-NHM-NMDA-117"><span>[</span>100<span>]</span></a></sup> One review suggested that, based upon animal testing, pathological (addiction-inducing) amphetamine use significantly reduces the level of intracellular magnesium throughout the brain.<sup id="cite_ref-Magnesium_87-3" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup> <a href="/wiki/Dietary_supplement" title="Dietary supplement">Supplemental magnesium</a><sup id="cite_ref-119" class="reference"><a href="#cite_note-119"><span>[</span>note 11<span>]</span></a></sup> treatment has been shown to reduce amphetamine <a href="/wiki/Self-administration" title="Self-administration">self-administration</a> (i.e., doses given to oneself) in humans, but it is not an effective <a href="/wiki/Monotherapy" title="Monotherapy" class="mw-redirect">monotherapy</a> for amphetamine addiction.<sup id="cite_ref-Magnesium_87-5" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Behavioral_treatments">Behavioral treatments</span></h4>
<p><a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a> is currently the most effective clinical treatment for psychostimulant addictions.<sup id="cite_ref-Nestler_CBT_94-1" class="reference"><a href="#cite_note-Nestler_CBT-94"><span>[</span>81<span>]</span></a></sup> Additionally, research on the <a href="/wiki/Neurobiological_effects_of_physical_exercise" title="Neurobiological effects of physical exercise">neurobiological effects of physical exercise</a> suggests that daily aerobic exercise, especially endurance exercise (e.g., <a href="/wiki/Marathon_running" title="Marathon running" class="mw-redirect">marathon running</a>), prevents the development of drug addiction and is an effective <a href="/wiki/Adjunct_therapy" title="Adjunct therapy" class="mw-redirect">adjunct therapy</a> (i.e., a supplemental treatment) for amphetamine addiction.<sup id="cite_ref-Natural_and_drug_addictions_91-7" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Running_vs_addiction_92-3" class="reference"><a href="#cite_note-Running_vs_addiction-92"><span>[</span>79<span>]</span></a></sup><sup id="cite_ref-Exercise_Rev_3_93-2" class="reference"><a href="#cite_note-Exercise_Rev_3-93"><span>[</span>80<span>]</span></a></sup> Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions.<sup id="cite_ref-Running_vs_addiction_92-4" class="reference"><a href="#cite_note-Running_vs_addiction-92"><span>[</span>79<span>]</span></a></sup><sup id="cite_ref-Exercise_Rev_3_93-3" class="reference"><a href="#cite_note-Exercise_Rev_3-93"><span>[</span>80<span>]</span></a></sup> In particular, <a href="/wiki/Aerobic_exercise" title="Aerobic exercise">aerobic exercise</a> decreases psychostimulant self-administration, reduces the <a href="/wiki/Reinstatement" title="Reinstatement" class="mw-redirect">reinstatement</a> (i.e., relapse) of drug-seeking, and induces increased <a href="/wiki/Dopamine_receptor_D2" title="Dopamine receptor D2">dopamine receptor D<sub>2</sub></a> (DRD2) density in the <a href="/wiki/Striatum" title="Striatum">striatum</a>.<sup id="cite_ref-Natural_and_drug_addictions_91-8" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup> This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density.<sup id="cite_ref-Natural_and_drug_addictions_91-9" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></p>
<center>
<table class="wikitable unsortable" style="width: 100%; text-align:center">
<caption>Summary of addiction-related plasticity</caption>
<tr>
<th scope="col" style="width: 25%;" rowspan="2">Form of neural or behavioral plasticity</th>
<th scope="col" style="width: 25%;" colspan="6">Type of reinforcer</th>
<th scope="col" style="width: 15%;" rowspan="2"><small>Sources</small></th>
</tr>
<tr>
<th scope="col" style="width: 15%;">Opiates</th>
<th scope="col" style="width: 15%;">Psychostimulants</th>
<th scope="col" style="width: 15%;">High fat or sugar food</th>
<th scope="col" style="width: 15%;"><a href="/wiki/Sexual_intercourse" title="Sexual intercourse">Sexual intercourse</a></th>
<th scope="col" style="width: 15%;"><a href="/wiki/Neurobiological_effects_of_physical_exercise" title="Neurobiological effects of physical exercise">Physical exercise<br />
(aerobic)</a></th>
<th scope="col" style="width: 15%;"><a href="/wiki/Environmental_enrichment_(neural)" title="Environmental enrichment (neural)">Environmental<br />
enrichment</a></th>
</tr>
<tr>
<td scope="row" style="height: 40px"><a href="/wiki/%CE%94FosB" title="ΔFosB" class="mw-redirect">ΔFosB</a> expression in<br />
<span class="nowrap">nucleus accumbens</span> <a href="/wiki/D1-type" title="D1-type" class="mw-redirect">D1-type</a> <a href="/wiki/Medium_spiny_neurons" title="Medium spiny neurons" class="mw-redirect"><abbr title="medium spiny neurons">MSNs</abbr></a></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-10" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="col" colspan="8">Behavioral plasticity</th>
</tr>
<tr>
<td scope="row" style="height: 40px">Escalation of intake</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-11" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br />
cross-sensitization</td>
<td>Yes</td>
<td>Not applicable</td>
<td>Yes</td>
<td>Yes</td>
<td>Attenuated</td>
<td>Attenuated</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-12" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br />
<a href="/wiki/Self-administration" title="Self-administration">self-administration</a></td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td></td>
<td>↓</td>
<td>↓</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-13" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br />
<a href="/wiki/Conditioned_place_preference" title="Conditioned place preference">conditioned place preference</a></td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-14" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px"><a href="/wiki/Reinstatement_of_drug-seeking_behavior" title="Reinstatement of drug-seeking behavior" class="mw-redirect">Reinstatement of drug-seeking behavior</a></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td></td>
<td>↓</td>
<td>↓</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-15" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="col" colspan="8">Neurochemical plasticity</th>
</tr>
<tr>
<td scope="row" style="height: 40px"><a href="/wiki/CAMP_response_element-binding_protein" title="CAMP response element-binding protein" class="mw-redirect"><abbr title="cAMP response element-binding protein">CREB</abbr></a> <a href="/wiki/Phosphorylation" title="Phosphorylation">phosphorylation</a><br />
in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td></td>
<td>↓</td>
<td>↓</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-16" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Sensitized dopamine response<br />
in the <span class="nowrap">nucleus accumbens</span></td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
<td></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-17" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Altered striatal dopamine signaling</td>
<td>↓<a href="/wiki/DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a href="/wiki/DRD3" title="DRD3" class="mw-redirect">DRD3</a></td>
<td>↑<a href="/wiki/DRD1" title="DRD1" class="mw-redirect">DRD1</a>, ↓<a href="/wiki/DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a href="/wiki/DRD3" title="DRD3" class="mw-redirect">DRD3</a></td>
<td>↑<a href="/wiki/DRD1" title="DRD1" class="mw-redirect">DRD1</a>, ↓<a href="/wiki/DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a href="/wiki/DRD3" title="DRD3" class="mw-redirect">DRD3</a></td>
<td></td>
<td>↑<a href="/wiki/DRD2" title="DRD2" class="mw-redirect">DRD2</a></td>
<td>↑<a href="/wiki/DRD2" title="DRD2" class="mw-redirect">DRD2</a></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-18" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Altered striatal opioid signaling</td>
<td>↑<a href="/wiki/%CE%9C-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td>
<td>↑<a href="/wiki/%CE%9C-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a><br />
↑<a href="/wiki/%CE%9A-opioid_receptor" title="Κ-opioid receptor">κ-opioid receptors</a></td>
<td>↑<a href="/wiki/%CE%9C-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td>
<td>↑<a href="/wiki/%CE%9C-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td>
<td>No change</td>
<td>No change</td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-19" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Changes in striatal <a href="/wiki/Opioid_peptide" title="Opioid peptide">opioid peptides</a></td>
<td>↑<a href="/wiki/Dynorphin" title="Dynorphin">dynorphin</a></td>
<td>↑<a href="/wiki/Dynorphin" title="Dynorphin">dynorphin</a></td>
<td>↓<a href="/wiki/Enkephalin" title="Enkephalin">enkephalin</a></td>
<td></td>
<td>↑<a href="/wiki/Dynorphin" title="Dynorphin">dynorphin</a></td>
<td>↑<a href="/wiki/Dynorphin" title="Dynorphin">dynorphin</a></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-20" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="col" colspan="8">Mesocorticolimbic synaptic plasticity</th>
</tr>
<tr>
<td scope="row" style="height: 40px">Number of dendrites in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td></td>
<td></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-21" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
<tr>
<td scope="row" style="height: 40px">Dendritic spine density in<br />
the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td></td>
<td></td>
<td><sup id="cite_ref-Natural_and_drug_addictions_91-22" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup></td>
</tr>
</table>
</center>
<h3><span class="mw-headline" id="Dependence_and_withdrawal">Dependence and withdrawal</span></h3>
<p>According to another Cochrane Collaboration review on <a href="/wiki/Drug_withdrawal" title="Drug withdrawal">withdrawal</a> in individuals who compulsively use amphetamine and methamphetamine, "when chronic heavy users abruptly discontinue amphetamine use, many report a time-limited withdrawal syndrome that occurs within 24&#160;hours of their last dose."<sup id="cite_ref-Cochrane_Withdrawal_120-0" class="reference"><a href="#cite_note-Cochrane_Withdrawal-120"><span>[</span>101<span>]</span></a></sup> This review noted that withdrawal symptoms in chronic, high-dose users are frequent, occurring in up to 87.6% of cases, and persist for three to four weeks with a marked "crash" phase occurring during the first week.<sup id="cite_ref-Cochrane_Withdrawal_120-1" class="reference"><a href="#cite_note-Cochrane_Withdrawal-120"><span>[</span>101<span>]</span></a></sup> Amphetamine withdrawal symptoms can include anxiety, <a href="/wiki/Craving_(withdrawal)" title="Craving (withdrawal)">drug craving</a>, <a href="/wiki/Dysphoria" title="Dysphoria">depressed mood</a>, <a href="/wiki/Fatigue_(medical)" title="Fatigue (medical)">fatigue</a>, <a href="/wiki/Hyperphagia" title="Hyperphagia" class="mw-redirect">increased appetite</a>, increased movement or <a href="/wiki/Psychomotor_retardation" title="Psychomotor retardation">decreased movement</a>, lack of motivation, sleeplessness or sleepiness, and <a href="/wiki/Lucid_dream" title="Lucid dream">lucid dreams</a>.<sup id="cite_ref-Cochrane_Withdrawal_120-2" class="reference"><a href="#cite_note-Cochrane_Withdrawal-120"><span>[</span>101<span>]</span></a></sup> The review indicated that withdrawal symptoms are associated with the degree of dependence, suggesting that therapeutic use would result in far milder discontinuation symptoms.<sup id="cite_ref-Cochrane_Withdrawal_120-3" class="reference"><a href="#cite_note-Cochrane_Withdrawal-120"><span>[</span>101<span>]</span></a></sup> Manufacturer prescribing information does not indicate the presence of withdrawal symptoms following discontinuation of amphetamine use after an extended period at therapeutic doses.<sup id="cite_ref-Dexedrine_FDA_66-1" class="reference"><a href="#cite_note-Dexedrine_FDA-66"><span>[</span>58<span>]</span></a></sup><sup id="cite_ref-121" class="reference"><a href="#cite_note-121"><span>[</span>102<span>]</span></a></sup><sup id="cite_ref-122" class="reference"><a href="#cite_note-122"><span>[</span>103<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Toxicity_and_psychosis">Toxicity and psychosis</span></h3>
<div class="hatnote">See also: <a href="/wiki/Stimulant_psychosis" title="Stimulant psychosis">Stimulant psychosis</a></div>
<p>In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic <a href="/wiki/Neurotoxicity" title="Neurotoxicity">neurotoxicity</a>, or damage to dopamine neurons, which is characterized by reduced transporter and receptor function.<sup id="cite_ref-Humans.26Animals_123-0" class="reference"><a href="#cite_note-Humans.26Animals-123"><span>[</span>104<span>]</span></a></sup> There is no evidence that amphetamine is directly neurotoxic in humans.<sup id="cite_ref-124" class="reference"><a href="#cite_note-124"><span>[</span>105<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_02_125-0" class="reference"><a href="#cite_note-Malenka_2009_02-125"><span>[</span>106<span>]</span></a></sup> However, large doses of amphetamine may cause indirect neurotoxicity as a result of increased oxidative stress from <a href="/wiki/Reactive_oxygen_species" title="Reactive oxygen species">reactive oxygen species</a> and <a href="/wiki/Autoxidation" title="Autoxidation">autoxidation</a> of dopamine.<sup id="cite_ref-pmid22392347_24-1" class="reference"><a href="#cite_note-pmid22392347-24"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-Autoxidation1_126-0" class="reference"><a href="#cite_note-Autoxidation1-126"><span>[</span>107<span>]</span></a></sup><sup id="cite_ref-Autoxidation2_127-0" class="reference"><a href="#cite_note-Autoxidation2-127"><span>[</span>108<span>]</span></a></sup></p>
<p>A severe amphetamine overdose can result in a stimulant psychosis that may involve a variety of symptoms, such as <a href="/wiki/Paranoia" title="Paranoia">paranoia</a> and <a href="/wiki/Delusion" title="Delusion">delusions</a>.<sup id="cite_ref-Cochrane_16-2" class="reference"><a href="#cite_note-Cochrane-16"><span>[</span>12<span>]</span></a></sup> A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about&#160;5–15% of users fail to recover completely.<sup id="cite_ref-Cochrane_16-3" class="reference"><a href="#cite_note-Cochrane-16"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Hofmann_128-0" class="reference"><a href="#cite_note-Hofmann-128"><span>[</span>109<span>]</span></a></sup> According to the same review, there is at least one trial that shows <a href="/wiki/Antipsychotic" title="Antipsychotic">antipsychotic</a> medications effectively resolve the symptoms of acute amphetamine psychosis.<sup id="cite_ref-Cochrane_16-4" class="reference"><a href="#cite_note-Cochrane-16"><span>[</span>12<span>]</span></a></sup> Psychosis very rarely arises from therapeutic use.<sup id="cite_ref-Stimulant_Misuse_17-2" class="reference"><a href="#cite_note-Stimulant_Misuse-17"><span>[</span>13<span>]</span></a></sup><sup id="cite_ref-FDA_Contra_Warnings_64-6" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>56<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Interactions">Interactions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=8" title="Edit section: Interactions">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">Monoamine oxidase inhibitors</a> (MAOIs) taken with Adderall may result in a <a href="/wiki/Hypertensive_crisis" title="Hypertensive crisis">hypertensive crisis</a> if taken within two weeks after last use of an MAOI type drug.<sup id="cite_ref-FDA_Interactions_129-0" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup></li>
<li><a href="/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">Inhibitors of enzymes</a> that directly metabolize amphetamine (particularly <a href="/wiki/FMO3" title="FMO3" class="mw-redirect">FMO3</a> and <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>) will prolong the elimination of amphetamine.<sup id="cite_ref-FDA_Interactions_129-1" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup><sup id="cite_ref-FMO_130-0" class="reference"><a href="#cite_note-FMO-130"><span>[</span>111<span>]</span></a></sup></li>
<li><a href="/wiki/Stimulants" title="Stimulants" class="mw-redirect">Stimulants</a> and <a href="/wiki/Antidepressants" title="Antidepressants" class="mw-redirect">antidepressants</a> (<a href="/wiki/Sedative" title="Sedative">sedatives</a> and <a href="/wiki/Depressant" title="Depressant">depressants</a>) may increase (decrease) the drug effects of Adderall, and vice versa.<sup id="cite_ref-FDA_Interactions_129-2" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup></li>
<li>Dietary <a href="/wiki/PH" title="PH">pH</a> affects the absorption and <a href="/wiki/Elimination_half-life" title="Elimination half-life" class="mw-redirect">elimination half-life</a> of Adderall; an alkaline diet increases the rate of absorption and decreases the rate of excretion, while acidic diets decrease absorption and increase excretion rates.<sup id="cite_ref-FDA_Interactions_129-3" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup></li>
</ul>
<h2><span class="mw-headline" id="Pharmacology">Pharmacology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=9" title="Edit section: Pharmacology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:542px;">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: #EDC9AF;margin-bottom:3px">Pharmacodynamics of amphetamine in a dopamine neuron<br />
<span class="noprint plainlinks navbar" style="white-space:nowrap;word-spacing:-.12em;"><a href="/wiki/Template:Amphetamine_pharmacodynamics" title="Template:Amphetamine pharmacodynamics"><span style="font-variant:small-caps;" title="View this template">v</span></a> <b>·</b> <a href="/wiki/Template_talk:Amphetamine_pharmacodynamics" title="Template talk:Amphetamine pharmacodynamics"><span style="font-variant:small-caps;" title="Discuss this template">t</span></a> <b>·</b> <a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Amphetamine_pharmacodynamics&amp;action=edit"><span style="font-variant:small-caps;color:#002bb8;" title="Edit this template">e</span></a></span></div>
<div style="position:relative; width:540px; height:685px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:540px; position:absolute"><a href="//commons.wikimedia.org/wiki/File:TAAR1_Dopamine.svg" title="commons:File:TAAR1 Dopamine.svg"><img alt="A pharmacodynamic model of amphetamine and TAAR1" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/540px-TAAR1_Dopamine.svg.png" width="540" height="685" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/810px-TAAR1_Dopamine.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/1080px-TAAR1_Dopamine.svg.png 2x" data-file-width="725" data-file-height="920" /></a></div>
<div style="text-align:center; font-size:14px; line-height:110%;">
<div id="annotation_190x45" style="position:absolute; left:190px; top:45px; line-height:110%"><span style="background-color:transparent; color:black"><span style="background-color:transparent;">via <b><a href="/wiki/Aromatic_L-amino_acid_decarboxylase" title="Aromatic L-amino acid decarboxylase">AADC</a></b></span></span></div>
</div>
</div>
<div class="thumbcaption" style="clear:left">
<div class="floatleft"><img alt="The image above contains clickable links" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/18px-Interactive_icon.svg.png" title="The image above contains clickable links" width="18" height="27" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/27px-Interactive_icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/36px-Interactive_icon.svg.png 2x" data-file-width="133" data-file-height="200" /></div>
Amphetamine enters the presynaptic neuron across the neuronal membrane or through <abbr title="dopamine transporter">DAT</abbr>. Once inside, it binds to <abbr title="trace amine-associated receptor 1">TAAR1</abbr> or enters synaptic vesicles through <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>. When amphetamine enters the synaptic vesicles through VMAT2, dopamine is released into the cytosol (yellow-orange area). When amphetamine binds to TAAR1, it reduces postsynaptic dopamine neuron firing rate via <a href="/wiki/G_protein-coupled_inwardly-rectifying_potassium_channel" title="G protein-coupled inwardly-rectifying potassium channel">potassium channels</a> and triggers <a href="/wiki/Protein_kinase_A" title="Protein kinase A">protein kinase A</a> (PKA) and <a href="/wiki/Protein_kinase_C" title="Protein kinase C">protein kinase C</a> (PKC) signaling, resulting in DAT phosphorylation. <span class="nowrap">PKA-phosphorylation</span> causes DAT to withdraw into the presynaptic neuron (<a href="/wiki/Endocytosis" title="Endocytosis">internalize</a>) and cease transport. <span class="nowrap">PKC-phosphorylated</span> DAT may either operate in reverse or, like <span class="nowrap">PKA-phosphorylated</span> DAT, internalize and cease transport. Amphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a <a href="/wiki/CAMKII%CE%B1" title="CAMKIIα" class="mw-redirect">CAMKIIα</a>-dependent pathway, in turn producing dopamine efflux.</div>
</div>
</div>
<h3><span class="mw-headline" id="Mechanism_of_action">Mechanism of action</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=10" title="Edit section: Mechanism of action">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">For a more complete and detailed description of amphetamine pharmacodynamics, see <a href="/wiki/Amphetamine#Pharmacodynamics" title="Amphetamine">Amphetamine#Pharmacodynamics</a>.</div>
<p>Amphetamine, the active ingredient of Adderall, works primarily by increasing the activity of the <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitters</a> <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> and <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> in the brain and more specifically, in the <a href="/wiki/Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a>, <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a>, and <a href="/wiki/Locus_coeruleus" title="Locus coeruleus">locus coeruleus</a> regions.<sup id="cite_ref-Malenka_2009_03_8-4" class="reference"><a href="#cite_note-Malenka_2009_03-8"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-cognition_enhancers_32-1" class="reference"><a href="#cite_note-cognition_enhancers-32"><span>[</span>27<span>]</span></a></sup> It also triggers the release of several other neurotransmitters (e.g., <a href="/wiki/Serotonin" title="Serotonin">serotonin</a>, <a href="/wiki/Histamine" title="Histamine">histamine</a>, and <a href="/wiki/Epinephrine" title="Epinephrine">epinephrine</a>, among others) from neurons and also the synthesis of <a href="/wiki/Neuropeptide" title="Neuropeptide">neuropeptides</a> (e.g., <a href="/wiki/Cocaine_and_amphetamine_regulated_transcript" title="Cocaine and amphetamine regulated transcript">cocaine and amphetamine regulated transcript</a> (CART) peptides).<sup id="cite_ref-E_Weihe_10-1" class="reference"><a href="#cite_note-E_Weihe-10"><span>[</span>7<span>]</span></a></sup><sup id="cite_ref-PubChem_Targets_131-0" class="reference"><a href="#cite_note-PubChem_Targets-131"><span>[</span>112<span>]</span></a></sup> Both active ingredients of Adderall, <a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a> and <a href="/wiki/Levoamphetamine" title="Levoamphetamine">levoamphetamine</a>, bind to the same <a href="/wiki/Biological_target" title="Biological target">biological targets</a>,<sup id="cite_ref-Westfall_19-22" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-TAAR1_stereoselective_132-0" class="reference"><a href="#cite_note-TAAR1_stereoselective-132"><span>[</span>113<span>]</span></a></sup> but their <a href="/wiki/Binding_affinities" title="Binding affinities" class="mw-redirect">binding affinities</a> (that is, <a href="/wiki/Potency_(pharmacology)" title="Potency (pharmacology)">potency</a>) differ somewhat.<sup id="cite_ref-Westfall_19-23" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-TAAR1_stereoselective_132-1" class="reference"><a href="#cite_note-TAAR1_stereoselective-132"><span>[</span>113<span>]</span></a></sup> Dextroamphetamine and levoamphetamine are both potent <a href="/wiki/Full_agonist" title="Full agonist" class="mw-redirect">full agonists</a> (activating compounds) of <a href="/wiki/Trace_amine-associated_receptor_1" title="Trace amine-associated receptor 1" class="mw-redirect">trace amine-associated receptor 1</a> (TAAR1) and interact with <a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">vesicular monoamine transporter 2</a> (VMAT2), with dextroamphetamine being the more potent agonist of TAAR1.<sup id="cite_ref-TAAR1_stereoselective_132-2" class="reference"><a href="#cite_note-TAAR1_stereoselective-132"><span>[</span>113<span>]</span></a></sup> Consequently, dextroamphetamine produces more <abbr title="central nervous system">CNS</abbr> stimulation than levoamphetamine;<sup id="cite_ref-TAAR1_stereoselective_132-3" class="reference"><a href="#cite_note-TAAR1_stereoselective-132"><span>[</span>113<span>]</span></a></sup><sup id="cite_ref-133" class="reference"><a href="#cite_note-133"><span>[</span>114<span>]</span></a></sup> however, levoamphetamine has slightly greater cardiovascular and peripheral effects.<sup id="cite_ref-Westfall_19-24" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Levoamphetamine provides Adderall with a quicker onset and longer-lasting effects than dextroamphetamine alone.<sup id="cite_ref-pmid15719230_134-0" class="reference"><a href="#cite_note-pmid15719230-134"><span>[</span>115<span>]</span></a></sup> It has been reported that certain children have a better clinical response to levoamphetamine.<sup id="cite_ref-135" class="reference"><a href="#cite_note-135"><span>[</span>116<span>]</span></a></sup><sup id="cite_ref-Arnold_136-0" class="reference"><a href="#cite_note-Arnold-136"><span>[</span>117<span>]</span></a></sup></p>
<p>In the absence of amphetamine, <abbr title="vesicular monoamine transporter 2">VMAT2</abbr> will normally move <a href="/wiki/Monoamine" title="Monoamine" class="mw-redirect">monoamines</a> (e.g., <a href="/wiki/Dopamine" title="Dopamine">dopamine</a>, <a href="/wiki/Histamine" title="Histamine">histamine</a>, <a href="/wiki/Serotonin" title="Serotonin">serotonin</a>, <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a>, etc.) from the <a href="/wiki/Intracellular_fluid" title="Intracellular fluid" class="mw-redirect">intracellular fluid</a> of a monoamine <a href="/wiki/Neuron" title="Neuron">neuron</a> into its <a href="/wiki/Synaptic_vesicle" title="Synaptic vesicle">synaptic vesicles</a>, which are essentially chemical storage units inside a neuron.<sup id="cite_ref-E_Weihe_10-2" class="reference"><a href="#cite_note-E_Weihe-10"><span>[</span>7<span>]</span></a></sup> When amphetamine enters a neuron and interacts with VMAT2, the transporter reverses its direction of transport, thereby releasing stored monoamines inside synaptic vesicles back into the neuron's intracellular fluid.<sup id="cite_ref-E_Weihe_10-3" class="reference"><a href="#cite_note-E_Weihe-10"><span>[</span>7<span>]</span></a></sup> Meanwhile, when amphetamine activates TAAR1, the receptor causes the neuron's <a href="/wiki/Cell_membrane" title="Cell membrane">cell membrane</a>-bound <a href="/wiki/Monoamine_transporter" title="Monoamine transporter">monoamine transporters</a> (i.e., the <a href="/wiki/Dopamine_transporter" title="Dopamine transporter">dopamine transporter</a>, <a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">norepinephrine transporter</a>, or <a href="/wiki/Serotonin_transporter" title="Serotonin transporter">serotonin transporter</a>) to either stop transporting molecules altogether (via <a href="/wiki/Endocytosis" title="Endocytosis">internalization</a>) or even transport them <i>in reverse</i>;<sup id="cite_ref-Miller_9-1" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup> in other words, the reversed membrane transporter will push dopamine, norepinephrine, and serotonin out of the neuron's intracellular fluid and into the <a href="/wiki/Synaptic_cleft" title="Synaptic cleft" class="mw-redirect">synaptic cleft</a>.<sup id="cite_ref-Miller_9-2" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup> In summary, by interacting with both VMAT2 and TAAR1, amphetamine releases neurotransmitters from synaptic vesicles (the effect from <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>) into the intracellular fluid where they subsequently exit the neuron through the membrane-bound, reversed monoamine transporters (the effect from <abbr title="trace amine-associated receptor 1">TAAR1</abbr>).<sup id="cite_ref-Miller_9-3" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-E_Weihe_10-4" class="reference"><a href="#cite_note-E_Weihe-10"><span>[</span>7<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pharmacokinetics">Pharmacokinetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=11" title="Edit section: Pharmacokinetics">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">This section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<p>The oral <a href="/wiki/Bioavailability" title="Bioavailability">bioavailability</a> of amphetamine varies with gastrointestinal pH;<sup id="cite_ref-FDA_Interactions_129-4" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup> it is well absorbed from the gut, and bioavailability is typically over&#160;75% for dextroamphetamine.<sup id="cite_ref-Drugbank-dexamph_137-0" class="reference"><a href="#cite_note-Drugbank-dexamph-137"><span>[</span>118<span>]</span></a></sup> Amphetamine is a weak base with a <a href="/wiki/Acid_dissociation_constant" title="Acid dissociation constant">pKa</a> of <span class="nowrap">9–10</span>;<sup id="cite_ref-FDA_Pharmacokinetics_138-0" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> consequently, when the pH is basic, more of the drug is in its <a href="/wiki/Lipid" title="Lipid">lipid</a> soluble <a href="/wiki/Free_base" title="Free base">free base</a> form, and more is absorbed through the lipid-rich <a href="/wiki/Cell_membranes" title="Cell membranes" class="mw-redirect">cell membranes</a> of the gut <a href="/wiki/Epithelium" title="Epithelium">epithelium</a>.<sup id="cite_ref-FDA_Pharmacokinetics_138-1" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-FDA_Interactions_129-5" class="reference"><a href="#cite_note-FDA_Interactions-129"><span>[</span>110<span>]</span></a></sup> Conversely, an acidic pH means the drug is predominantly in a water-soluble <a href="/wiki/Cation" title="Cation" class="mw-redirect">cationic</a> (salt) form, and less is absorbed.<sup id="cite_ref-FDA_Pharmacokinetics_138-2" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> Approximately <span class="nowrap">15–40%</span> of amphetamine circulating in the bloodstream is bound to <a href="/wiki/Plasma_protein" title="Plasma protein" class="mw-redirect">plasma proteins</a>.<sup id="cite_ref-Drugbank-amph_139-0" class="reference"><a href="#cite_note-Drugbank-amph-139"><span>[</span>120<span>]</span></a></sup></p>
<p>The <a href="/wiki/Biological_half-life" title="Biological half-life">half-life</a> of amphetamine enantiomers differ and vary with urine pH.<sup id="cite_ref-FDA_Pharmacokinetics_138-3" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are <span class="nowrap">9–11</span>&#160;hours and <span class="nowrap">11–14</span>&#160;hours, respectively.<sup id="cite_ref-FDA_Pharmacokinetics_138-4" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> An acidic diet will reduce the enantiomer half-lives to <span class="nowrap">8–11</span>&#160;hours; an alkaline diet will increase the range to <span class="nowrap">16–31</span>&#160;hours.<sup id="cite_ref-Pubchem_Kinetics_140-0" class="reference"><a href="#cite_note-Pubchem_Kinetics-140"><span>[</span>121<span>]</span></a></sup><sup id="cite_ref-pH-dependent_half-lives_141-0" class="reference"><a href="#cite_note-pH-dependent_half-lives-141"><span>[</span>122<span>]</span></a></sup> The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3&#160;hours and 7&#160;hours post-dose respectively.<sup id="cite_ref-FDA_Pharmacokinetics_138-5" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> Amphetamine is eliminated via the kidneys, with <span class="nowrap">30–40%</span> of the drug being excreted unchanged at normal urinary pH.<sup id="cite_ref-FDA_Pharmacokinetics_138-6" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> When the urinary pH is basic, amphetamine is in its free base form, so less is excreted.<sup id="cite_ref-FDA_Pharmacokinetics_138-7" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of&#160;1% to a high of&#160;75%, depending mostly upon whether urine is too basic or acidic, respectively.<sup id="cite_ref-FDA_Pharmacokinetics_138-8" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> Amphetamine is usually eliminated within two days of the last oral dose.<sup id="cite_ref-Pubchem_Kinetics_140-1" class="reference"><a href="#cite_note-Pubchem_Kinetics-140"><span>[</span>121<span>]</span></a></sup> Apparent half-life and duration of effect increase with repeated use and accumulation of the drug.<sup id="cite_ref-Flomenbaum_2006_142-0" class="reference"><a href="#cite_note-Flomenbaum_2006-142"><span>[</span>123<span>]</span></a></sup></p>
<p><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>, <a href="/wiki/Dopamine_%CE%B2-hydroxylase" title="Dopamine β-hydroxylase" class="mw-redirect">dopamine β-hydroxylase</a>, <a href="/wiki/Flavin-containing_monooxygenase_3" title="Flavin-containing monooxygenase 3" class="mw-redirect">flavin-containing monooxygenase 3</a>, <a href="/wiki/Butyrate-CoA_ligase" title="Butyrate-CoA ligase" class="mw-redirect">butyrate-CoA ligase</a>, and <a href="/wiki/Glycine_N-acyltransferase" title="Glycine N-acyltransferase">glycine N-acyltransferase</a> are the enzymes known to metabolize amphetamine or its metabolites in humans.<sup id="cite_ref-149" class="reference"><a href="#cite_note-149"><span>[</span>sources 9<span>]</span></a></sup> Amphetamine has a variety of excreted metabolic products, including <span class="nowrap"><a href="/wiki/4-hydroxyamphetamine" title="4-hydroxyamphetamine" class="mw-redirect">4-hydroxyamphetamine</a></span>, <span class="nowrap"><a href="/wiki/4-hydroxynorephedrine" title="4-hydroxynorephedrine" class="mw-redirect">4-hydroxynorephedrine</a></span>, <span class="nowrap"><a href="/wiki/4-hydroxyphenylacetone" title="4-hydroxyphenylacetone" class="mw-redirect">4-hydroxyphenylacetone</a></span>, <a href="/wiki/Benzoic_acid" title="Benzoic acid">benzoic acid</a>, <a href="/wiki/Hippuric_acid" title="Hippuric acid">hippuric acid</a>, <a href="/wiki/Norephedrine" title="Norephedrine" class="mw-redirect">norephedrine</a>, and <a href="/wiki/Phenylacetone" title="Phenylacetone">phenylacetone</a>.<sup id="cite_ref-FDA_Pharmacokinetics_138-10" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-Pubchem_Kinetics_140-2" class="reference"><a href="#cite_note-Pubchem_Kinetics-140"><span>[</span>121<span>]</span></a></sup><sup id="cite_ref-Metabolites_150-0" class="reference"><a href="#cite_note-Metabolites-150"><span>[</span>130<span>]</span></a></sup> Among these metabolites, the active <a href="/wiki/Sympathomimetics" title="Sympathomimetics" class="mw-redirect">sympathomimetics</a> are <span class="nowrap">4‑hydroxyamphetamine</span>,<sup id="cite_ref-151" class="reference"><a href="#cite_note-151"><span>[</span>131<span>]</span></a></sup> <span class="nowrap">4‑hydroxynorephedrine</span>,<sup id="cite_ref-152" class="reference"><a href="#cite_note-152"><span>[</span>132<span>]</span></a></sup> and norephedrine.<sup id="cite_ref-153" class="reference"><a href="#cite_note-153"><span>[</span>133<span>]</span></a></sup> The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination.<sup id="cite_ref-FDA_Pharmacokinetics_138-11" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-Pubchem_Kinetics_140-3" class="reference"><a href="#cite_note-Pubchem_Kinetics-140"><span>[</span>121<span>]</span></a></sup> The known pathways and detectable metabolites in humans include the following:<sup id="cite_ref-FDA_Pharmacokinetics_138-12" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-FMO_130-2" class="reference"><a href="#cite_note-FMO-130"><span>[</span>111<span>]</span></a></sup><sup id="cite_ref-Metabolites_150-1" class="reference"><a href="#cite_note-Metabolites-150"><span>[</span>130<span>]</span></a></sup></p>
<div class="thumb center" style="margin: 1em auto;">
<div class="thumbinner" style="width:692px;">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: transparent;margin-bottom:3px">Metabolic pathways of amphetamine</div>
<div style="position:relative; width:690px; height:375px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:-10px; top:3px; width:700px; position:absolute"><a href="//commons.wikimedia.org/wiki/File:Amph_Pathway.png" title="commons:File:Amph Pathway.png"><img alt="Graphic of several routes of amphetamine metabolism" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4e/Amph_Pathway.png/700px-Amph_Pathway.png" width="700" height="386" srcset="//upload.wikimedia.org/wikipedia/commons/4/4e/Amph_Pathway.png 1.5x, //upload.wikimedia.org/wikipedia/commons/4/4e/Amph_Pathway.png 2x" data-file-width="725" data-file-height="400" /></a></div>
<div style="text-align:center; font-size:16px; line-height:110%;">
<div id="annotation_10x350" style="position:absolute; left:10px; top:350px; line-height:110%"><span style="background-color:transparent; color:black"><span style="background-color:transparent;"><a href="/wiki/4-Hydroxyphenylacetone" title="4-Hydroxyphenylacetone">4-Hydroxyphenylacetone</a></span></span></div>
<div id="annotation_220x350" style="position:absolute; left:220px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Phenylacetone" title="Phenylacetone">Phenylacetone</a></span></div>
<div id="annotation_390x350" style="position:absolute; left:390px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Benzoic_acid" title="Benzoic acid">Benzoic acid</a></span></div>
<div id="annotation_560x350" style="position:absolute; left:560px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Hippuric_acid" title="Hippuric acid">Hippuric acid</a></span></div>
<div id="annotation_45x220" style="position:absolute; left:45px; top:220px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></span></div>
<div id="annotation_300x220" style="position:absolute; left:300px; top:220px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></span></div>
<div id="annotation_255x90" style="position:absolute; left:255px; top:90px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine">4-Hydroxyamphetamine</a></span></div>
<div id="annotation_490x90" style="position:absolute; left:490px; top:90px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/P-Hydroxynorephedrine" title="P-Hydroxynorephedrine">4-Hydroxynorephedrine</a></span></div>
<div id="annotation_145x115" style="position:absolute; left:145px; top:115px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_385x115" style="position:absolute; left:385px; top:115px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_165x270" style="position:absolute; left:165px; top:270px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_190x160" style="position:absolute; left:190px; top:160px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Beta-<br />
Hydroxylation</span></div>
<div id="annotation_415x20" style="position:absolute; left:415px; top:20px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Beta-<br />
Hydroxylation</span></div>
<div id="annotation_210x220" style="position:absolute; left:210px; top:220px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Oxidative<br />
Deamination</span></div>
<div id="annotation_335x282" style="position:absolute; left:335px; top:282px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Oxidation</span></div>
<div id="annotation_480x270" style="position:absolute; left:480px; top:270px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Glycine<br />
Conjugation</span></div>
</div>
</div>
<div class="thumbcaption" style="clear:left">
<div class="floatleft"><img alt="The image above contains clickable links" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/18px-Interactive_icon.svg.png" title="The image above contains clickable links" width="18" height="27" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/27px-Interactive_icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/36px-Interactive_icon.svg.png 2x" data-file-width="133" data-file-height="200" /></div>
The primary active metabolites of amphetamine are <span class="nowrap">4-hydroxyamphetamine</span> and norephedrine;<sup id="cite_ref-Metabolites_150-2" class="reference"><a href="#cite_note-Metabolites-150"><span>[</span>130<span>]</span></a></sup> at normal urine pH, about <span class="nowrap">30–40%</span> of amphetamine is excreted unchanged and roughly&#160;50% is excreted as the inactive metabolites (bottom row).<sup id="cite_ref-FDA_Pharmacokinetics_138-13" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> The remaining <span class="nowrap">10–20%</span> is excreted as the active metabolites.<sup id="cite_ref-FDA_Pharmacokinetics_138-14" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup> Benzoic acid is metabolized by butyrate-CoA ligase into an intermediate product, <a href="/wiki/Benzoyl-CoA" title="Benzoyl-CoA">benzoyl-CoA</a>,<sup id="cite_ref-Benzoic1_147-1" class="reference"><a href="#cite_note-Benzoic1-147"><span>[</span>128<span>]</span></a></sup> which is then metabolized by glycine N-acyltransferase into hippuric acid.<sup id="cite_ref-Benzoic2_148-1" class="reference"><a href="#cite_note-Benzoic2-148"><span>[</span>129<span>]</span></a></sup></div>
</div>
</div>
<div style="clear:both;"></div>
<h3><span class="mw-headline" id="Related_endogenous_compounds">Related endogenous compounds</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=12" title="Edit section: Related endogenous compounds">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">This section is <a href="/wiki/Transclusion" title="Transclusion">transcluded</a> from <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a>. <small style="font-style: normal">(<a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">edit</a> | <a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=history">history</a>)</small></div>
<div class="hatnote">For more details on related compounds, see <a href="/wiki/Trace_amine" title="Trace amine">Trace amine</a>.</div>
<p>Amphetamine has a very similar structure and function to the <a href="//en.wiktionary.org/wiki/endogenous" class="extiw" title="wikt:endogenous">endogenous</a> trace amines, which are naturally occurring <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitter</a> molecules produced in the human body and brain.<sup id="cite_ref-Miller_9-4" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_11-1" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup> Among this group, the most closely related compounds are <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamine</a>, the parent compound of amphetamine, and <span class="nowrap"><a href="/wiki/N-methylphenethylamine" title="N-methylphenethylamine" class="mw-redirect"><i>N</i>-methylphenethylamine</a></span>, an <a href="/wiki/Isomer" title="Isomer">isomer</a> of amphetamine (i.e., it has an identical molecular formula).<sup id="cite_ref-Miller_9-5" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_11-2" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_154-0" class="reference"><a href="#cite_note-Renaissance_GPCR-154"><span>[</span>134<span>]</span></a></sup> In humans, phenethylamine is produced directly from <a href="/wiki/L-phenylalanine" title="L-phenylalanine" class="mw-redirect">L-phenylalanine</a> by the <a href="/wiki/Aromatic_amino_acid_decarboxylase" title="Aromatic amino acid decarboxylase" class="mw-redirect">aromatic amino acid decarboxylase</a> (AADC) enzyme, which converts <a href="/wiki/L-DOPA" title="L-DOPA">L-DOPA</a> into dopamine as well.<sup id="cite_ref-Trace_Amines_11-3" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_154-1" class="reference"><a href="#cite_note-Renaissance_GPCR-154"><span>[</span>134<span>]</span></a></sup> In turn, <span class="nowrap"><i>N</i>‑methylphenethylamine</span> is metabolized from phenethylamine by <a href="/wiki/Phenylethanolamine_N-methyltransferase" title="Phenylethanolamine N-methyltransferase">phenylethanolamine N-methyltransferase</a>, the same enzyme that metabolizes norepinephrine into epinephrine.<sup id="cite_ref-Trace_Amines_11-4" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_154-2" class="reference"><a href="#cite_note-Renaissance_GPCR-154"><span>[</span>134<span>]</span></a></sup> Like amphetamine, both phenethylamine and <span class="nowrap"><i>N</i>‑methylphenethylamine</span> regulate monoamine neurotransmission via <abbr title="trace amine-associated receptor 1">TAAR1</abbr>;<sup id="cite_ref-Miller_9-6" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_154-3" class="reference"><a href="#cite_note-Renaissance_GPCR-154"><span>[</span>134<span>]</span></a></sup> unlike amphetamine, both of these substances are broken down by <a href="/wiki/Monoamine_oxidase_B" title="Monoamine oxidase B">monoamine oxidase B</a>, and therefore have a shorter half-life than amphetamine.<sup id="cite_ref-Trace_Amines_11-5" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_154-4" class="reference"><a href="#cite_note-Renaissance_GPCR-154"><span>[</span>134<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History.2C_society.2C_and_culture">History, society, and culture</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=13" title="Edit section: History, society, and culture">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote relarticle mainarticle">Main article: <a href="/wiki/History_and_culture_of_substituted_amphetamines" title="History and culture of substituted amphetamines">History and culture of substituted amphetamines</a></div>
<p>Richwood Pharmaceuticals, which later merged with <a href="/wiki/Shire_plc" title="Shire plc" class="mw-redirect">Shire plc</a>, introduced the current Adderall brand in 1996 as an instant-release tablet.<sup id="cite_ref-155" class="reference"><a href="#cite_note-155"><span>[</span>135<span>]</span></a></sup> In 2006, Shire agreed to sell rights to the Adderall name for this instant-release medication to <a href="/wiki/Duramed_Pharmaceuticals" title="Duramed Pharmaceuticals" class="mw-redirect">Duramed Pharmaceuticals</a>.<sup id="cite_ref-Duramed_156-0" class="reference"><a href="#cite_note-Duramed-156"><span>[</span>136<span>]</span></a></sup> DuraMed Pharmaceuticals was acquired by <a href="/wiki/Teva_Pharmaceuticals" title="Teva Pharmaceuticals" class="mw-redirect">Teva Pharmaceuticals</a> in 2008 during their <a href="/wiki/Mergers_and_acquisitions" title="Mergers and acquisitions">acquisition</a> of <a href="/wiki/Barr_Pharmaceuticals" title="Barr Pharmaceuticals">Barr Pharmaceuticals</a>, including Barr's Duramed division.<sup id="cite_ref-test_157-0" class="reference"><a href="#cite_note-test-157"><span>[</span>137<span>]</span></a></sup></p>
<p>The first generic version of Adderall IR was introduced to market in 2002.<sup id="cite_ref-NDCD_2-1" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup> Later on, Barr and Shire reached a settlement agreement permitting Barr to offer a generic form of the drug beginning in April 2009.<sup id="cite_ref-NDCD_2-2" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-158" class="reference"><a href="#cite_note-158"><span>[</span>138<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Commercial_formulation">Commercial formulation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=14" title="Edit section: Commercial formulation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Chemically, Adderall is a mixture of several amphetamine salts; specifically, it is composed of equal parts (by <a href="/wiki/Mass" title="Mass">mass</a>) of amphetamine <a href="/wiki/Aspartic_acid" title="Aspartic acid">aspartate monohydrate</a>, amphetamine <a href="/wiki/Sulfate" title="Sulfate">sulfate</a>, dextroamphetamine sulfate, and dextroamphetamine <a href="/wiki/Saccharate" title="Saccharate" class="mw-redirect">saccharate</a>.<sup id="cite_ref-Adderall_XR_all_pages_40-2" class="reference"><a href="#cite_note-Adderall_XR_all_pages-40"><span>[</span>34<span>]</span></a></sup> This drug mixture has slightly stronger <abbr title="central nervous system">CNS</abbr> effects than racemic amphetamine due to the higher proportion of dextroamphetamine.<sup id="cite_ref-Miller_9-7" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-Westfall_19-25" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup> Adderall is produced as both an immediate release (IR) and extended release (XR) formulation.<sup id="cite_ref-NDCD_2-3" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-Adderall_IR_23-2" class="reference"><a href="#cite_note-Adderall_IR-23"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-Adderall_XR_all_pages_40-3" class="reference"><a href="#cite_note-Adderall_XR_all_pages-40"><span>[</span>34<span>]</span></a></sup> As of December 2013<sup class="plainlinks noprint asof-tag update" style="display:none;"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Adderall&amp;action=edit">[update]</a></sup>, ten different companies have produced generic Adderall IR at one point, while <a href="/wiki/Teva_Pharmaceutical_Industries" title="Teva Pharmaceutical Industries">Teva Pharmaceutical Industries</a>, <a href="/wiki/Actavis" title="Actavis">Actavis</a>, and <a href="/wiki/Barr_Pharmaceuticals" title="Barr Pharmaceuticals">Barr Pharmaceuticals</a> currently manufacture generic Adderall XR.<sup id="cite_ref-NDCD_2-4" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup> <a href="/wiki/Shire_plc" title="Shire plc" class="mw-redirect">Shire plc</a>, the company that held the original patent for Adderall and Adderall XR, still manufactures brand name Adderall XR, but not Adderall IR.<sup id="cite_ref-NDCD_2-5" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Comparison_to_other_formulations">Comparison to other formulations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=15" title="Edit section: Comparison to other formulations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Adderall is one of several formulations of pharmaceutical amphetamine, including singular or mixed enantiomers and as an enantiomer prodrug. The table below compares these medications (based on US approved forms):</p>
<div style="clear:both;"></div>
<table class="wikitable">
<caption>Amphetamine base in marketed amphetamine medications</caption>
<tr>
<th colspan="2" rowspan="3">drug</th>
<th rowspan="3">formula</th>
<th colspan="2"><a href="/wiki/Molecular_mass" title="Molecular mass">molecular mass</a><br />
<sup id="cite_ref-160" class="reference"><a href="#cite_note-160"><span>[</span>note 12<span>]</span></a></sup></th>
<th colspan="3">amphetamine base<br />
<sup id="cite_ref-161" class="reference"><a href="#cite_note-161"><span>[</span>note 13<span>]</span></a></sup></th>
<th colspan="2">amphetamine base<br />
in equal doses</th>
<th rowspan="3">doses with<br />
equal base<br />
content<br />
<sup id="cite_ref-162" class="reference"><a href="#cite_note-162"><span>[</span>note 14<span>]</span></a></sup></th>
</tr>
<tr>
<th colspan="2"><span style="font-weight:normal;">(g/mol)</span></th>
<th colspan="3"><span style="font-weight:normal;">(percent)</span></th>
<th colspan="2"><span style="font-weight:normal;">(30&#160;mg dose)</span></th>
</tr>
<tr>
<th>total</th>
<th>base</th>
<th>total</th>
<th>dextro-</th>
<th>levo-</th>
<th>dextro-</th>
<th>levo-</th>
</tr>
<tr>
<td colspan="2"><b>dextroamphetamine sulfate</b><sup id="cite_ref-damph1_163-0" class="reference"><a href="#cite_note-damph1-163"><span>[</span>140<span>]</span></a></sup><sup id="cite_ref-damph2_164-0" class="reference"><a href="#cite_note-damph2-164"><span>[</span>141<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td>
<center>368.49</center>
</td>
<td>
<center>270.41</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>—</center>
</td>
<td>
<center>22.0&#160;mg</center>
</td>
<td>
<center>—</center>
</td>
<td>
<center>30.0&#160;mg</center>
</td>
</tr>
<tr>
<th colspan="11"></th>
</tr>
<tr>
<td colspan="2"><b>amphetamine sulfate</b><sup id="cite_ref-Amph_sulfate_mass_165-0" class="reference"><a href="#cite_note-Amph_sulfate_mass-165"><span>[</span>142<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td>
<center>368.49</center>
</td>
<td>
<center>270.41</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>36.69%</center>
</td>
<td>
<center>36.69%</center>
</td>
<td>
<center>11.0&#160;mg</center>
</td>
<td>
<center>11.0&#160;mg</center>
</td>
<td>
<center>30.0&#160;mg</center>
</td>
</tr>
<tr>
<th colspan="11"></th>
</tr>
<tr>
<td colspan="2"><b>Adderall</b></td>
<td></td>
<td></td>
<td></td>
<td>
<center>62.57%</center>
</td>
<td>
<center>47.49%</center>
</td>
<td>
<center>15.08%</center>
</td>
<td>
<center>14.2&#160;mg</center>
</td>
<td>
<center>4.5&#160;mg</center>
</td>
<td>
<center>35.2&#160;mg</center>
</td>
</tr>
<tr>
<td>25%</td>
<td>dextroamphetamine sulfate<sup id="cite_ref-damph1_163-1" class="reference"><a href="#cite_note-damph1-163"><span>[</span>140<span>]</span></a></sup><sup id="cite_ref-damph2_164-1" class="reference"><a href="#cite_note-damph2-164"><span>[</span>141<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td>
<center>368.49</center>
</td>
<td>
<center>270.41</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>—</center>
</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25%</td>
<td>amphetamine sulfate<sup id="cite_ref-Amph_sulfate_mass_165-1" class="reference"><a href="#cite_note-Amph_sulfate_mass-165"><span>[</span>142<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td>
<center>368.49</center>
</td>
<td>
<center>270.41</center>
</td>
<td>
<center>73.38%</center>
</td>
<td>
<center>36.69%</center>
</td>
<td>
<center>36.69%</center>
</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25%</td>
<td>dextroamphetamine saccharate<sup id="cite_ref-166" class="reference"><a href="#cite_note-166"><span>[</span>143<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•C<sub>6</sub>H<sub>10</sub>O<sub>8</sub></td>
<td>
<center>480.55</center>
</td>
<td>
<center>270.41</center>
</td>
<td>
<center>56.27%</center>
</td>
<td>
<center>56.27%</center>
</td>
<td>
<center>—</center>
</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25%</td>
<td>amphetamine aspartate monohydrate<sup id="cite_ref-amph2_167-0" class="reference"><a href="#cite_note-amph2-167"><span>[</span>144<span>]</span></a></sup></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)•C<sub>4</sub>H<sub>7</sub>NO<sub>4</sub>•H<sub>2</sub>O</td>
<td>
<center>286.32</center>
</td>
<td>
<center>135.21</center>
</td>
<td>
<center>47.22%</center>
</td>
<td>
<center>23.61%</center>
</td>
<td>
<center>23.61%</center>
</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<th colspan="11"></th>
</tr>
<tr>
<td colspan="2"><b>lisdexamfetamine dimesylate</b><sup id="cite_ref-168" class="reference"><a href="#cite_note-168"><span>[</span>145<span>]</span></a></sup></td>
<td>C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O•(CH<sub>4</sub>O<sub>3</sub>S)<sub>2</sub></td>
<td>
<center>455.49</center>
</td>
<td>
<center>135.21</center>
</td>
<td>
<center>29.68%</center>
</td>
<td>
<center>29.68%</center>
</td>
<td>
<center>—</center>
</td>
<td>
<center>8.9&#160;mg</center>
</td>
<td>
<center>—</center>
</td>
<td>
<center>74.2&#160;mg</center>
</td>
</tr>
<tr>
<th colspan="11"></th>
</tr>
<tr>
<td colspan="2"><b>amphetamine base suspension</b><sup id="cite_ref-169" class="reference"><a href="#cite_note-169"><span>[</span>note 15<span>]</span></a></sup><sup id="cite_ref-Dyanavel_71-5" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup></td>
<td>C<sub>9</sub>H<sub>13</sub>N</td>
<td>
<center>135.21</center>
</td>
<td>
<center>135.21</center>
</td>
<td>
<center>100%</center>
</td>
<td>
<center>76.19%</center>
</td>
<td>
<center>23.81%</center>
</td>
<td>
<center>22.9&#160;mg</center>
</td>
<td>
<center>7.1&#160;mg</center>
</td>
<td>
<center>22.0&#160;mg</center>
</td>
</tr>
</table>
<h3><span class="mw-headline" id="Past_formulations">Past formulations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=16" title="Edit section: Past formulations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Rexar, a pharmaceutical company, reformulated another drug, branded as Obetrol, and continued to sell this new formulation under the same brand name. This new unapproved formulation was later rebranded and sold as Adderall by Richwood after it acquired Rexar resulting in FDA warning in 1994. Richwood submitted this formulation as NDA 11-522 and Adderall gained FDA approval for the treatment of attention-deficit/hyperactivity disorder on 13 February 1996.<sup id="cite_ref-HND_170-0" class="reference"><a href="#cite_note-HND-170"><span>[</span>146<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Legal_status">Legal status</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=17" title="Edit section: Legal status">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li>In Canada, amphetamines are in Schedule I of the <a href="/wiki/Controlled_Drugs_and_Substances_Act" title="Controlled Drugs and Substances Act">Controlled Drugs and Substances Act</a>, and can only be obtained by prescription.<sup id="cite_ref-urlControlled_Drugs_and_Substances_Act_171-0" class="reference"><a href="#cite_note-urlControlled_Drugs_and_Substances_Act-171"><span>[</span>147<span>]</span></a></sup></li>
<li>In Japan, the use, production, and import of any medicine containing amphetamine are prohibited.<sup id="cite_ref-url_Japan_import_172-0" class="reference"><a href="#cite_note-url_Japan_import-172"><span>[</span>148<span>]</span></a></sup></li>
<li>In South Korea, amphetamines are prohibited.<sup id="cite_ref-urlMoving_to_Korea_brings_medical.2C_social_changes_173-0" class="reference"><a href="#cite_note-urlMoving_to_Korea_brings_medical.2C_social_changes-173"><span>[</span>149<span>]</span></a></sup></li>
<li>In Thailand, Amphetamines are classified as Type 1 Narcotics.<sup id="cite_ref-174" class="reference"><a href="#cite_note-174"><span>[</span>150<span>]</span></a></sup></li>
<li>In the United Kingdom, amphetamines are regarded as <a href="/wiki/Misuse_of_Drugs_Act_1971" title="Misuse of Drugs Act 1971">Class B</a> drugs. The maximum penalty for unauthorized possession is five years in prison and an unlimited fine. The maximum penalty for illegal supply is 14&#160;years in prison and an unlimited fine.<sup id="cite_ref-175" class="reference"><a href="#cite_note-175"><span>[</span>151<span>]</span></a></sup></li>
<li>In the United States, amphetamine is a <a href="/wiki/Schedule_II_(US)" title="Schedule II (US)" class="mw-redirect">Schedule II</a> prescription drug, classified as a <abbr title="central nervous system">CNS</abbr> stimulant.<sup id="cite_ref-176" class="reference"><a href="#cite_note-176"><span>[</span>152<span>]</span></a></sup></li>
<li>Internationally (<a href="/wiki/United_Nations" title="United Nations">United Nations</a>), amphetamine is in Schedule II of the <a href="/wiki/Convention_on_Psychotropic_Substances" title="Convention on Psychotropic Substances">Convention on Psychotropic Substances</a>.<sup id="cite_ref-isbn92-1-148223-2_177-0" class="reference"><a href="#cite_note-isbn92-1-148223-2-177"><span>[</span>153<span>]</span></a></sup><sup id="cite_ref-178" class="reference"><a href="#cite_note-178"><span>[</span>154<span>]</span></a></sup></li>
</ul>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=18" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="noprint portal tright" style="border:solid #aaa 1px;margin:0.5em 0 0.5em 1em">
<table style="background:#f9f9f9;font-size:85%;line-height:110%;max-width:175px">
<tr style="vertical-align:middle">
<td style="text-align:center"><a href="/wiki/File:Rod_of_Asclepius2.svg" class="image"><img alt="Portal icon" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e3/Rod_of_Asclepius2.svg/8px-Rod_of_Asclepius2.svg.png" width="8" height="28" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e3/Rod_of_Asclepius2.svg/13px-Rod_of_Asclepius2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e3/Rod_of_Asclepius2.svg/17px-Rod_of_Asclepius2.svg.png 2x" data-file-width="251" data-file-height="804" /></a></td>
<td style="padding:0 0.2em;vertical-align:middle;font-style:italic;font-weight:bold"><a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine portal</a></td>
</tr>
<tr style="vertical-align:middle">
<td style="text-align:center"><a href="/wiki/File:Portal-puzzle.svg" class="image"><img alt="Portal icon" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/32px-Portal-puzzle.svg.png" width="32" height="28" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/48px-Portal-puzzle.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/64px-Portal-puzzle.svg.png 2x" data-file-width="32" data-file-height="28" /></a></td>
<td style="padding:0 0.2em;vertical-align:middle;font-style:italic;font-weight:bold"><a href="/wiki/Portal:Pharmacology" title="Portal:Pharmacology" class="mw-redirect">Pharmacology portal</a></td>
</tr>
</table>
</div>
<ul>
<li><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></li>
<li><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></li>
<li><a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a></li>
</ul>
<h2><span class="mw-headline" id="Notes">Notes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=19" title="Edit section: Notes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist" style="list-style-type: decimal;">
<ol class="references">
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text">The US nonproprietary name of Adderall is <b>dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate</b>.<sup id="cite_ref-Amph_Uses_1-0" class="reference"><a href="#cite_note-Amph_Uses-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-NDCD_2-0" class="reference"><a href="#cite_note-NDCD-2"><span>[</span>2<span>]</span></a></sup></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><a href="/wiki/Enantiomer" title="Enantiomer">Enantiomers</a> are molecules that are "mirror images" of one another; they are structurally identical but of the opposite orientation, like left and right hands. The amphetamine compound properly refers to a <a href="/wiki/Racemate" title="Racemate" class="mw-redirect">racemate</a>, which is an equal parts mixture of the two enantiomers (i.e., a mixture of 50%&#160;levoamphetamine and 50%&#160;dextroamphetamine).</span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text">Cochrane Collaboration reviews are high quality meta-analytic systematic reviews of randomized controlled trials.<sup id="cite_ref-pmid16052183_36-0" class="reference"><a href="#cite_note-pmid16052183-36"><span>[</span>31<span>]</span></a></sup></span></li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text">The statements supported by the USFDA come from prescribing information, which is the copyrighted intellectual property of the manufacturer and approved by the USFDA. USFDA contraindications are not necessarily intended to limit medical practice but limit claims by pharmaceutical companies.<sup id="cite_ref-pmid8545689_61-0" class="reference"><a href="#cite_note-pmid8545689-61"><span>[</span>55<span>]</span></a></sup></span></li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text">According to one review, amphetamine can be prescribed to individuals with a history of abuse provided that appropriate medication controls are employed, such as requiring daily pick-ups of the medication from the prescribing physician.<sup id="cite_ref-Amph_Uses_1-3" class="reference"><a href="#cite_note-Amph_Uses-1"><span>[</span>1<span>]</span></a></sup></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text">In individuals who experience sub-normal height and weight gains, a rebound to normal levels is expected to occur if stimulant therapy is briefly interrupted.<sup id="cite_ref-Millichap_29-3" class="reference"><a href="#cite_note-Millichap-29"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Long-Term_Outcomes_Medications_31-2" class="reference"><a href="#cite_note-Long-Term_Outcomes_Medications-31"><span>[</span>26<span>]</span></a></sup><sup id="cite_ref-pmid18295156_69-0" class="reference"><a href="#cite_note-pmid18295156-69"><span>[</span>61<span>]</span></a></sup> The average reduction in final adult height from continuous stimulant therapy over a 3&#160;year period is 2&#160;cm.<sup id="cite_ref-pmid18295156_69-1" class="reference"><a href="#cite_note-pmid18295156-69"><span>[</span>61<span>]</span></a></sup></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text">The 95%&#160;confidence interval indicates that there is a 95%&#160;probability that the true number of deaths lies between 3,425 and 4,145.</span></li>
<li id="cite_note-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-106">^</a></b></span> <span class="reference-text">Transcription factors are proteins that increase or decrease the <a href="/wiki/Gene_expression" title="Gene expression">expression</a> of specific genes.<sup id="cite_ref-NHM-Transcription_factor_105-0" class="reference"><a href="#cite_note-NHM-Transcription_factor-105"><span>[</span>91<span>]</span></a></sup></span></li>
<li id="cite_note-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-107">^</a></b></span> <span class="reference-text">In simpler terms, this <i>necessary and sufficient</i> relationship means that ΔFosB overexpression in the nucleus accumbens and addiction-related behavioral and neural adaptations always occur together and never occur alone.</span></li>
<li id="cite_note-118"><span class="mw-cite-backlink"><b><a href="#cite_ref-118">^</a></b></span> <span class="reference-text">NMDA receptors are voltage-dependent <a href="/wiki/Ligand-gated_ion_channels" title="Ligand-gated ion channels" class="mw-redirect">ligand-gated ion channels</a> that requires simultaneous binding of glutamate and a co-agonist (<a href="/wiki/D-serine" title="D-serine" class="mw-redirect"><span class="smallcaps"><span style="FONT-VARIANT: SMALL-CAPS; TEXT-TRANSFORM: LOWERCASE;">D</span></span>-serine</a> or <a href="/wiki/Glycine" title="Glycine">glycine</a>) to open the ion channel.<sup id="cite_ref-NHM-NMDA_117-0" class="reference"><a href="#cite_note-NHM-NMDA-117"><span>[</span>100<span>]</span></a></sup></span></li>
<li id="cite_note-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-119">^</a></b></span> <span class="reference-text">The review indicated that <a href="/wiki/Magnesium_aspartate" title="Magnesium aspartate">magnesium L-aspartate</a> and <a href="/wiki/Magnesium_chloride" title="Magnesium chloride">magnesium chloride</a> produce significant changes in addictive behavior;<sup id="cite_ref-Magnesium_87-4" class="reference"><a href="#cite_note-Magnesium-87"><span>[</span>74<span>]</span></a></sup> other forms of magnesium were not mentioned.</span></li>
<li id="cite_note-160"><span class="mw-cite-backlink"><b><a href="#cite_ref-160">^</a></b></span> <span class="reference-text">For uniformity, molecular masses were calculated using the Lenntech Molecular Weight Calculator.<sup id="cite_ref-159" class="reference"><a href="#cite_note-159"><span>[</span>139<span>]</span></a></sup> and were within 0.01g/mol of published pharmaceutical values.</span></li>
<li id="cite_note-161"><span class="mw-cite-backlink"><b><a href="#cite_ref-161">^</a></b></span> <span class="reference-text">Amphetamine base percentage = molecular mass<sub>base</sub> / molecular mass<sub>total</sub>. Amphetamine base percentage for Adderall = sum of component percentages / 4.</span></li>
<li id="cite_note-162"><span class="mw-cite-backlink"><b><a href="#cite_ref-162">^</a></b></span> <span class="reference-text">dose = (1 / amphetamine base percentage) × scaling factor = (molecular mass<sub>total</sub> / molecular mass<sub>base</sub>) × scaling factor. The values in this column were scaled to a 30&#160;mg dose of dextroamphetamine. <i>Due to pharmacological differences between these medications (e.g., differences in the release, absorption, conversion, concentration, differing effects of enantiomers, half-life, etc), the listed values should not be considered equipotent doses.</i></span></li>
<li id="cite_note-169"><span class="mw-cite-backlink"><b><a href="#cite_ref-169">^</a></b></span> <span class="reference-text">This product (Dyanavel XR) is an oral <a href="/wiki/Suspension_(chemistry)" title="Suspension (chemistry)">suspension</a> (i.e., a drug that is suspended in a liquid and <a href="/wiki/Oral_administration" title="Oral administration">taken by mouth</a>) that contains 2.5&#160;mg/mL of amphetamine base.<sup id="cite_ref-Dyanavel_71-2" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup> The amphetamine base contains dextro- to levo-amphetamine in a ratio of 3.2:1,<sup id="cite_ref-Dyanavel_71-3" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup> which is approximately the ratio in Adderall. The product uses an ion exchange resin to achieve extended release of the amphetamine base.<sup id="cite_ref-Dyanavel_71-4" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Reference_notes">Reference notes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=20" title="Edit section: Reference notes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist" style="list-style-type: decimal;">
<ol class="references">
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Amph_Uses_1-1" class="reference"><a href="#cite_note-Amph_Uses-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Libido_5-0" class="reference"><a href="#cite_note-Libido-5"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-Nonmedical_6-0" class="reference"><a href="#cite_note-Nonmedical-6"><span>[</span>4<span>]</span></a></sup></span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Malenka_2009_03_8-0" class="reference"><a href="#cite_note-Malenka_2009_03-8"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-Miller_9-0" class="reference"><a href="#cite_note-Miller-9"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-E_Weihe_10-0" class="reference"><a href="#cite_note-E_Weihe-10"><span>[</span>7<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_11-0" class="reference"><a href="#cite_note-Trace_Amines-11"><span>[</span>8<span>]</span></a></sup></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><sup id="cite_ref-FDA_Abuse_.26_OD_13-0" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-0" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_15-0" class="reference"><a href="#cite_note-Malenka_2009-15"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Cochrane_16-0" class="reference"><a href="#cite_note-Cochrane-16"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Stimulant_Misuse_17-0" class="reference"><a href="#cite_note-Stimulant_Misuse-17"><span>[</span>13<span>]</span></a></sup><sup id="cite_ref-EncycOfPsychopharm_18-0" class="reference"><a href="#cite_note-EncycOfPsychopharm-18"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Westfall_19-0" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span>[</span>16<span>]</span></a></sup></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><sup id="cite_ref-FDA_Effects_14-8" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Westfall_19-5" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-pmid18295156_69-3" class="reference"><a href="#cite_note-pmid18295156-69"><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-Dyanavel_71-1" class="reference"><a href="#cite_note-Dyanavel-71"><span>[</span>62<span>]</span></a></sup><sup id="cite_ref-rhinitis_72-0" class="reference"><a href="#cite_note-rhinitis-72"><span>[</span>63<span>]</span></a></sup></span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><sup id="cite_ref-74" class="reference"><a href="#cite_note-74"><span>[</span>64<span>]</span></a></sup><sup id="cite_ref-pmid22043968_75-0" class="reference"><a href="#cite_note-pmid22043968-75"><span>[</span>65<span>]</span></a></sup><sup id="cite_ref-76" class="reference"><a href="#cite_note-76"><span>[</span>66<span>]</span></a></sup><sup id="cite_ref-pmid22161946_77-0" class="reference"><a href="#cite_note-pmid22161946-77"><span>[</span>67<span>]</span></a></sup></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Libido_5-1" class="reference"><a href="#cite_note-Libido-5"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_14-10" class="reference"><a href="#cite_note-FDA_Effects-14"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Westfall_19-15" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Merck_Manual_Amphetamines_79-0" class="reference"><a href="#cite_note-Merck_Manual_Amphetamines-79"><span>[</span>68<span>]</span></a></sup></span></li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Acute_amph_toxicity_95-0" class="reference"><a href="#cite_note-Acute_amph_toxicity-95"><span>[</span>82<span>]</span></a></sup><sup id="cite_ref-FDA_Abuse_.26_OD_13-7" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-13"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-Westfall_19-20" class="reference"><a href="#cite_note-Westfall-19"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Amphetamine_toxidrome_83-1" class="reference"><a href="#cite_note-Amphetamine_toxidrome-83"><span>[</span>71<span>]</span></a></sup><sup id="cite_ref-Albertson_2011_96-0" class="reference"><a href="#cite_note-Albertson_2011-96"><span>[</span>83<span>]</span></a></sup></span></li>
<li id="cite_note-110"><span class="mw-cite-backlink"><b><a href="#cite_ref-110">^</a></b></span> <span class="reference-text"><sup id="cite_ref-What_the_.CE.94FosB.3F_88-4" class="reference"><a href="#cite_note-What_the_.CE.94FosB.3F-88"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Natural_and_drug_addictions_91-2" class="reference"><a href="#cite_note-Natural_and_drug_addictions-91"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-Nestler_103-3" class="reference"><a href="#cite_note-Nestler-103"><span>[</span>89<span>]</span></a></sup><sup id="cite_ref-Alcoholism_.CE.94FosB_108-0" class="reference"><a href="#cite_note-Alcoholism_.CE.94FosB-108"><span>[</span>92<span>]</span></a></sup><sup id="cite_ref-MPH_.CE.94FosB_109-0" class="reference"><a href="#cite_note-MPH_.CE.94FosB-109"><span>[</span>93<span>]</span></a></sup></span></li>
<li id="cite_note-149"><span class="mw-cite-backlink"><b><a href="#cite_ref-149">^</a></b></span> <span class="reference-text"><sup id="cite_ref-FDA_Pharmacokinetics_138-9" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-138"><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-Substituted_amphetamines.2C_FMO.2C_and_DBH_143-0" class="reference"><a href="#cite_note-Substituted_amphetamines.2C_FMO.2C_and_DBH-143"><span>[</span>124<span>]</span></a></sup><sup id="cite_ref-DBH_amph_primary_144-0" class="reference"><a href="#cite_note-DBH_amph_primary-144"><span>[</span>125<span>]</span></a></sup><sup id="cite_ref-DBH_4-HA_primary_145-0" class="reference"><a href="#cite_note-DBH_4-HA_primary-145"><span>[</span>126<span>]</span></a></sup><sup id="cite_ref-FMO_130-1" class="reference"><a href="#cite_note-FMO-130"><span>[</span>111<span>]</span></a></sup><sup id="cite_ref-FMO3-Primary_146-0" class="reference"><a href="#cite_note-FMO3-Primary-146"><span>[</span>127<span>]</span></a></sup><sup id="cite_ref-Benzoic1_147-0" class="reference"><a href="#cite_note-Benzoic1-147"><span>[</span>128<span>]</span></a></sup><sup id="cite_ref-Benzoic2_148-0" class="reference"><a href="#cite_note-Benzoic2-148"><span>[</span>129<span>]</span></a></sup></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Adderall&amp;action=edit&amp;section=21" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-Amph_Uses-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amph_Uses_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amph_Uses_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Amph_Uses_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Amph_Uses_1-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194">"Amphetamine, past and present – a pharmacological and clinical perspective"</a>. <i>J. Psychopharmacol.</i> <b>27</b> (6): 479–496. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F0269881113482532">10.1177/0269881113482532</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194">3666194</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23539642">23539642</a>. <q>Mixed enantiomers/mixed salts amphetamine (3:1 d:l isomers)</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine%2C+past+and+present+%93+a+pharmacological+and+clinical+perspective&amp;rft.au=Heal+DJ%2C+Smith+SL%2C+Gosden+J%2C+Nutt+DJ&amp;rft.date=2013-06&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3666194&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3666194&amp;rft_id=info%3Adoi%2F10.1177%2F0269881113482532&amp;rft_id=info%3Apmid%2F23539642&amp;rft.issue=6&amp;rft.jtitle=J.+Psychopharmacol.&amp;rft.pages=479-496&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NDCD-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-NDCD_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NDCD_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NDCD_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NDCD_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NDCD_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-NDCD_2-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20131216080856/http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&amp;numberperpage=160&amp;searchfield=amphetamine&amp;searchtype=ActiveIngredient&amp;OrderBy=ProprietaryName">"National Drug Code Amphetamine Search Results"</a>. <i>National Drug Code Directory</i>. United States Food and Drug Administration. Archived from <a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&amp;numberperpage=160&amp;searchfield=amphetamine&amp;searchtype=ActiveIngredient&amp;OrderBy=ProprietaryName">the original</a> on 7 February 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">16 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=National+Drug+Code+Amphetamine+Search+Results&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fndc%2Fresults.cfm%3Fbeginrow%3D1%26numberperpage%3D160%26searchfield%3Damphetamine%26searchtype%3DActiveIngredient%26OrderBy%3DProprietaryName&amp;rft.jtitle=National+Drug+Code+Directory&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Libido-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-Libido_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Libido_5-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Montgomery KA (June 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750">"Sexual desire disorders"</a>. <i>Psychiatry (Edgmont)</i> <b>5</b> (6): 50–55. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750">2695750</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19727285">19727285</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Sexual+desire+disorders&amp;rft.au=Montgomery+KA&amp;rft.date=2008-06&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2695750&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2695750&amp;rft_id=info%3Apmid%2F19727285&amp;rft.issue=6&amp;rft.jtitle=Psychiatry+%28Edgmont%29&amp;rft.pages=50-55&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nonmedical-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nonmedical_6-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S (January 2008). "Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature". <i>J. Am. Acad. Child Adolesc. Psychiatry</i> <b>47</b> (1): 21–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2Fchi.0b013e31815a56f1">10.1097/chi.0b013e31815a56f1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18174822">18174822</a>. <q>Stimulant misuse appears to occur both for performance enhancement and their euphorogenic effects, the latter being related to the intrinsic properties of the stimulants (e.g., IR versus ER profile)&#160;...<br />
Although useful in the treatment of ADHD, stimulants are controlled II substances with a history of preclinical and human studies showing potential abuse liability.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Misuse+and+diversion+of+stimulants+prescribed+for+ADHD%3A+a+systematic+review+of+the+literature&amp;rft.au=Wilens+TE%2C+Adler+LA%2C+Adams+J%2C+Sgambati+S%2C+Rotrosen+J%2C+Sawtelle+R%2C+Utzinger+L%2C+Fusillo+S&amp;rft.date=2008-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2Fchi.0b013e31815a56f1&amp;rft_id=info%3Apmid%2F18174822&amp;rft.issue=1&amp;rft.jtitle=J.+Am.+Acad.+Child+Adolesc.+Psychiatry&amp;rft.pages=21-31&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=47" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009_03-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Malenka_2009_03_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_8-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_8-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_8-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. pp.&#160;154–157. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+6%3A+Widely+Projecting+Systems%3A+Monoamines%2C+Acetylcholine%2C+and+Orexin&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=154-157&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Miller-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Miller_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Miller_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Miller_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Miller_9-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Miller_9-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Miller_9-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Miller_9-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Miller_9-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Miller GM (January 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101">"The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity"</a>. <i>J. Neurochem.</i> <b>116</b> (2): 164–76. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1471-4159.2010.07109.x">10.1111/j.1471-4159.2010.07109.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101">3005101</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21073468">21073468</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+emerging+role+of+trace+amine-associated+receptor+1+in+the+functional+regulation+of+monoamine+transporters+and+dopaminergic+activity&amp;rft.au=Miller+GM&amp;rft.date=2011-01&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3005101&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3005101&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1471-4159.2010.07109.x&amp;rft_id=info%3Apmid%2F21073468&amp;rft.issue=2&amp;rft.jtitle=J.+Neurochem.&amp;rft.pages=164-76&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=116" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-E_Weihe-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-E_Weihe_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-E_Weihe_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-E_Weihe_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-E_Weihe_10-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-E_Weihe_10-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Eiden LE, Weihe E (January 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197">"VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse"</a>. <i>Ann. N. Y. Acad. Sci.</i> <b>1216</b>: 86–98. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1749-6632.2010.05906.x">10.1111/j.1749-6632.2010.05906.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197">4183197</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21272013">21272013</a>. <q>VMAT2 is the CNS vesicular transporter for not only the biogenic amines <abbr title="dopamine">DA</abbr>, <abbr title="norepinephrine">NE</abbr>, <abbr title="epinephrine">EPI</abbr>, <abbr title="serotonin">5-HT</abbr>, and <abbr title="histamine">HIS</abbr>, but likely also for the trace amines <abbr title="tyramine">TYR</abbr>, <abbr title="phenethylamine">PEA</abbr>, and thyronamine (THYR)&#160;... [Trace aminergic] neurons in mammalian CNS would be identiﬁable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=VMAT2%3A+a+dynamic+regulator+of+brain+monoaminergic+neuronal+function+interacting+with+drugs+of+abuse&amp;rft.au=Eiden+LE%2C+Weihe+E&amp;rft.date=2011-01&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4183197&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4183197&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1749-6632.2010.05906.x&amp;rft_id=info%3Apmid%2F21272013&amp;rft.jtitle=Ann.+N.+Y.+Acad.+Sci.&amp;rft.pages=86-98&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1216" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Trace_Amines-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Trace_Amines_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Trace_Amines_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Trace_Amines_11-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Trace_Amines_11-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Trace_Amines_11-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Trace_Amines_11-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". <i>Pharmacol. Ther.</i> <b>125</b> (3): 363–375. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pharmthera.2009.11.005">10.1016/j.pharmthera.2009.11.005</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19948186">19948186</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+vascular+effects+of+trace+amines+and+amphetamines&amp;rft.au=Broadley+KJ&amp;rft.date=2010-03&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2009.11.005&amp;rft_id=info%3Apmid%2F19948186&amp;rft.issue=3&amp;rft.jtitle=Pharmacol.+Ther.&amp;rft.pages=363-375&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=125" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Abuse_.26_OD-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Abuse_.26_OD_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_13-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. p.&#160;11<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Effects-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Effects_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDA_Effects_14-13"><sup><i><b>n</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.&#160;4–8<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=4-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-Malenka_2009_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Malenka_2009_15-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Malenka_2009_15-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Malenka_2009_15-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Malenka_2009_15-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Malenka_2009_15-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.&#160;318. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. <q>Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in normal subjects and those with ADHD. ... stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks&#160;... through indirect stimulation of dopamine and norepinephrine receptors.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+13%3A+Higher+Cognitive+Function+and+Behavioral+Control&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=318&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_16-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cochrane_16-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cochrane_16-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Cochrane_16-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Shoptaw SJ, Kao U, Ling W (January 2009). Shoptaw SJ, Ali R, ed. "Treatment for amphetamine psychosis". <i>Cochrane Database Syst. Rev.</i> (1): CD003026. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD003026.pub3">10.1002/14651858.CD003026.pub3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19160215">19160215</a>. <q>A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention&#160;...<br />
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983)&#160;...<br />
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Treatment+for+amphetamine+psychosis&amp;rft.au=Shoptaw+SJ%2C+Kao+U%2C+Ling+W&amp;rft.date=2009-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003026.pub3&amp;rft_id=info%3Apmid%2F19160215&amp;rft.issue=1&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003026&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Stimulant_Misuse-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-Stimulant_Misuse_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Stimulant_Misuse_17-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Stimulant_Misuse_17-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">Greydanus D. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131103155156/http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf">"Stimulant Misuse: Strategies to Manage a Growing Problem"</a> <span style="font-size:85%;">(PDF)</span>. <i>American College Health Association</i> (Review Article). ACHA Professional Development Program. p.&#160;20. Archived from <a rel="nofollow" class="external text" href="http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf">the original</a> <span style="font-size:85%;">(PDF)</span> on 3 November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Stimulant+Misuse%3A+Strategies+to+Manage+a+Growing+Problem&amp;rft.au=Greydanus+D&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.acha.org%2Fprof_dev%2FADHD_docs%2FADHD_PDprogram_Article2.pdf&amp;rft.jtitle=American+College+Health+Association&amp;rft.pages=20&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EncycOfPsychopharm-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-EncycOfPsychopharm_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-EncycOfPsychopharm_18-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Stolerman IP (2010). Stolerman IP, ed. <i>Encyclopedia of Psychopharmacology</i>. Berlin, Germany; London, England: Springer. p.&#160;78. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9783540686989" title="Special:BookSources/9783540686989">9783540686989</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.au=Stolerman+IP&amp;rft.btitle=Encyclopedia+of+Psychopharmacology&amp;rft.date=2010&amp;rft.genre=book&amp;rft.isbn=9783540686989&amp;rft.pages=78&amp;rft.place=Berlin%2C+Germany%3B+London%2C+England&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Westfall-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-Westfall_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Westfall_19-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Westfall_19-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Westfall_19-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Westfall_19-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Westfall_19-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Westfall_19-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Westfall_19-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Westfall_19-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Westfall_19-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Westfall_19-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Westfall_19-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Westfall_19-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Westfall_19-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Westfall_19-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Westfall_19-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Westfall_19-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Westfall_19-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Westfall_19-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Westfall_19-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Westfall_19-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Westfall_19-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Westfall_19-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Westfall_19-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Westfall_19-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Westfall_19-25"><sup><i><b>z</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Westfall DP, Westfall TC (2010). <a rel="nofollow" class="external text" href="http://www.accessmedicine.com/content.aspx?aID=16661601">"Miscellaneous Sympathomimetic Agonists"</a>. In Brunton LL, Chabner BA, Knollmann BC. <i>Goodman &amp; Gilman's Pharmacological Basis of Therapeutics</i> (12th ed.). New York, USA: McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071624428" title="Special:BookSources/9780071624428">9780071624428</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Miscellaneous+Sympathomimetic+Agonists&amp;rft.au=Westfall+DP%2C+Westfall+TC&amp;rft.btitle=Goodman+%26+Gilman%27s+Pharmacological+Basis+of+Therapeutics&amp;rft.date=2010&amp;rft.edition=12th&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.accessmedicine.com%2Fcontent.aspx%3FaID%3D16661601&amp;rft.isbn=9780071624428&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><cite class="citation journal">Cooper, WO; Habel, LA; Sox, CM; Chan, KA; Arbogast, PG; Cheetham, TC; Murray, KT; Quinn, VP; Stein, CM; Callahan, ST; Fireman, BH; Fish, FA; Kirshner, HS; O'Duffy, A; Connell, FA; Ray, WA (17 November 2011). "ADHD drugs and serious cardiovascular events in children and young adults.". <i>The New England Journal of Medicine</i> <b>365</b> (20): 1896–904. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa1110212">10.1056/NEJMoa1110212</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22043968">22043968</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=ADHD+drugs+and+serious+cardiovascular+events+in+children+and+young+adults.&amp;rft.aufirst=WO&amp;rft.au=Habel%2C+LA%3B+Sox%2C+CM%3B+Chan%2C+KA%3B+Arbogast%2C+PG%3B+Cheetham%2C+TC%3B+Murray%2C+KT%3B+Quinn%2C+VP%3B+Stein%2C+CM%3B+Callahan%2C+ST%3B+Fireman%2C+BH%3B+Fish%2C+FA%3B+Kirshner%2C+HS%3B+O%27Duffy%2C+A%3B+Connell%2C+FA%3B+Ray%2C+WA&amp;rft.aulast=Cooper&amp;rft.date=2011-11-17&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1110212&amp;rft_id=info%3Apmid%2F22043968&amp;rft.issue=20&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.pages=1896-904&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=365" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20140404185709/http://www.drugabuse.gov/drugs-abuse/prescription-drugs">"Prescription Drugs"</a>. National Institute on Drug Abuse. Archived from <a rel="nofollow" class="external text" href="http://www.drugabuse.gov/drugs-abuse/prescription-drugs">the original</a> on 4 April 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">23 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Prescription+Drugs&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fdrugs-abuse%2Fprescription-drugs&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Adderall_IR-23"><span class="mw-cite-backlink">^ <a href="#cite_ref-Adderall_IR_23-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Adderall_IR_23-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Adderall_IR_23-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf">"Adderall IR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Barr Laboratories, Inc. March 2007. pp.&#160;1–5<span class="reference-accessdate">. Retrieved <span class="nowrap">2 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+IR+Prescribing+Information&amp;rft.date=2007-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F011522s040lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=1-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22392347-24"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22392347_24-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22392347_24-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (August 2012). "Toxicity of amphetamines: an update". <i>Arch. Toxicol.</i> <b>86</b> (8): 1167–1231. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs00204-012-0815-5">10.1007/s00204-012-0815-5</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22392347">22392347</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Toxicity+of+amphetamines%3A+an+update&amp;rft.au=Carvalho+M%2C+Carmo+H%2C+Costa+VM%2C+Capela+JP%2C+Pontes+H%2C+Remi%C3%A3o+F%2C+Carvalho+F%2C+Bastos+Mde+L&amp;rft.date=2012-08&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00204-012-0815-5&amp;rft_id=info%3Apmid%2F22392347&amp;rft.issue=8&amp;rft.jtitle=Arch.+Toxicol.&amp;rft.pages=1167-1231&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=86" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-AbuseAndAbnormalities-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-AbuseAndAbnormalities_25-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Berman S, O'Neill J, Fears S, Bartzokis G, London ED (October 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923">"Abuse of amphetamines and structural abnormalities in the brain"</a>. <i>Ann. N. Y. Acad. Sci.</i> <b>1141</b>: 195–220. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1196%2Fannals.1441.031">10.1196/annals.1441.031</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923">2769923</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18991959">18991959</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Abuse+of+amphetamines+and+structural+abnormalities+in+the+brain&amp;rft.au=Berman+S%2C+O%27Neill+J%2C+Fears+S%2C+Bartzokis+G%2C+London+ED&amp;rft.date=2008-10&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2769923&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2769923&amp;rft_id=info%3Adoi%2F10.1196%2Fannals.1441.031&amp;rft_id=info%3Apmid%2F18991959&amp;rft.jtitle=Ann.+N.+Y.+Acad.+Sci.&amp;rft.pages=195-220&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1141" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_1-26"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_1_26-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_1_26-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". <i>JAMA Psychiatry</i> <b>70</b> (2): 185–198. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1001%2Fjamapsychiatry.2013.277">10.1001/jamapsychiatry.2013.277</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23247506">23247506</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Meta-analysis+of+functional+magnetic+resonance+imaging+studies+of+inhibition+and+attention+in+attention-deficit%2Fhyperactivity+disorder%3A+exploring+task-specific%2C+stimulant+medication%2C+and+age+effects&amp;rft.au=Hart+H%2C+Radua+J%2C+Nakao+T%2C+Mataix-Cols+D%2C+Rubia+K&amp;rft.date=2013-02&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Fjamapsychiatry.2013.277&amp;rft_id=info%3Apmid%2F23247506&amp;rft.issue=2&amp;rft.jtitle=JAMA+Psychiatry&amp;rft.pages=185-198&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=70" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_2-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_2_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_2_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446">"Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies"</a>. <i>J. Clin. Psychiatry</i> <b>74</b> (9): 902–917. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.4088%2FJCP.12r08287">10.4088/JCP.12r08287</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446">3801446</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24107764">24107764</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Effect+of+psychostimulants+on+brain+structure+and+function+in+ADHD%3A+a+qualitative+literature+review+of+magnetic+resonance+imaging-based+neuroimaging+studies&amp;rft.au=Spencer+TJ%2C+Brown+A%2C+Seidman+LJ%2C+Valera+EM%2C+Makris+N%2C+Lomedico+A%2C+Faraone+SV%2C+Biederman+J&amp;rft.date=2013-09&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3801446&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3801446&amp;rft_id=info%3Adoi%2F10.4088%2FJCP.12r08287&amp;rft_id=info%3Apmid%2F24107764&amp;rft.issue=9&amp;rft.jtitle=J.+Clin.+Psychiatry&amp;rft.pages=902-917&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_3-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_3_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_3_28-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects.". <i>Acta psychiatrica Scand.</i> <b>125</b> (2): 114–126. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1600-0447.2011.01786.x">10.1111/j.1600-0447.2011.01786.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22118249">22118249</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Meta-analysis+of+structural+MRI+studies+in+children+and+adults+with+attention+deficit+hyperactivity+disorder+indicates+treatment+effects.&amp;rft.au=Frodl+T%2C+Skokauskas+N&amp;rft.date=2012-02&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.2011.01786.x&amp;rft_id=info%3Apmid%2F22118249&amp;rft.issue=2&amp;rft.jtitle=Acta+psychiatrica+Scand.&amp;rft.pages=114-126&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=125" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Millichap-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-Millichap_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Millichap_29-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Millichap_29-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Millichap_29-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Millichap JG (2010). "Chapter 9: Medications for ADHD". In Millichap JG. <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York, USA: Springer. pp.&#160;121–123, 125–127. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781441913968" title="Special:BookSources/9781441913968">9781441913968</a>. <q>Ongoing research has provided answers to many of the parents’ concerns, and has confirmed the effectiveness and safety of the long-term use of medication.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+9%3A+Medications+for+ADHD&amp;rft.au=Millichap+JG&amp;rft.btitle=Attention+Deficit+Hyperactivity+Disorder+Handbook%3A+A+Physician%27s+Guide+to+ADHD&amp;rft.date=2010&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9781441913968&amp;rft.pages=121-123%2C+125-127&amp;rft.place=New+York%2C+USA&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Long-term_2015-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-Long-term_2015_30-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (February 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791">"Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review"</a>. <i>PLoS ONE</i> <b>10</b> (2): e0116407. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1371%2Fjournal.pone.0116407">10.1371/journal.pone.0116407</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791">4340791</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25714373">25714373</a>. <q>The highest proportion of improved outcomes was reported with combination treatment (83% of outcomes). Among significantly improved outcomes, the largest effect sizes were found for combination treatment. The greatest improvements were associated with academic, self-esteem, or social function outcomes.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Effect+of+treatment+modality+on+long-term+outcomes+in+attention-deficit%2Fhyperactivity+disorder%3A+a+systematic+review&amp;rft.au=Caci%2C+H&amp;rft.aufirst=LE&amp;rft.au=Hodgkins%2C+P&amp;rft.au=Kahle%2C+J&amp;rft.aulast=Arnold&amp;rft.au=Young%2C+S&amp;rft.date=2015-02&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4340791&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4340791&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0116407&amp;rft_id=info%3Apmid%2F25714373&amp;rft.issue=2&amp;rft.jtitle=PLoS+ONE&amp;rft.pages=e0116407&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Long-Term_Outcomes_Medications-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-Long-Term_Outcomes_Medications_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Long-Term_Outcomes_Medications_31-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Long-Term_Outcomes_Medications_31-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Huang YS, Tsai MH (July 2011). "Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge". <i>CNS Drugs</i> <b>25</b> (7): 539–554. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2165%2F11589380-000000000-00000">10.2165/11589380-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21699268">21699268</a>. <q>Recent studies have demonstrated that stimulants, along with the non-stimulants atomoxetine and extended-release guanfacine, are continuously effective for more than 2-year treatment periods with few and tolerable adverse effects.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Long-term+outcomes+with+medications+for+attention-deficit+hyperactivity+disorder%3A+current+status+of+knowledge&amp;rft.au=Huang+YS%2C+Tsai+MH&amp;rft.date=2011-07&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F11589380-000000000-00000&amp;rft_id=info%3Apmid%2F21699268&amp;rft.issue=7&amp;rft.jtitle=CNS+Drugs&amp;rft.pages=539-554&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-cognition_enhancers-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-cognition_enhancers_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cognition_enhancers_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Bidwell LC, McClernon FJ, Kollins SH (August 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150">"Cognitive enhancers for the treatment of ADHD"</a>. <i>Pharmacol. Biochem. Behav.</i> <b>99</b> (2): 262–274. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pbb.2011.05.002">10.1016/j.pbb.2011.05.002</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150">3353150</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21596055">21596055</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Cognitive+enhancers+for+the+treatment+of+ADHD&amp;rft.au=Bidwell+LC%2C+McClernon+FJ%2C+Kollins+SH&amp;rft.date=2011-08&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3353150&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3353150&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pbb.2011.05.002&amp;rft_id=info%3Apmid%2F21596055&amp;rft.issue=2&amp;rft.jtitle=Pharmacol.+Biochem.+Behav.&amp;rft.pages=262-274&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Long-term_36-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-Long-term_36_33-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Parker J, Wales G, Chalhoub N, Harpin V (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407">"The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials"</a>. <i>Psychol. Res. Behav. Manag.</i> <b>6</b>: 87–99. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2147%2FPRBM.S49114">10.2147/PRBM.S49114</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407">3785407</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24082796">24082796</a>. <q>Only one paper<sup>53</sup> examining outcomes beyond 36 months met the review criteria.&#160;... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+long-term+outcomes+of+interventions+for+the+management+of+attention-deficit+hyperactivity+disorder+in+children+and+adolescents%3A+a+systematic+review+of+randomized+controlled+trials&amp;rft.au=Chalhoub%2C+N&amp;rft.aufirst=J&amp;rft.au=Harpin%2C+V&amp;rft.aulast=Parker&amp;rft.au=Wales%2C+G&amp;rft.date=2013-09&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3785407&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3785407&amp;rft_id=info%3Adoi%2F10.2147%2FPRBM.S49114&amp;rft_id=info%3Apmid%2F24082796&amp;rft.jtitle=Psychol.+Res.+Behav.+Manag.&amp;rft.pages=87-99&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Millichap_3-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-Millichap_3_34-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Millichap JG (2010). "Chapter 9: Medications for ADHD". In Millichap JG. <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York, USA: Springer. pp.&#160;111–113. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781441913968" title="Special:BookSources/9781441913968">9781441913968</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+9%3A+Medications+for+ADHD&amp;rft.au=Millichap+JG&amp;rft.btitle=Attention+Deficit+Hyperactivity+Disorder+Handbook%3A+A+Physician%27s+Guide+to+ADHD&amp;rft.date=2010&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9781441913968&amp;rft.pages=111-113&amp;rft.place=New+York%2C+USA&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ADHD-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-ADHD_35-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder">"Stimulants for Attention Deficit Hyperactivity Disorder"</a>. <i>WebMD</i>. Healthwise. 12 April 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">12 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Stimulants+for+Attention+Deficit+Hyperactivity+Disorder&amp;rft.date=2010-04-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.webmd.com%2Fadd-adhd%2Fchildhood-adhd%2Fstimulants-for-attention-deficit-hyperactivity-disorder&amp;rft.jtitle=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16052183-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16052183_36-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Scholten RJ, Clarke M, Hetherington J (August 2005). "The Cochrane Collaboration". <i>Eur. J. Clin. Nutr</i>. 59 Suppl 1: S147–S149; discussion S195–S196. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.ejcn.1602188">10.1038/sj.ejcn.1602188</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16052183">16052183</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+Cochrane+Collaboration&amp;rft.au=Scholten+RJ%2C+Clarke+M%2C+Hetherington+J&amp;rft.date=2005-08&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.ejcn.1602188&amp;rft_id=info%3Apmid%2F16052183&amp;rft.jtitle=Eur.+J.+Clin.+Nutr.&amp;rft.pages=S147-S149%3B+discussion+S195-S196&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59+Suppl+1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_Amphetamines_ADHD-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_Amphetamines_ADHD_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_Amphetamines_ADHD_38-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M (June 2011). Castells X, ed. "Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults". <i>Cochrane Database Syst. Rev.</i> (6): CD007813. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD007813.pub2">10.1002/14651858.CD007813.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21678370">21678370</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamines+for+Attention+Deficit+Hyperactivity+Disorder+%28ADHD%29+in+adults&amp;rft.au=Castells+X%2C+Ramos-Quiroga+JA%2C+Bosch+R%2C+Nogueira+M%2C+Casas+M&amp;rft.date=2011-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007813.pub2&amp;rft_id=info%3Apmid%2F21678370&amp;rft.issue=6&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD007813&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation journal">Pringsheim T, Steeves T (April 2011). Pringsheim T, ed. "Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders". <i>Cochrane Database Syst. Rev.</i> (4): CD007990. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD007990.pub2">10.1002/14651858.CD007990.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21491404">21491404</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Pharmacological+treatment+for+Attention+Deficit+Hyperactivity+Disorder+%28ADHD%29+in+children+with+comorbid+tic+disorders&amp;rft.au=Pringsheim+T%2C+Steeves+T&amp;rft.date=2011-04&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007990.pub2&amp;rft_id=info%3Apmid%2F21491404&amp;rft.issue=4&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD007990&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Adderall_XR_all_pages-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-Adderall_XR_all_pages_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Adderall_XR_all_pages_40-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Adderall_XR_all_pages_40-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Adderall_XR_all_pages_40-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MMX-PMH-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-MMX-PMH_41-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Truven Health Analytics. <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0008973/?report=details">"Amphetamine/Dextroamphetamine (By mouth)"</a>. <i>PubMed Health</i>. Micromedex Consumer Medication Information<span class="reference-accessdate">. Retrieved <span class="nowrap">4 September</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine%2FDextroamphetamine+%28By+mouth%29&amp;rft.au=Truven+Health+Analytics&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmedhealth%2FPMHT0008973%2F%3Freport%3Ddetails&amp;rft.jtitle=PubMed+Health&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Unambiguous_PFC_D1_A2-42"><span class="mw-cite-backlink">^ <a href="#cite_ref-Unambiguous_PFC_D1_A2_42-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Unambiguous_PFC_D1_A2_42-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Spencer RC, Devilbiss DM, Berridge CW (June 2015). "The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex". <i>Biol. Psychiatry</i> <b>77</b> (11): 940–950. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.biopsych.2014.09.013">10.1016/j.biopsych.2014.09.013</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25499957">25499957</a>. <q>The procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants has only recently been systematically investigated. Findings from this research unambiguously demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2 and dopamine D1 receptors.&#160;... This differential modulation of PFC-dependent processes across dose appears to be associated with the differential involvement of noradrenergic α2 versus α1 receptors. Collectively, this evidence indicates that at low, clinically relevant doses, psychostimulants are devoid of the behavioral and neurochemical actions that define this class of drugs and instead act largely as cognitive enhancers (improving PFC-dependent function). This information has potentially important clinical implications as well as relevance for public health policy regarding the widespread clinical use of psychostimulants and for the development of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other conditions associated with PFC dysregulation.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+Cognition-Enhancing+Effects+of+Psychostimulants+Involve+Direct+Action+in+the+Prefrontal+Cortex&amp;rft.au=Berridge%2C+CW&amp;rft.au=Devilbiss%2C+DM&amp;rft.aufirst=RC&amp;rft.aulast=Spencer&amp;rft.date=2015-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.biopsych.2014.09.013&amp;rft_id=info%3Apmid%2F25499957&amp;rft.issue=11&amp;rft.jtitle=Biol.+Psychiatry&amp;rft.pages=940-950&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=77" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cognitive_and_motivational_effects-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-Cognitive_and_motivational_effects_43-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ilieva IP, Hook CJ, Farah MJ (January 2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". <i>J. Cogn. Neurosci.</i>: 1–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1162%2Fjocn_a_00776">10.1162/jocn_a_00776</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25591060">25591060</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Prescription+Stimulants%27+Effects+on+Healthy+Inhibitory+Control%2C+Working+Memory%2C+and+Episodic+Memory%3A+A+Meta-analysis&amp;rft.au=Farah%2C+MJ&amp;rft.aufirst=IP&amp;rft.au=Hook%2C+CJ&amp;rft.aulast=Ilieva&amp;rft.date=2015-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1162%2Fjocn_a_00776&amp;rft_id=info%3Apmid%2F25591060&amp;rft.jtitle=J.+Cogn.+Neurosci.&amp;rft.pages=1-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11337538-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11337538_44-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Devous MD, Trivedi MH, Rush AJ (April 2001). "Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers". <i>J. Nucl. Med.</i> <b>42</b> (4): 535–542. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11337538">11337538</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Regional+cerebral+blood+flow+response+to+oral+amphetamine+challenge+in+healthy+volunteers&amp;rft.au=Devous+MD%2C+Trivedi+MH%2C+Rush+AJ&amp;rft.date=2001-04&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F11337538&amp;rft.issue=4&amp;rft.jtitle=J.+Nucl.+Med.&amp;rft.pages=535-542&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_NAcc-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-Malenka_NAcc_45-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 10: Neural and Neuroendocrine Control of the Internal Milieu". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.&#160;266. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. <q>Dopamine acts in the nucleus accumbens to attach motivational significance to stimuli associated with reward.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+10%3A+Neural+and+Neuroendocrine+Control+of+the+Internal+Milieu&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=266&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Continuum-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-Continuum_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Continuum_46-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Continuum_46-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). "Psychostimulants and cognition: a continuum of behavioral and cognitive activation". <i>Pharmacol. Rev.</i> <b>66</b> (1): 193–221. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1124%2Fpr.112.007054">10.1124/pr.112.007054</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24344115">24344115</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Psychostimulants+and+cognition%3A+a+continuum+of+behavioral+and+cognitive+activation&amp;rft.au=Wood+S%2C+Sage+JR%2C+Shuman+T%2C+Anagnostaras+SG&amp;rft.date=2014-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1124%2Fpr.112.007054&amp;rft_id=info%3Apmid%2F24344115&amp;rft.issue=1&amp;rft.jtitle=Pharmacol.+Rev.&amp;rft.pages=193-221&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=66" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Test_taking_aid-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-Test_taking_aid_47-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Twohey M (26 March 2006). <a rel="nofollow" class="external text" href="https://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902">"Pills become an addictive study aid"</a>. <i>JS Online</i>. Archived from <a rel="nofollow" class="external text" href="http://www.jsonline.com/story/index.aspx?id=410902">the original</a> on 15 August 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Pills+become+an+addictive+study+aid&amp;rft.au=Twohey+M&amp;rft.date=2006-03-26&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.jsonline.com%2Fstory%2Findex.aspx%3Fid%3D410902&amp;rft.jtitle=JS+Online&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16999660-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16999660_48-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223">"Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration"</a>. <i>Pharmacotherapy</i> <b>26</b> (10): 1501–1510. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1592%2Fphco.26.10.1501">10.1592/phco.26.10.1501</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223">1794223</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16999660">16999660</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Illicit+use+of+specific+prescription+stimulants+among+college+students%3A+prevalence%2C+motives%2C+and+routes+of+administration&amp;rft.au=Teter+CJ%2C+McCabe+SE%2C+LaGrange+K%2C+Cranford+JA%2C+Boyd+CJ&amp;rft.date=2006-10&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1794223&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1794223&amp;rft_id=info%3Adoi%2F10.1592%2Fphco.26.10.1501&amp;rft_id=info%3Apmid%2F16999660&amp;rft.issue=10&amp;rft.jtitle=Pharmacotherapy&amp;rft.pages=1501-1510&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Diversion_prevalence_1-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-Diversion_prevalence_1_49-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, Kuhar B (September 2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338">"Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants"</a>. <i>Psychol. Res. Behav. Manag.</i> <b>7</b>: 223–249. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2147%2FPRBM.S47013">10.2147/PRBM.S47013</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338">4164338</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25228824">25228824</a>. <q>misuse of prescription stimulants has become a serious problem on college campuses across the US and has been recently documented in other countries as well.&#160;... Indeed, large numbers of students claim to have engaged in the nonmedical use of prescription stimulants, which is reflected in lifetime prevalence rates of prescription stimulant misuse ranging from 5% to nearly 34% of students.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Pharmacological+interventions+for+adolescents+and+adults+with+ADHD%3A+stimulant+and+nonstimulant+medications+and+misuse+of+prescription+stimulants&amp;rft.aufirst=LL&amp;rft.au=Gudmundsdottir%2C+BG&amp;rft.au=Kuhar%2C+B&amp;rft.aulast=Weyandt&amp;rft.au=Marraccini%2C+ME&amp;rft.au=Munro%2C+BA&amp;rft.au=Oster%2C+DR&amp;rft.au=Zavras%2C+BM&amp;rft.date=2014-09&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4164338&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4164338&amp;rft_id=info%3Adoi%2F10.2147%2FPRBM.S47013&amp;rft_id=info%3Apmid%2F25228824&amp;rft.jtitle=Psychol.+Res.+Behav.+Manag.&amp;rft.pages=223-249&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Diversion_prevalence_2-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-Diversion_prevalence_2_50-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Clemow DB, Walker DJ (September 2014). "The potential for misuse and abuse of medications in ADHD: a review". <i>Postgrad. Med.</i> <b>126</b> (5): 64–81. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3810%2Fpgm.2014.09.2801">10.3810/pgm.2014.09.2801</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25295651">25295651</a>. <q>Overall, the data suggest that ADHD medication misuse and diversion are common health care problems for stimulant medications, with the prevalence believed to be approximately 5% to 10% of high school students and 5% to 35% of college students, depending on the study.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=The+potential+for+misuse+and+abuse+of+medications+in+ADHD%3A+a+review&amp;rft.aufirst=DB&amp;rft.aulast=Clemow&amp;rft.au=Walker%2C+DJ&amp;rft.date=2014-09&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3810%2Fpgm.2014.09.2801&amp;rft_id=info%3Apmid%2F25295651&amp;rft.issue=5&amp;rft.jtitle=Postgrad.+Med.&amp;rft.pages=64-81&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=126" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ergogenics-51"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ergogenics_51-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ergogenics_51-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ergogenics_51-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Liddle DG, Connor DJ (June 2013). "Nutritional supplements and ergogenic AIDS". <i>Prim. Care</i> <b>40</b> (2): 487–505. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pop.2013.02.009">10.1016/j.pop.2013.02.009</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23668655">23668655</a>. <q>Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training&#160;...<br />
Physiologic and performance effects<br />
&#160;• Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation<br />
&#160;• Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40<br />
&#160;• Improved reaction time<br />
&#160;• Increased muscle strength and delayed muscle fatigue<br />
&#160;• Increased acceleration<br />
&#160;• Increased alertness and attention to task</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Nutritional+supplements+and+ergogenic+AIDS&amp;rft.au=Liddle+DG%2C+Connor+DJ&amp;rft.date=2013-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pop.2013.02.009&amp;rft_id=info%3Apmid%2F23668655&amp;rft.issue=2&amp;rft.jtitle=Prim.+Care&amp;rft.pages=487-505&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=40" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCAA-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-NCAA_52-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Bracken NM (January 2012). <a rel="nofollow" class="external text" href="http://www.ncaapublications.com/productdownloads/SAHS09.pdf">"National Study of Substance Use Trends Among NCAA College Student-Athletes"</a> <span style="font-size:85%;">(PDF)</span>. <i>NCAA Publications</i>. National Collegiate Athletic Association<span class="reference-accessdate">. Retrieved <span class="nowrap">8 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=National+Study+of+Substance+Use+Trends+Among+NCAA+College+Student-Athletes&amp;rft.au=Bracken+NM&amp;rft.date=2012-01&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.ncaapublications.com%2Fproductdownloads%2FSAHS09.pdf&amp;rft.jtitle=NCAA+Publications&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-WADA_.26_AD_regulation-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-WADA_.26_AD_regulation_53-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Docherty JR (June 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527">"Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)"</a>. <i>Br. J. Pharmacol.</i> <b>154</b> (3): 606–622. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fbjp.2008.124">10.1038/bjp.2008.124</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527">2439527</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18500382">18500382</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Pharmacology+of+stimulants+prohibited+by+the+World+Anti-Doping+Agency+%28WADA%29&amp;rft.au=Docherty+JR&amp;rft.date=2008-06&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2439527&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2439527&amp;rft_id=info%3Adoi%2F10.1038%2Fbjp.2008.124&amp;rft_id=info%3Apmid%2F18500382&amp;rft.issue=3&amp;rft.jtitle=Br.+J.+Pharmacol.&amp;rft.pages=606-622&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=154" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ergogenics2-54"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ergogenics2_54-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ergogenics2_54-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ergogenics2_54-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Ergogenics2_54-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Parr JW (July 2011). "Attention-deficit hyperactivity disorder and the athlete: new advances and understanding". <i>Clin. Sports Med.</i> <b>30</b> (3): 591–610. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.csm.2011.03.007">10.1016/j.csm.2011.03.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21658550">21658550</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Attention-deficit+hyperactivity+disorder+and+the+athlete%3A+new+advances+and+understanding&amp;rft.au=Parr+JW&amp;rft.date=2011-07&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.csm.2011.03.007&amp;rft_id=info%3Apmid%2F21658550&amp;rft.issue=3&amp;rft.jtitle=Clin.+Sports+Med.&amp;rft.pages=591-610&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Roelands_2013-55"><span class="mw-cite-backlink">^ <a href="#cite_ref-Roelands_2013_55-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Roelands_2013_55-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Roelands_2013_55-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). "Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing". <i>Sports Med.</i> <b>43</b> (5): 301–311. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs40279-013-0030-4">10.1007/s40279-013-0030-4</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23456493">23456493</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Neurophysiological+determinants+of+theoretical+concepts+and+mechanisms+involved+in+pacing&amp;rft.au=Roelands+B%2C+de+Koning+J%2C+Foster+C%2C+Hettinga+F%2C+Meeusen+R&amp;rft.date=2013-05&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs40279-013-0030-4&amp;rft_id=info%3Apmid%2F23456493&amp;rft.issue=5&amp;rft.jtitle=Sports+Med.&amp;rft.pages=301-311&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=43" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph-DA_reaction_time-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-Amph-DA_reaction_time_56-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Parker KL, Lamichhane D, Caetano MS, Narayanan NS (October 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949">"Executive dysfunction in Parkinson's disease and timing deficits"</a>. <i>Front. Integr. Neurosci.</i> <b>7</b>: 75. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3389%2Ffnint.2013.00075">10.3389/fnint.2013.00075</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949">3813949</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24198770">24198770</a>. <q>Manipulations of dopaminergic signaling profoundly influence interval timing, leading to the hypothesis that dopamine influences internal pacemaker, or “clock,” activity. For instance, amphetamine, which increases concentrations of dopamine at the synaptic cleft advances the start of responding during interval timing, whereas antagonists of D2 type dopamine receptors typically slow timing;... Depletion of dopamine in healthy volunteers impairs timing, while amphetamine releases synaptic dopamine and speeds up timing.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Executive+dysfunction+in+Parkinson%27s+disease+and+timing+deficits&amp;rft.au=Parker+KL%2C+Lamichhane+D%2C+Caetano+MS%2C+Narayanan+NS&amp;rft.date=2013-10&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3813949&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3813949&amp;rft_id=info%3Adoi%2F10.3389%2Ffnint.2013.00075&amp;rft_id=info%3Apmid%2F24198770&amp;rft.jtitle=Front.+Integr.+Neurosci.&amp;rft.pages=75&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Leon-57"><span class="mw-cite-backlink">^ <a href="#cite_ref-Leon_57-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Leon_57-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">Leon Moore, David. <a rel="nofollow" class="external text" href="http://www.usatoday.com/story/sports/nfl/2012/11/27/adderall-in-pro-sports/1730431/">"Do pro sports leagues have an Adderall problem?"</a>. USA TODAY<span class="reference-accessdate">. Retrieved <span class="nowrap">4 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.aufirst=David&amp;rft.aulast=Leon+Moore&amp;rft.btitle=Do+pro+sports+leagues+have+an+Adderall+problem%3F&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.usatoday.com%2Fstory%2Fsports%2Fnfl%2F2012%2F11%2F27%2Fadderall-in-pro-sports%2F1730431%2F&amp;rft.pub=USA+TODAY&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs/commonly-abused-prescription-drugs-chart">"Commonly Abused Prescription Drugs Chart"</a>. National Institute on Drug Abuse<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Commonly+Abused+Prescription+Drugs+Chart&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fdrugs-abuse%2Fcommonly-abused-drugs%2Fcommonly-abused-prescription-drugs-chart&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.drugabuse.gov/publications/infofacts/stimulant-adhd-medications-methylphenidate-amphetamines">"Stimulant ADHD Medications – Methylphenidate and Amphetamines"</a>. National Institute on Drug Abuse<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Stimulant+ADHD+Medications+%93+Methylphenidate+and+Amphetamines&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fpublications%2Finfofacts%2Fstimulant-adhd-medications-methylphenidate-amphetamines&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NIDA-60"><span class="mw-cite-backlink">^ <a href="#cite_ref-NIDA_60-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NIDA_60-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-methylphenidate-amphetamines">"National Institute on Drug Abuse. 2009. Stimulant ADHD Medications – Methylphenidate and Amphetamines"</a>. National Institute on Drug Abuse<span class="reference-accessdate">. Retrieved <span class="nowrap">27 February</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=National+Institute+on+Drug+Abuse.+2009.+Stimulant+ADHD+Medications+%93+Methylphenidate+and+Amphetamines&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fpublications%2Fdrugfacts%2Fstimulant-adhd-medications-methylphenidate-amphetamines&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8545689-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid8545689_61-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kessler S (January 1996). "Drug therapy in attention-deficit hyperactivity disorder". <i>South. Med. J.</i> <b>89</b> (1): 33–38. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2F00007611-199601000-00005">10.1097/00007611-199601000-00005</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8545689">8545689</a>. <q>statements on package inserts are not intended to limit medical practice. Rather they are intended to limit claims by pharmaceutical companies.&#160;... the FDA asserts explicitly, and the courts have upheld that clinical decisions are to be made by physicians and patients in individual situations.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Drug+therapy+in+attention-deficit+hyperactivity+disorder&amp;rft.aufirst=S&amp;rft.aulast=Kessler&amp;rft.date=1996-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F00007611-199601000-00005&amp;rft_id=info%3Apmid%2F8545689&amp;rft.issue=1&amp;rft.jtitle=South.+Med.+J.&amp;rft.pages=33-38&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Contra_Warnings-64"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Contra_Warnings_64-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.&#160;4–6<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=4-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-International-65"><span class="mw-cite-backlink">^ <a href="#cite_ref-International_65-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-International_65-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-International_65-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-International_65-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-International_65-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-International_65-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-International_65-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-International_65-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-International_65-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-International_65-9"><sup><i><b>j</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">Heedes G, Ailakis J. <a rel="nofollow" class="external text" href="http://www.inchem.org/documents/pims/pharm/pim934.htm">"Amphetamine (PIM 934)"</a>. <i>INCHEM</i>. International Programme on Chemical Safety<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine+%28PIM+934%29&amp;rft.au=Heedes+G%2C+Ailakis+J&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.inchem.org%2Fdocuments%2Fpims%2Fpharm%2Fpim934.htm&amp;rft.jtitle=INCHEM&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Dexedrine_FDA-66"><span class="mw-cite-backlink">^ <a href="#cite_ref-Dexedrine_FDA_66-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Dexedrine_FDA_66-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017078s047lbl.pdf">"Dexedrine Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Amedra Pharmaceuticals LLC. October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">4 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Dexedrine+Prescribing+Information&amp;rft.date=2013-10&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F017078s047lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Review_MAOI-amph-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-Review_MAOI-amph_67-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Feinberg SS (November 2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". <i>J. Clin. Psychiatry</i> <b>65</b> (11): 1520–1524. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.4088%2Fjcp.v65n1113">10.4088/jcp.v65n1113</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15554766">15554766</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Combining+stimulants+with+monoamine+oxidase+inhibitors%3A+a+review+of+uses+and+one+possible+additional+indication&amp;rft.aufirst=SS&amp;rft.aulast=Feinberg&amp;rft.date=2004-11&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.4088%2Fjcp.v65n1113&amp;rft_id=info%3Apmid%2F15554766&amp;rft.issue=11&amp;rft.jtitle=J.+Clin.+Psychiatry&amp;rft.pages=1520-1524&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=65" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Primary_MAOI-amph-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-Primary_MAOI-amph_68-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Stewart JW, Deliyannides DA, McGrath PJ (June 2014). "How treatable is refractory depression?". <i>J. Affect. Disord.</i> <b>167</b>: 148–152. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.jad.2014.05.047">10.1016/j.jad.2014.05.047</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24972362">24972362</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=How+treatable+is+refractory+depression%3F&amp;rft.au=Deliyannides%2C+DA&amp;rft.aufirst=JW&amp;rft.aulast=Stewart&amp;rft.au=McGrath%2C+PJ&amp;rft.date=2014-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jad.2014.05.047&amp;rft_id=info%3Apmid%2F24972362&amp;rft.jtitle=J.+Affect.+Disord.&amp;rft.pages=148-152&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=167" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18295156-69"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid18295156_69-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18295156_69-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid18295156_69-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid18295156_69-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Vitiello B (April 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826">"Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function"</a>. <i>Child Adolesc. Psychiatr. Clin. N. Am.</i> <b>17</b> (2): 459–474. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.chc.2007.11.010">10.1016/j.chc.2007.11.010</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826">2408826</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18295156">18295156</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Understanding+the+risk+of+using+medications+for+attention+deficit+hyperactivity+disorder+with+respect+to+physical+growth+and+cardiovascular+function&amp;rft.au=Vitiello+B&amp;rft.date=2008-04&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2408826&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2408826&amp;rft_id=info%3Adoi%2F10.1016%2Fj.chc.2007.11.010&amp;rft_id=info%3Apmid%2F18295156&amp;rft.issue=2&amp;rft.jtitle=Child+Adolesc.+Psychiatr.+Clin.+N.+Am.&amp;rft.pages=459-474&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Dyanavel-71"><span class="mw-cite-backlink">^ <a href="#cite_ref-Dyanavel_71-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Dyanavel_71-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Dyanavel_71-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Dyanavel_71-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Dyanavel_71-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Dyanavel_71-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.trispharma.com/DXRUSPI.pdf">"Dyanavel XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. Tris Pharmaceuticals. October 2015. pp.&#160;1–16<span class="reference-accessdate">. Retrieved <span class="nowrap">23 November</span> 2015</span>. <q>DYANAVEL XR contains <span class="nowrap">d-amphetamine</span> and <span class="nowrap">l-amphetamine</span> in a ratio of 3.2 to 1&#160;... The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6–12 years) were: epistaxis, allergic rhinitis and upper abdominal pain.&#160;...<br />
DOSAGE FORMS AND STRENGTHS<br />
Extended-release oral suspension contains 2.5 mg amphetamine base per mL.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Dyanavel+XR+Prescribing+Information&amp;rft.date=2015-10&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.trispharma.com%2FDXRUSPI.pdf&amp;rft.pages=1-16&amp;rft.pub=Tris+Pharmaceuticals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-rhinitis-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-rhinitis_72-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ramey JT, Bailen E, Lockey RF (2006). <a rel="nofollow" class="external text" href="http://www.jiaci.org/issues/vol16issue03/1.pdf">"Rhinitis medicamentosa"</a> <span style="font-size:85%;">(PDF)</span>. <i>J. Investig. Allergol. Clin. Immunol.</i> <b>16</b> (3): 148–155. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16784007">16784007</a><span class="reference-accessdate">. Retrieved <span class="nowrap">29 April</span> 2015</span>. <q>Table 2. Decongestants Causing Rhinitis Medicamentosa<br />
– Nasal decongestants:<br />
&#160; – Sympathomimetic:<br />
&#160;&#160; • Amphetamine</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Rhinitis+medicamentosa&amp;rft.au=Bailen%2C+E&amp;rft.aufirst=JT&amp;rft.aulast=Ramey&amp;rft.au=Lockey%2C+RF&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.jiaci.org%2Fissues%2Fvol16issue03%2F1.pdf&amp;rft_id=info%3Apmid%2F16784007&amp;rft.issue=3&amp;rft.jtitle=J.+Investig.+Allergol.+Clin.+Immunol.&amp;rft.pages=148-155&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults"</a>. <i>United States Food and Drug Administration</i>. 20 December 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">4 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=FDA+Drug+Safety+Communication%3A+Safety+Review+Update+of+Medications+used+to+treat+Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29+in+children+and+young+adults&amp;rft.date=2011-12-20&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm277770.htm&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22043968-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22043968_75-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (November 2011). "ADHD drugs and serious cardiovascular events in children and young adults". <i>N. Engl. J. Med.</i> <b>365</b> (20): 1896–1904. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa1110212">10.1056/NEJMoa1110212</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22043968">22043968</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=ADHD+drugs+and+serious+cardiovascular+events+in+children+and+young+adults&amp;rft.au=Cooper+WO%2C+Habel+LA%2C+Sox+CM%2C+Chan+KA%2C+Arbogast+PG%2C+Cheetham+TC%2C+Murray+KT%2C+Quinn+VP%2C+Stein+CM%2C+Callahan+ST%2C+Fireman+BH%2C+Fish+FA%2C+Kirshner+HS%2C+O%27Duffy+A%2C+Connell+FA%2C+Ray+WA&amp;rft.date=2011-11&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1110212&amp;rft_id=info%3Apmid%2F22043968&amp;rft.issue=20&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1896-1904&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=365" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/DrugSafety/ucm279858.htm">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults"</a>. <i>United States Food and Drug Administration</i>. 15 December 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">4 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=FDA+Drug+Safety+Communication%3A+Safety+Review+Update+of+Medications+used+to+treat+Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29+in+adults&amp;rft.date=2011-12-15&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm279858.htm&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22161946-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22161946_77-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (December 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308">"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults"</a>. <i>JAMA</i> <b>306</b> (24): 2673–2683. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1001%2Fjama.2011.1830">10.1001/jama.2011.1830</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308">3350308</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22161946">22161946</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=ADHD+medications+and+risk+of+serious+cardiovascular+events+in+young+and+middle-aged+adults&amp;rft.au=Habel+LA%2C+Cooper+WO%2C+Sox+CM%2C+Chan+KA%2C+Fireman+BH%2C+Arbogast+PG%2C+Cheetham+TC%2C+Quinn+VP%2C+Dublin+S%2C+Boudreau+DM%2C+Andrade+SE%2C+Pawloski+PA%2C+Raebel+MA%2C+Smith+DH%2C+Achacoso+N%2C+Uratsu+C%2C+Go+AS%2C+Sidney+S%2C+Nguyen-Huynh+MN%2C+Ray+WA%2C+Selby+JV&amp;rft.date=2011-12&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3350308&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3350308&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2011.1830&amp;rft_id=info%3Apmid%2F22161946&amp;rft.issue=24&amp;rft.jtitle=JAMA&amp;rft.pages=2673-2683&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=306" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Merck_Manual_Amphetamines-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-Merck_Manual_Amphetamines_79-0">^</a></b></span> <span class="reference-text"><cite class="citation web">O'Connor PG (February 2012). <a rel="nofollow" class="external text" href="http://www.merckmanuals.com/professional/special_subjects/drug_use_and_dependence/amphetamines.html">"Amphetamines"</a>. <i>Merck Manual for Health Care Professionals</i>. Merck<span class="reference-accessdate">. Retrieved <span class="nowrap">8 May</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamines&amp;rft.au=O%27Connor+PG&amp;rft.date=2012-02&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fprofessional%2Fspecial_subjects%2Fdrug_use_and_dependence%2Famphetamines.html&amp;rft.jtitle=Merck+Manual+for+Health+Care+Professionals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Human_CPP-81"><span class="mw-cite-backlink">^ <a href="#cite_ref-Human_CPP_81-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Human_CPP_81-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Childs E, de Wit H (May 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956">"Amphetamine-induced place preference in humans"</a>. <i>Biol. Psychiatry</i> <b>65</b> (10): 900–904. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.biopsych.2008.11.016">10.1016/j.biopsych.2008.11.016</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956">2693956</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19111278">19111278</a>. <q>This study demonstrates that humans, like nonhumans, prefer a place associated with amphetamine administration. These findings support the idea that subjective responses to a drug contribute to its ability to establish place conditioning.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine-induced+place+preference+in+humans&amp;rft.au=de+Wit%2C+H&amp;rft.aufirst=E&amp;rft.aulast=Childs&amp;rft.date=2009-05&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2693956&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2693956&amp;rft_id=info%3Adoi%2F10.1016%2Fj.biopsych.2008.11.016&amp;rft_id=info%3Apmid%2F19111278&amp;rft.issue=10&amp;rft.jtitle=Biol.+Psychiatry&amp;rft.pages=900-904&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=65" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Addiction_glossary-82"><span class="mw-cite-backlink">^ <a href="#cite_ref-Addiction_glossary_82-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Addiction_glossary_82-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.&#160;364–375. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+Addictive+Disorders&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=364-375&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amphetamine_toxidrome-83"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amphetamine_toxidrome_83-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amphetamine_toxidrome_83-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Spiller HA, Hays HL, Aleguas A (June 2013). "Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management". <i>CNS Drugs</i> <b>27</b> (7): 531–543. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs40263-013-0084-8">10.1007/s40263-013-0084-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23757186">23757186</a>. <q>Amphetamine, dextroamphetamine, and methylphenidate act as substrates for the cellular monoamine transporter, especially the dopamine transporter (DAT) and less so the norepinephrine (NET) and serotonin transporter. The mechanism of toxicity is primarily related to excessive extracellular dopamine, norepinephrine, and serotonin.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Overdose+of+drugs+for+attention-deficit+hyperactivity+disorder%3A+clinical+presentation%2C+mechanisms+of+toxicity%2C+and+management&amp;rft.au=Spiller+HA%2C+Hays+HL%2C+Aleguas+A&amp;rft.date=2013-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs40263-013-0084-8&amp;rft_id=info%3Apmid%2F23757186&amp;rft.issue=7&amp;rft.jtitle=CNS+Drugs&amp;rft.pages=531-543&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-GDB2013-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-GDB2013_85-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Collaborators (2015). <a rel="nofollow" class="external text" href="http://www.thelancet.com/cms/attachment/2023546115/2043770889/mmc1.pdf">"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013"</a> <span style="font-size:85%;">(PDF)</span>. <i>Lancet</i> <b>385</b> (9963): 117–171. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2814%2961682-2">10.1016/S0140-6736(14)61682-2</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604">4340604</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25530442">25530442</a><span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2015</span>. <q>Amphetamine use disorders&#160;... 3,788&#160;(3,425–4,145)</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Global%2C+regional%2C+and+national+age-sex+specific+all-cause+and+cause-specific+mortality+for+240+causes+of+death%2C+1990%932013%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2013&amp;rft.au=Collaborators&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4340604&amp;rft_id=http%3A%2F%2Fwww.thelancet.com%2Fcms%2Fattachment%2F2023546115%2F2043770889%2Fmmc1.pdf&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2814%2961682-2&amp;rft_id=info%3Apmid%2F25530442&amp;rft.issue=9963&amp;rft.jtitle=Lancet&amp;rft.pages=117-171&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=385" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amphetamine_KEGG_.E2.80.93_.CE.94FosB-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-Amphetamine_KEGG_.E2.80.93_.CE.94FosB_86-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Kanehisa Laboratories (10 October 2014). <a rel="nofollow" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05031">"Amphetamine – Homo sapiens (human)"</a>. <i>KEGG Pathway</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine+%93+Homo+sapiens+%28human%29&amp;rft.au=Kanehisa+Laboratories&amp;rft.date=2014-10-10&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.genome.jp%2Fkegg-bin%2Fshow_pathway%3Fhsa05031&amp;rft.jtitle=KEGG+Pathway&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Magnesium-87"><span class="mw-cite-backlink">^ <a href="#cite_ref-Magnesium_87-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Magnesium_87-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Magnesium_87-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Magnesium_87-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Magnesium_87-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Magnesium_87-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Nechifor M (March 2008). "Magnesium in drug dependences". <i>Magnes. Res.</i> <b>21</b> (1): 5–15. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18557129">18557129</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Magnesium+in+drug+dependences&amp;rft.au=Nechifor+M&amp;rft.date=2008-03&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F18557129&amp;rft.issue=1&amp;rft.jtitle=Magnes.+Res.&amp;rft.pages=5-15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-What_the_.CE.94FosB.3F-88"><span class="mw-cite-backlink">^ <a href="#cite_ref-What_the_.CE.94FosB.3F_88-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-What_the_.CE.94FosB.3F_88-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-What_the_.CE.94FosB.3F_88-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-What_the_.CE.94FosB.3F_88-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-What_the_.CE.94FosB.3F_88-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Ruffle JK (November 2014). "Molecular neurobiology of addiction: what's all the (Δ)FosB about?". <i>Am. J. Drug Alcohol Abuse</i> <b>40</b> (6): 428–437. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3109%2F00952990.2014.933840">10.3109/00952990.2014.933840</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25083822">25083822</a>. <q>ΔFosB is an essential transcription factor implicated in the molecular and behavioral pathways of addiction following repeated drug exposure.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Molecular+neurobiology+of+addiction%3A+what%27s+all+the+%28%CE%94%29FosB+about%3F&amp;rft.au=Ruffle+JK&amp;rft.date=2014-11&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3109%2F00952990.2014.933840&amp;rft_id=info%3Apmid%2F25083822&amp;rft.issue=6&amp;rft.jtitle=Am.+J.+Drug+Alcohol+Abuse&amp;rft.pages=428-437&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=40" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cellular_basis-89"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cellular_basis_89-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cellular_basis_89-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cellular_basis_89-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cellular_basis_89-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Cellular_basis_89-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Nestler EJ (December 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681">"Cellular basis of memory for addiction"</a>. <i>Dialogues Clin. Neurosci.</i> <b>15</b> (4): 431–443. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681">3898681</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24459410">24459410</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Cellular+basis+of+memory+for+addiction&amp;rft.au=Nestler+EJ&amp;rft.date=2013-12&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3898681&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3898681&amp;rft_id=info%3Apmid%2F24459410&amp;rft.issue=4&amp;rft.jtitle=Dialogues+Clin.+Neurosci.&amp;rft.pages=431-443&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler1-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nestler1_90-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Robison AJ, Nestler EJ (November 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i>Nat. Rev. Neurosci.</i> <b>12</b> (11): 623–637. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrn3111">10.1038/nrn3111</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277">3272277</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21989194">21989194</a>. <q>ΔFosB serves as one of the master control proteins governing this structural plasticity.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Transcriptional+and+epigenetic+mechanisms+of+addiction&amp;rft.au=Robison+AJ%2C+Nestler+EJ&amp;rft.date=2011-11&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=info%3Adoi%2F10.1038%2Fnrn3111&amp;rft_id=info%3Apmid%2F21989194&amp;rft.issue=11&amp;rft.jtitle=Nat.+Rev.+Neurosci.&amp;rft.pages=623-637&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Natural_and_drug_addictions-91"><span class="mw-cite-backlink">^ <a href="#cite_ref-Natural_and_drug_addictions_91-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Natural_and_drug_addictions_91-22"><sup><i><b>w</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Olsen CM (December 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704">"Natural rewards, neuroplasticity, and non-drug addictions"</a>. <i>Neuropharmacology</i> <b>61</b> (7): 1109–1122. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.neuropharm.2011.03.010">10.1016/j.neuropharm.2011.03.010</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704">3139704</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21459101">21459101</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Natural+rewards%2C+neuroplasticity%2C+and+non-drug+addictions&amp;rft.au=Olsen+CM&amp;rft.date=2011-12&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3139704&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3139704&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2011.03.010&amp;rft_id=info%3Apmid%2F21459101&amp;rft.issue=7&amp;rft.jtitle=Neuropharmacology&amp;rft.pages=1109-1122&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Running_vs_addiction-92"><span class="mw-cite-backlink">^ <a href="#cite_ref-Running_vs_addiction_92-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Running_vs_addiction_92-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Running_vs_addiction_92-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Running_vs_addiction_92-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Running_vs_addiction_92-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047">"Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis"</a>. <i>Neurosci. Biobehav. Rev.</i> <b>37</b> (8): 1622–1644. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.neubiorev.2013.06.011">10.1016/j.neubiorev.2013.06.011</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047">3788047</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23806439">23806439</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Exercise+as+a+novel+treatment+for+drug+addiction%3A+a+neurobiological+and+stage-dependent+hypothesis&amp;rft.au=Lynch+WJ%2C+Peterson+AB%2C+Sanchez+V%2C+Abel+J%2C+Smith+MA&amp;rft.date=2013-09&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788047&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788047&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2013.06.011&amp;rft_id=info%3Apmid%2F23806439&amp;rft.issue=8&amp;rft.jtitle=Neurosci.+Biobehav.+Rev.&amp;rft.pages=1622-1644&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=37" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Exercise_Rev_3-93"><span class="mw-cite-backlink">^ <a href="#cite_ref-Exercise_Rev_3_93-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Exercise_Rev_3_93-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Exercise_Rev_3_93-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Exercise_Rev_3_93-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Linke SE, Ussher M (January 2015). "Exercise-based treatments for substance use disorders: evidence, theory, and practicality". <i>Am. J. Drug Alcohol Abuse</i> <b>41</b> (1): 7–15. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3109%2F00952990.2014.976708">10.3109/00952990.2014.976708</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25397661">25397661</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Exercise-based+treatments+for+substance+use+disorders%3A+evidence%2C+theory%2C+and+practicality&amp;rft.aufirst=SE&amp;rft.aulast=Linke&amp;rft.au=Ussher%2C+M&amp;rft.date=2015-01&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3109%2F00952990.2014.976708&amp;rft_id=info%3Apmid%2F25397661&amp;rft.issue=1&amp;rft.jtitle=Am.+J.+Drug+Alcohol+Abuse&amp;rft.pages=7-15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=41" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler_CBT-94"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nestler_CBT_94-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nestler_CBT_94-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.&#160;386. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. <q>Currently, cognitive–behavioral therapies are the most successful treatment available for preventing the relapse of psychostimulant use.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+Addictive+Disorders&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=386&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Acute_amph_toxicity-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-Acute_amph_toxicity_95-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Greene SL, Kerr F, Braitberg G (October 2008). "Review article: amphetamines and related drugs of abuse". <i>Emerg. Med. Australas</i> <b>20</b> (5): 391–402. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1742-6723.2008.01114.x">10.1111/j.1742-6723.2008.01114.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18973636">18973636</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Review+article%3A+amphetamines+and+related+drugs+of+abuse&amp;rft.au=Greene+SL%2C+Kerr+F%2C+Braitberg+G&amp;rft.date=2008-10&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1742-6723.2008.01114.x&amp;rft_id=info%3Apmid%2F18973636&amp;rft.issue=5&amp;rft.jtitle=Emerg.+Med.+Australas&amp;rft.pages=391-402&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Albertson_2011-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-Albertson_2011_96-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Albertson TE (2011). "Amphetamines". In Olson KR, Anderson IB, Benowitz NL, Blanc PD, Kearney TE, Kim-Katz SY, Wu AHB. <i>Poisoning &amp; Drug Overdose</i> (6th ed.). New York: McGraw-Hill Medical. pp.&#160;77–79. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071668330" title="Special:BookSources/9780071668330">9780071668330</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamines&amp;rft.au=Albertson+TE&amp;rft.btitle=Poisoning+%26+Drug+Overdose&amp;rft.date=2011&amp;rft.edition=6th&amp;rft.genre=bookitem&amp;rft.isbn=9780071668330&amp;rft.pages=77-79&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler_Labs_Glossary-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nestler_Labs_Glossary_98-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://neuroscience.mssm.edu/nestler/glossary.html">"Glossary of Terms"</a>. <i>Mount Sinai School of Medicine</i>. Department of Neuroscience<span class="reference-accessdate">. Retrieved <span class="nowrap">9 February</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Glossary+of+Terms&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fneuroscience.mssm.edu%2Fnestler%2Fglossary.html&amp;rft.jtitle=Mount+Sinai+School+of+Medicine&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Addiction_risk-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-Addiction_risk_99-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kollins SH (May 2008). "A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders". <i>Curr. Med. Res. Opin.</i> <b>24</b> (5): 1345–1357. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1185%2F030079908X280707">10.1185/030079908X280707</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18384709">18384709</a>. <q>When oral formulations of psychostimulants are used at recommended doses and frequencies, they are unlikely to yield effects consistent with abuse potential in patients with ADHD.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=A+qualitative+review+of+issues+arising+in+the+use+of+psycho-stimulant+medications+in+patients+with+ADHD+and+co-morbid+substance+use+disorders&amp;rft.aufirst=SH&amp;rft.aulast=Kollins&amp;rft.date=2008-05&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1185%2F030079908X280707&amp;rft_id=info%3Apmid%2F18384709&amp;rft.issue=5&amp;rft.jtitle=Curr.+Med.+Res.+Opin.&amp;rft.pages=1345-1357&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html">"Amphetamines: Drug Use and Abuse"</a>. <i>Merck Manual Home Edition</i>. Merck. February 2003. Archived from <a rel="nofollow" class="external text" href="http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html">the original</a> on 17 February 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">28 February</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamines%3A+Drug+Use+and+Abuse&amp;rft.date=2003-02&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fhome%2Fspecial_subjects%2Fdrug_use_and_abuse%2Famphetamines.html&amp;rft.jtitle=Merck+Manual+Home+Edition&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text"><cite class="citation journal">Perez-Mana C, Castells X, Torrens M, Capella D, Farre M (September 2013). Pérez-Mañá C, ed. "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". <i>Cochrane Database Syst. Rev.</i> <b>9</b>: CD009695. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD009695.pub2">10.1002/14651858.CD009695.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23996457">23996457</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Efficacy+of+psychostimulant+drugs+for+amphetamine+abuse+or+dependence&amp;rft.au=Perez-Mana+C%2C+Castells+X%2C+Torrens+M%2C+Capella+D%2C+Farre+M&amp;rft.date=2013-09&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009695.pub2&amp;rft_id=info%3Apmid%2F23996457&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD009695&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_102-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Hyman SE, Malenka RC, Nestler EJ (July 2006). "Neural mechanisms of addiction: the role of reward-related learning and memory". <i>Annu. Rev. Neurosci.</i> <b>29</b>: 565–598. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1146%2Fannurev.neuro.29.051605.113009">10.1146/annurev.neuro.29.051605.113009</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16776597">16776597</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Neural+mechanisms+of+addiction%3A+the+role+of+reward-related+learning+and+memory&amp;rft.au=Hyman+SE%2C+Malenka+RC%2C+Nestler+EJ&amp;rft.date=2006-07&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.neuro.29.051605.113009&amp;rft_id=info%3Apmid%2F16776597&amp;rft.jtitle=Annu.+Rev.+Neurosci.&amp;rft.pages=565-598&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler-103"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nestler_103-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nestler_103-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Nestler_103-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Nestler_103-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Nestler_103-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Nestler_103-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Nestler_103-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Nestler_103-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Robison AJ, Nestler EJ (November 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i>Nat. Rev. Neurosci.</i> <b>12</b> (11): 623–637. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrn3111">10.1038/nrn3111</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277">3272277</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21989194">21989194</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Transcriptional+and+epigenetic+mechanisms+of+addiction&amp;rft.au=Robison+AJ%2C+Nestler+EJ&amp;rft.date=2011-11&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=info%3Adoi%2F10.1038%2Fnrn3111&amp;rft_id=info%3Apmid%2F21989194&amp;rft.issue=11&amp;rft.jtitle=Nat.+Rev.+Neurosci.&amp;rft.pages=623-637&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Addiction_genetics-104"><span class="mw-cite-backlink">^ <a href="#cite_ref-Addiction_genetics_104-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_104-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_104-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_104-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_104-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Steiner H, Van Waes V (January 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776">"Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants"</a>. <i>Prog. Neurobiol.</i> <b>100</b>: 60–80. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pneurobio.2012.10.001">10.1016/j.pneurobio.2012.10.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776">3525776</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23085425">23085425</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Addiction-related+gene+regulation%3A+risks+of+exposure+to+cognitive+enhancers+vs.+other+psychostimulants&amp;rft.au=Steiner+H%2C+Van+Waes+V&amp;rft.date=2013-01&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3525776&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3525776&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pneurobio.2012.10.001&amp;rft_id=info%3Apmid%2F23085425&amp;rft.jtitle=Prog.+Neurobiol.&amp;rft.pages=60-80&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NHM-Transcription_factor-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-NHM-Transcription_factor_105-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 4: Signal Transduction in the Brain". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.&#160;94. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+4%3A+Signal+Transduction+in+the+Brain&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=94&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Alcoholism_.CE.94FosB-108"><span class="mw-cite-backlink"><b><a href="#cite_ref-Alcoholism_.CE.94FosB_108-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Kanehisa Laboratories (29 October 2014). <a rel="nofollow" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354">"Alcoholism – Homo sapiens (human)"</a>. <i>KEGG Pathway</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Alcoholism+%93+Homo+sapiens+%28human%29&amp;rft.au=Kanehisa+Laboratories&amp;rft.date=2014-10-29&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.genome.jp%2Fkegg-bin%2Fshow_pathway%3Fhsa05034%2B2354&amp;rft.jtitle=KEGG+Pathway&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MPH_.CE.94FosB-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-MPH_.CE.94FosB_109-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365">"Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>106</b> (8): 2915–2920. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.0813179106">10.1073/pnas.0813179106</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365">2650365</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19202072">19202072</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Methylphenidate-induced+dendritic+spine+formation+and+DeltaFosB+expression+in+nucleus+accumbens&amp;rft.au=Baron%2C+M&amp;rft.aufirst=Y&amp;rft.au=Greengard%2C+P&amp;rft.aulast=Kim&amp;rft.au=Nairn%2C+AC&amp;rft.au=Sands%2C+A&amp;rft.au=Teylan%2C+MA&amp;rft.date=2009-02&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2650365&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2650365&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.0813179106&amp;rft_id=info%3Apmid%2F19202072&amp;rft.issue=8&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=2915-2920&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler_2014_epigenetics-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nestler_2014_epigenetics_111-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Nestler EJ (January 2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384">"Epigenetic mechanisms of drug addiction"</a>. <i>Neuropharmacology</i>. 76 Pt B: 259–268. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.neuropharm.2013.04.004">10.1016/j.neuropharm.2013.04.004</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384">3766384</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23643695">23643695</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Epigenetic+mechanisms+of+drug+addiction&amp;rft.aufirst=EJ&amp;rft.aulast=Nestler&amp;rft.date=2014-01&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3766384&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3766384&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2013.04.004&amp;rft_id=info%3Apmid%2F23643695&amp;rft.jtitle=Neuropharmacology&amp;rft.pages=259-268&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=76+Pt+B" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-.CE.94FosB_reward-112"><span class="mw-cite-backlink">^ <a href="#cite_ref-.CE.94FosB_reward_112-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-.CE.94FosB_reward_112-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M (March 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958">"Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms"</a>. <i>J. Psychoactive Drugs</i> <b>44</b> (1): 38–55. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F02791072.2012.662112">10.1080/02791072.2012.662112</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958">4040958</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22641964">22641964</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Sex%2C+drugs%2C+and+rock+%27n%27+roll%3A+hypothesizing+common+mesolimbic+activation+as+a+function+of+reward+gene+polymorphisms&amp;rft.au=Blum+K%2C+Werner+T%2C+Carnes+S%2C+Carnes+P%2C+Bowirrat+A%2C+Giordano+J%2C+Oscar-Berman+M%2C+Gold+M&amp;rft.date=2012-03&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4040958&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4040958&amp;rft_id=info%3Adoi%2F10.1080%2F02791072.2012.662112&amp;rft_id=info%3Apmid%2F22641964&amp;rft.issue=1&amp;rft.jtitle=J.+Psychoactive+Drugs&amp;rft.pages=38-55&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=44" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph_and_sex_addiction-113"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amph_and_sex_addiction_113-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amph_and_sex_addiction_113-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Pitchers KK, Vialou V, Nestler EJ, Laviolette SR, Lehman MN, Coolen LM (February 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508">"Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator"</a>. <i>J. Neurosci.</i> <b>33</b> (8): 3434–3442. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1523%2FJNEUROSCI.4881-12.2013">10.1523/JNEUROSCI.4881-12.2013</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508">3865508</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23426671">23426671</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Natural+and+drug+rewards+act+on+common+neural+plasticity+mechanisms+with+%CE%94FosB+as+a+key+mediator&amp;rft.au=Pitchers+KK%2C+Vialou+V%2C+Nestler+EJ%2C+Laviolette+SR%2C+Lehman+MN%2C+Coolen+LM&amp;rft.date=2013-02&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3865508&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3865508&amp;rft_id=info%3Adoi%2F10.1523%2FJNEUROSCI.4881-12.2013&amp;rft_id=info%3Apmid%2F23426671&amp;rft.issue=8&amp;rft.jtitle=J.+Neurosci.&amp;rft.pages=3434-3442&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid24716825-114"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid24716825_114-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Stoops WW, Rush CR (May 2014). "Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research". <i>Expert Rev Clin Pharmacol</i> <b>7</b> (3): 363–374. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1586%2F17512433.2014.909283">10.1586/17512433.2014.909283</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24716825">24716825</a>. <q>Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Combination+pharmacotherapies+for+stimulant+use+disorder%3A+a+review+of+clinical+findings+and+recommendations+for+future+research&amp;rft.aufirst=WW&amp;rft.aulast=Stoops&amp;rft.au=Rush%2C+CR&amp;rft.date=2014-05&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1586%2F17512433.2014.909283&amp;rft_id=info%3Apmid%2F24716825&amp;rft.issue=3&amp;rft.jtitle=Expert+Rev+Clin+Pharmacol&amp;rft.pages=363-374&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_2013_treatments-115"><span class="mw-cite-backlink"><b><a href="#cite_ref-Cochrane_2013_treatments_115-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Perez-Mana C, Castells X, Torrens M, Capella D, Farre M (September 2013). "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". <i>Cochrane Database Syst. Rev.</i> <b>9</b>: CD009695. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD009695.pub2">10.1002/14651858.CD009695.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23996457">23996457</a>. <q>To date, no pharmacological treatment has been approved for [addiction], and psychotherapy remains the mainstay of treatment.&#160;... Results of this review do not support the use of psychostimulant medications at the tested doses as a replacement therapy</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Efficacy+of+psychostimulant+drugs+for+amphetamine+abuse+or+dependence&amp;rft.au=Capella%2C+D&amp;rft.au=Castells%2C+X&amp;rft.au=Farre%2C+M&amp;rft.aufirst=C&amp;rft.aulast=Perez-Mana&amp;rft.au=Torrens%2C+M&amp;rft.date=2013-09&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009695.pub2&amp;rft_id=info%3Apmid%2F23996457&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD009695&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23039267-116"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23039267_116-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Forray A, Sofuoglu M (February 2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4014020">"Future pharmacological treatments for substance use disorders"</a>. <i>Br. J. Clin. Pharmacol.</i> <b>77</b> (2): 382–400. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2125.2012.04474.x">10.1111/j.1365-2125.2012.04474.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4014020">4014020</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23039267">23039267</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Future+pharmacological+treatments+for+substance+use+disorders&amp;rft.aufirst=A&amp;rft.aulast=Forray&amp;rft.au=Sofuoglu%2C+M&amp;rft.date=2014-02&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4014020&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4014020&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2125.2012.04474.x&amp;rft_id=info%3Apmid%2F23039267&amp;rft.issue=2&amp;rft.jtitle=Br.+J.+Clin.+Pharmacol.&amp;rft.pages=382-400&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=77" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NHM-NMDA-117"><span class="mw-cite-backlink">^ <a href="#cite_ref-NHM-NMDA_117-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NHM-NMDA_117-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 5: Excitatory and Inhibitory Amino Acids". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. pp.&#160;124–125. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+5%3A+Excitatory+and+Inhibitory+Amino+Acids&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=124-125&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_Withdrawal-120"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_Withdrawal_120-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_120-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_120-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_120-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Shoptaw SJ, Kao U, Heinzerling K, Ling W (April 2009). Shoptaw SJ, ed. "Treatment for amphetamine withdrawal". <i>Cochrane Database Syst. Rev.</i> (2): CD003021. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD003021.pub2">10.1002/14651858.CD003021.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19370579">19370579</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Treatment+for+amphetamine+withdrawal&amp;rft.au=Shoptaw+SJ%2C+Kao+U%2C+Heinzerling+K%2C+Ling+W&amp;rft.date=2009-04&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003021.pub2&amp;rft_id=info%3Apmid%2F19370579&amp;rft.issue=2&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003021&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-121"><span class="mw-cite-backlink"><b><a href="#cite_ref-121">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf">"Adderall IR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Barr Laboratories, Inc. March 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">4 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+IR+Prescribing+Information&amp;rft.date=2007-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F011522s040lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-122"><span class="mw-cite-backlink"><b><a href="#cite_ref-122">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Humans.26Animals-123"><span class="mw-cite-backlink"><b><a href="#cite_ref-Humans.26Animals_123-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Advokat C (July 2007). "Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD". <i>J. Atten. Disord.</i> <b>11</b> (1): 8–16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F1087054706295605">10.1177/1087054706295605</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17606768">17606768</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Update+on+amphetamine+neurotoxicity+and+its+relevance+to+the+treatment+of+ADHD&amp;rft.au=Advokat+C&amp;rft.date=2007-07&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1087054706295605&amp;rft_id=info%3Apmid%2F17606768&amp;rft.issue=1&amp;rft.jtitle=J.+Atten.+Disord.&amp;rft.pages=8-16&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-124"><span class="mw-cite-backlink"><b><a href="#cite_ref-124">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9">"Amphetamine"</a>. <i>Hazardous Substances Data Bank</i>. National Library of Medicine<span class="reference-accessdate">. Retrieved <span class="nowrap">26 February</span> 2014</span>. <q>Direct toxic damage to vessels seems unlikely because of the dilution that occurs before the drug reaches the cerebral circulation.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Ftoxnet.nlm.nih.gov%2Fcgi-bin%2Fsis%2Fsearch%2Fr%3Fdbs%2Bhsdb%3A%40term%2B%40rn%2B%40rel%2B300-62-9&amp;rft.jtitle=Hazardous+Substances+Data+Bank&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009_02-125"><span class="mw-cite-backlink"><b><a href="#cite_ref-Malenka_2009_02_125-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and addictive disorders". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.&#160;370. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. <q>Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+addictive+disorders&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=370&amp;rft.place=New+York%2C+USA&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Autoxidation1-126"><span class="mw-cite-backlink"><b><a href="#cite_ref-Autoxidation1_126-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sulzer D, Zecca L (February 2000). "Intraneuronal dopamine-quinone synthesis: a review". <i>Neurotox. Res.</i> <b>1</b> (3): 181–195. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2FBF03033289">10.1007/BF03033289</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12835101">12835101</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Intraneuronal+dopamine-quinone+synthesis%3A+a+review&amp;rft.au=Sulzer+D%2C+Zecca+L&amp;rft.date=2000-02&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2FBF03033289&amp;rft_id=info%3Apmid%2F12835101&amp;rft.issue=3&amp;rft.jtitle=Neurotox.+Res.&amp;rft.pages=181-195&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Autoxidation2-127"><span class="mw-cite-backlink"><b><a href="#cite_ref-Autoxidation2_127-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Miyazaki I, Asanuma M (June 2008). "Dopaminergic neuron-specific oxidative stress caused by dopamine itself". <i>Acta Med. Okayama</i> <b>62</b> (3): 141–150. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18596830">18596830</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Dopaminergic+neuron-specific+oxidative+stress+caused+by+dopamine+itself&amp;rft.au=Miyazaki+I%2C+Asanuma+M&amp;rft.date=2008-06&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F18596830&amp;rft.issue=3&amp;rft.jtitle=Acta+Med.+Okayama&amp;rft.pages=141-150&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=62" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Hofmann-128"><span class="mw-cite-backlink"><b><a href="#cite_ref-Hofmann_128-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Hofmann FG (1983). <i>A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects</i> (2nd ed.). New York, USA: Oxford University Press. p.&#160;329. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780195030570" title="Special:BookSources/9780195030570">9780195030570</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.au=Hofmann+FG&amp;rft.btitle=A+Handbook+on+Drug+and+Alcohol+Abuse%3A+The+Biomedical+Aspects&amp;rft.date=1983&amp;rft.edition=2nd&amp;rft.genre=book&amp;rft.isbn=9780195030570&amp;rft.pages=329&amp;rft.place=New+York%2C+USA&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Interactions-129"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Interactions_129-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_129-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_129-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_129-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_129-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_129-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;8–10<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=8-10&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FMO-130"><span class="mw-cite-backlink">^ <a href="#cite_ref-FMO_130-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FMO_130-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FMO_130-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Krueger SK, Williams DE (June 2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602">"Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism"</a>. <i>Pharmacol. Ther.</i> <b>106</b> (3): 357–387. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pharmthera.2005.01.001">10.1016/j.pharmthera.2005.01.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602">1828602</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15922018">15922018</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Mammalian+flavin-containing+monooxygenases%3A+structure%2Ffunction%2C+genetic+polymorphisms+and+role+in+drug+metabolism&amp;rft.au=Krueger+SK%2C+Williams+DE&amp;rft.date=2005-06&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1828602&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1828602&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2005.01.001&amp;rft_id=info%3Apmid%2F15922018&amp;rft.issue=3&amp;rft.jtitle=Pharmacol.+Ther.&amp;rft.pages=357-387&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span><br />
"<a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602/table/T5/">Table 5: N-containing drugs and xenobiotics oxygenated by FMO</a>"</span></li>
<li id="cite_note-PubChem_Targets-131"><span class="mw-cite-backlink"><b><a href="#cite_ref-PubChem_Targets_131-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x301">"Amphetamine: Biomolecular Interactions and Pathways"</a>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine%3A+Biomolecular+Interactions+and+Pathways&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23x301&amp;rft.jtitle=PubChem+Compound&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TAAR1_stereoselective-132"><span class="mw-cite-backlink">^ <a href="#cite_ref-TAAR1_stereoselective_132-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-TAAR1_stereoselective_132-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-TAAR1_stereoselective_132-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-TAAR1_stereoselective_132-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Lewin AH, Miller GM, Gilmour B (December 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3236098">"Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class"</a>. <i>Bioorg. Med. Chem.</i> <b>19</b> (23): 7044–7048. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.bmc.2011.10.007">10.1016/j.bmc.2011.10.007</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3236098">3236098</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22037049">22037049</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Trace+amine-associated+receptor+1+is+a+stereoselective+binding+site+for+compounds+in+the+amphetamine+class&amp;rft.au=Lewin+AH%2C+Miller+GM%2C+Gilmour+B&amp;rft.date=2011-12&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3236098&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3236098&amp;rft_id=info%3Adoi%2F10.1016%2Fj.bmc.2011.10.007&amp;rft_id=info%3Apmid%2F22037049&amp;rft.issue=23&amp;rft.jtitle=Bioorg.+Med.+Chem.&amp;rft.pages=7044-7048&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-133"><span class="mw-cite-backlink"><b><a href="#cite_ref-133">^</a></b></span> <span class="reference-text"><cite class="citation journal">Smith R C, Davis J M (June 1977). "Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man". <i><a href="/wiki/Psychopharmacology_(journal)" title="Psychopharmacology (journal)">Psychopharmacology</a></i> <b>53</b> (1): 1–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fbf00426687">10.1007/bf00426687</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/407607">407607</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Comparative+effects+of+d-amphetamine%2C+l-amphetamine%2C+and+methylphenidate+on+mood+in+man&amp;rft.au=Smith+R+C%2C+Davis+J+M&amp;rft.date=1977-06&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fbf00426687&amp;rft_id=info%3Apmid%2F407607&amp;rft.issue=1&amp;rft.jtitle=Psychopharmacology&amp;rft.pages=1-12&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=53" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15719230-134"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15719230_134-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA (March 2005). "Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core". <i>Psychopharmacology (Berl.)</i> <b>178</b> (2–3): 250–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs00213-004-2012-6">10.1007/s00213-004-2012-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15719230">15719230</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Differential+effects+of+amphetamine+isomers+on+dopamine+release+in+the+rat+striatum+and+nucleus+accumbens+core&amp;rft.au=Glaser+PE%2C+Thomas+TC%2C+Joyce+BM%2C+Castellanos+FX%2C+Gerhardt+GA&amp;rft.date=2005-03&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00213-004-2012-6&amp;rft_id=info%3Apmid%2F15719230&amp;rft.issue=2%933&amp;rft.jtitle=Psychopharmacology+%28Berl.%29&amp;rft.pages=250-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=178" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-135"><span class="mw-cite-backlink"><b><a href="#cite_ref-135">^</a></b></span> <span class="reference-text"><cite class="citation book">Anthony, E. (11 November 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Ob7eBwAAQBAJ"><i>Explorations in Child Psychiatry</i></a>. Springer Science &amp; Business Media. pp.&#160;93–4. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781468421279" title="Special:BookSources/9781468421279">9781468421279</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.aufirst=E.&amp;rft.aulast=Anthony&amp;rft.btitle=Explorations+in+Child+Psychiatry&amp;rft.date=2013-11-11&amp;rft.genre=book&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DOb7eBwAAQBAJ&amp;rft.isbn=9781468421279&amp;rft.pages=93-4&amp;rft.pub=Springer+Science+%26+Business+Media&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Arnold-136"><span class="mw-cite-backlink"><b><a href="#cite_ref-Arnold_136-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Arnold LE (2000). "Methyiphenidate vs. Amphetamine: Comparative review". <i>Journal of Attention Disorders</i> <b>3</b> (4): 200–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F108705470000300403">10.1177/108705470000300403</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Methyiphenidate+vs.+Amphetamine%3A+Comparative+review&amp;rft.au=Arnold+LE&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F108705470000300403&amp;rft.issue=4&amp;rft.jtitle=Journal+of+Attention+Disorders&amp;rft.pages=200-11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Drugbank-dexamph-137"><span class="mw-cite-backlink"><b><a href="#cite_ref-Drugbank-dexamph_137-0">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB01576#pharmacology">"Pharmacology"</a>. <i>Dextroamphetamine</i>. <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Dextroamphetamine&amp;rft.btitle=DrugBank&amp;rft.date=2013-02-08&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01576%23pharmacology&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Pharmacokinetics-138"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Pharmacokinetics_138-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_138-14"><sup><i><b>o</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.&#160;12–13<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=2013-12&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=12-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Drugbank-amph-139"><span class="mw-cite-backlink"><b><a href="#cite_ref-Drugbank-amph_139-0">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#pharmacology">"Pharmacology"</a>. <i>Amphetamine</i>. <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine&amp;rft.btitle=DrugBank&amp;rft.date=2013-02-08&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23pharmacology&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Pubchem_Kinetics-140"><span class="mw-cite-backlink">^ <a href="#cite_ref-Pubchem_Kinetics_140-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_140-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_140-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_140-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#section=Pharmacology-and-Biochemistry">"Pharmacology and Biochemistry"</a>. <i>Amphetamine</i>. <i>Pubchem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">12 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Amphetamine&amp;rft.btitle=Pubchem+Compound&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23section%3DPharmacology-and-Biochemistry&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pH-dependent_half-lives-141"><span class="mw-cite-backlink"><b><a href="#cite_ref-pH-dependent_half-lives_141-0">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9">"Biological Half-Life"</a>. <i>AMPHETAMINE</i>. <i>United States National Library of Medicine – Toxnet</i>. Hazardous Substances Data Bank<span class="reference-accessdate">. Retrieved <span class="nowrap">5 January</span> 2014</span>. <q>Concentrations of (14)C-amphetamine declined less rapidly in the plasma of human subjects maintained on an alkaline diet (urinary pH &gt; 7.5) than those on an acid diet (urinary pH &lt; 6). Plasma half-lives of amphetamine ranged between 16-31 hr &amp; 8-11 hr, respectively, &amp; the excretion of (14)C in 24 hr urine was 45 &amp; 70%.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=AMPHETAMINE&amp;rft.btitle=United+States+National+Library+of+Medicine+%93+Toxnet&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Ftoxnet.nlm.nih.gov%2Fcgi-bin%2Fsis%2Fsearch%2Fr%3Fdbs%2Bhsdb%3A%40term%2B%40rn%2B%40rel%2B300-62-9&amp;rft.pub=Hazardous+Substances+Data+Bank&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Flomenbaum_2006-142"><span class="mw-cite-backlink"><b><a href="#cite_ref-Flomenbaum_2006_142-0">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia">Richard RA (1999). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/books/NBK64323/">"Route of Administration"</a>. <i>Chapter 5—Medical Aspects of Stimulant Use Disorders</i>. <i>National Center for Biotechnology Information Bookshelf</i>. Treatment Improvement Protocol 33. Substance Abuse and Mental Health Services Administration.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Chapter+5%94Medical+Aspects+of+Stimulant+Use+Disorders&amp;rft.au=Richard+RA&amp;rft.btitle=National+Center+for+Biotechnology+Information+Bookshelf&amp;rft.date=1999&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK64323%2F&amp;rft.pub=Substance+Abuse+and+Mental+Health+Services+Administration&amp;rft.series=Treatment+Improvement+Protocol+33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Substituted_amphetamines.2C_FMO.2C_and_DBH-143"><span class="mw-cite-backlink"><b><a href="#cite_ref-Substituted_amphetamines.2C_FMO.2C_and_DBH_143-0">^</a></b></span> <span class="reference-text"><cite class="citation book">Glennon RA (2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Sd6ot9ul-bUC&amp;pg=PA646&amp;q=substituted%20derivatives%20substituents%20hydroxyamphetamine%20flavin%20monooxygenase#v=onepage">"Phenylisopropylamine stimulants: amphetamine-related agents"</a>. In Lemke TL, Williams DA, Roche VF, Zito W. <i>Foye's principles of medicinal chemistry</i> (7th ed.). Philadelphia, USA: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. pp.&#160;646–648. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781609133450" title="Special:BookSources/9781609133450">9781609133450</a><span class="reference-accessdate">. Retrieved <span class="nowrap">11 September</span> 2015</span>. <q>The phase 1 metabolism of amphetamine analogs is catalyzed by two systems: cytochrome P450 and flavin monooxygenase.&#160;... Amphetamine can also undergo aromatic hydroxylation to <i>p</i>-hydroxyamphetamine. &#160;... Subsequent oxidation at the benzylic position by DA β-hydroxylase affords <i>p</i>-hydroxynorephedrine. Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Phenylisopropylamine+stimulants%3A+amphetamine-related+agents&amp;rft.au=Glennon+RA&amp;rft.btitle=Foye%27s+principles+of+medicinal+chemistry&amp;rft.date=2013&amp;rft.edition=7th&amp;rft.genre=bookitem&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DSd6ot9ul-bUC%26pg%3DPA646%26q%3Dsubstituted%2520derivatives%2520substituents%2520hydroxyamphetamine%2520flavin%2520monooxygenase%23v%3Donepage&amp;rft.isbn=9781609133450&amp;rft.pages=646-648&amp;rft.place=Philadelphia%2C+USA&amp;rft.pub=Wolters+Kluwer+Health%2FLippincott+Williams+%26+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DBH_amph_primary-144"><span class="mw-cite-backlink"><b><a href="#cite_ref-DBH_amph_primary_144-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Taylor KB (January 1974). <a rel="nofollow" class="external text" href="http://www.jbc.org/content/249/2/454.full.pdf">"Dopamine-beta-hydroxylase. Stereochemical course of the reaction"</a> <span style="font-size:85%;">(PDF)</span>. <i>J. Biol. Chem.</i> <b>249</b> (2): 454–458. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/4809526">4809526</a><span class="reference-accessdate">. Retrieved <span class="nowrap">6 November</span> 2014</span>. <q>Dopamine-β-hydroxylase catalyzed the removal of the pro-R hydrogen atom and the production of 1-norephedrine, (2S,1R)-2-amino-1-hydroxyl-1-phenylpropane, from d-amphetamine.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Dopamine-beta-hydroxylase.+Stereochemical+course+of+the+reaction&amp;rft.au=Taylor+KB&amp;rft.date=1974-01&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.jbc.org%2Fcontent%2F249%2F2%2F454.full.pdf&amp;rft_id=info%3Apmid%2F4809526&amp;rft.issue=2&amp;rft.jtitle=J.+Biol.+Chem.&amp;rft.pages=454-458&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=249" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DBH_4-HA_primary-145"><span class="mw-cite-backlink"><b><a href="#cite_ref-DBH_4-HA_primary_145-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Horwitz D, Alexander RW, Lovenberg W, Keiser HR (May 1973). "Human serum dopamine-β-hydroxylase. Relationship to hypertension and sympathetic activity". <i>Circ. Res.</i> <b>32</b> (5): 594–599. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1161%2F01.RES.32.5.594">10.1161/01.RES.32.5.594</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/4713201">4713201</a>. <q>Subjects with exceptionally low levels of serum dopamine-β-hydroxylase activity showed normal cardiovascular function and normal β-hydroxylation of an administered synthetic substrate, hydroxyamphetamine.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Human+serum+dopamine-%CE%B2-hydroxylase.+Relationship+to+hypertension+and+sympathetic+activity&amp;rft.au=Horwitz+D%2C+Alexander+RW%2C+Lovenberg+W%2C+Keiser+HR&amp;rft.date=1973-05&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1161%2F01.RES.32.5.594&amp;rft_id=info%3Apmid%2F4713201&amp;rft.issue=5&amp;rft.jtitle=Circ.+Res.&amp;rft.pages=594-599&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=32" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FMO3-Primary-146"><span class="mw-cite-backlink"><b><a href="#cite_ref-FMO3-Primary_146-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Cashman JR, Xiong YN, Xu L, Janowsky A (March 1999). "N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication". <i>J. Pharmacol. Exp. Ther.</i> <b>288</b> (3): 1251–1260. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10027866">10027866</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=N-oxygenation+of+amphetamine+and+methamphetamine+by+the+human+flavin-containing+monooxygenase+%28form+3%29%3A+role+in+bioactivation+and+detoxication&amp;rft.au=Cashman+JR%2C+Xiong+YN%2C+Xu+L%2C+Janowsky+A&amp;rft.date=1999-03&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F10027866&amp;rft.issue=3&amp;rft.jtitle=J.+Pharmacol.+Exp.+Ther.&amp;rft.pages=1251-1260&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=288" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Benzoic1-147"><span class="mw-cite-backlink">^ <a href="#cite_ref-Benzoic1_147-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Benzoic1_147-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://www.brenda-enzymes.info/enzyme.php?ecno=6.2.1.2&amp;Suchword=&amp;organism%5B%5D=Homo+sapiens&amp;show_tm=0">"Substrate/Product"</a>. <i>butyrate-CoA ligase</i>. <i>BRENDA</i>. Technische Universität Braunschweig<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=butyrate-CoA+ligase&amp;rft.btitle=BRENDA&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.brenda-enzymes.info%2Fenzyme.php%3Fecno%3D6.2.1.2%26Suchword%3D%26organism%255B%255D%3DHomo%2Bsapiens%26show_tm%3D0&amp;rft.pub=Technische+Universit%C3%A4t+Braunschweig.&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Benzoic2-148"><span class="mw-cite-backlink">^ <a href="#cite_ref-Benzoic2_148-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Benzoic2_148-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://www.brenda-enzymes.info/enzyme.php?ecno=2.3.1.13&amp;Suchword=&amp;organism%5B%5D=Homo+sapiens&amp;show_tm=0">"Substrate/Product"</a>. <i>glycine N-acyltransferase</i>. <i>BRENDA</i>. Technische Universität Braunschweig<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=glycine+N-acyltransferase&amp;rft.btitle=BRENDA&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.brenda-enzymes.info%2Fenzyme.php%3Fecno%3D2.3.1.13%26Suchword%3D%26organism%255B%255D%3DHomo%2Bsapiens%26show_tm%3D0&amp;rft.pub=Technische+Universit%C3%A4t+Braunschweig.&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Metabolites-150"><span class="mw-cite-backlink">^ <a href="#cite_ref-Metabolites_150-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Metabolites_150-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Metabolites_150-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G (September 2002). "Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection". <i>J. Pharm. Biomed. Anal.</i> <b>30</b> (2): 247–255. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0731-7085%2802%2900330-8">10.1016/S0731-7085(02)00330-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12191709">12191709</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Simultaneous+determination+of+amphetamine+and+one+of+its+metabolites+by+HPLC+with+electrochemical+detection&amp;rft.au=Santagati+NA%2C+Ferrara+G%2C+Marrazzo+A%2C+Ronsisvalle+G&amp;rft.date=2002-09&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0731-7085%2802%2900330-8&amp;rft_id=info%3Apmid%2F12191709&amp;rft.issue=2&amp;rft.jtitle=J.+Pharm.+Biomed.+Anal.&amp;rft.pages=247-255&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-151"><span class="mw-cite-backlink"><b><a href="#cite_ref-151">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3651">"Compound Summary"</a>. <i>p-Hydroxyamphetamine</i>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=p-Hydroxyamphetamine&amp;rft.btitle=PubChem+Compound&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3651&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-152"><span class="mw-cite-backlink"><b><a href="#cite_ref-152">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11099">"Compound Summary"</a>. <i>p-Hydroxynorephedrine</i>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=p-Hydroxynorephedrine&amp;rft.btitle=PubChem+Compound&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D11099&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-153"><span class="mw-cite-backlink"><b><a href="#cite_ref-153">^</a></b></span> <span class="reference-text"><cite class="citation encyclopaedia"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934">"Compound Summary"</a>. <i>Phenylpropanolamine</i>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Phenylpropanolamine&amp;rft.btitle=PubChem+Compound&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D26934&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Renaissance_GPCR-154"><span class="mw-cite-backlink">^ <a href="#cite_ref-Renaissance_GPCR_154-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_154-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_154-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_154-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_154-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". <i>Trends Pharmacol. Sci.</i> <b>26</b> (5): 274–281. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.tips.2005.03.007">10.1016/j.tips.2005.03.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15860375">15860375</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=A+renaissance+in+trace+amines+inspired+by+a+novel+GPCR+family&amp;rft.au=Lindemann+L%2C+Hoener+MC&amp;rft.date=2005-05&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.tips.2005.03.007&amp;rft_id=info%3Apmid%2F15860375&amp;rft.issue=5&amp;rft.jtitle=Trends+Pharmacol.+Sci.&amp;rft.pages=274-281&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-155"><span class="mw-cite-backlink"><b><a href="#cite_ref-155">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/11522S010_Adderall.pdf">"APPROVAL LETTER"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i><span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=APPROVAL+LETTER&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F96%2F11522S010_Adderall.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Duramed-156"><span class="mw-cite-backlink"><b><a href="#cite_ref-Duramed_156-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.genericsweb.com/news/generics_industry_news_archive/August2006.html">"August 2006 News Archives: Barr and Shire Sign Three Agreements"</a>. GenericsWeb<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>. <q>WOODCLIFF LAKE, N.J., Aug. 14 /PRNewswire-FirstCall/ – Barr Pharmaceuticals, Inc. today announced that its subsidiary Duramed Pharmaceuticals, Inc. and Shire plc have signed a Product Acquisition Agreement for ADDERALL(R) (immediate-release mixed amphetamine salts) tablets and a Product Development Agreement for six proprietary products, and that its subsidiary Barr Laboratories, Inc. (Barr) has signed a Settlement and License Agreement relating to the resolution of two pending patent cases involving Shire's ADDERALL XR(R)&#160;...</q></cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=August+2006+News+Archives%3A+Barr+and+Shire+Sign+Three+Agreements&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.genericsweb.com%2Fnews%2Fgenerics_industry_news_archive%2FAugust2006.html&amp;rft.pub=GenericsWeb&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-test-157"><span class="mw-cite-backlink"><b><a href="#cite_ref-test_157-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.drugs.com/news/teva-completes-acquisition-barr-15356.html">"Teva Completes Acquisition of Barr"</a>. Drugs.com<span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Teva+Completes+Acquisition+of+Barr&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.drugs.com%2Fnews%2Fteva-completes-acquisition-barr-15356.html&amp;rft.pub=Drugs.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-158"><span class="mw-cite-backlink"><b><a href="#cite_ref-158">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20090409082544/http://www.forbes.com/feeds/ap/2009/04/02/ap6248888.html">"Teva sells 1st generic of Adderall XL in US"</a>. Forbes Magazine. Associated Press. 2 April 2009. Archived from <a rel="nofollow" class="external text" href="http://www.forbes.com/feeds/ap/2009/04/02/ap6248888.html">the original</a> on 9 April 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">22 April</span> 2009</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Teva+sells+1st+generic+of+Adderall+XL+in+US&amp;rft.date=2009-04-02&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.forbes.com%2Ffeeds%2Fap%2F2009%2F04%2F02%2Fap6248888.html&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-159"><span class="mw-cite-backlink"><b><a href="#cite_ref-159">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm">"Molecular Weight Calculator"</a>. Lenntech<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Molecular+Weight+Calculator&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.lenntech.com%2Fcalculators%2Fmolecular%2Fmolecular-weight-calculator.htm&amp;rft.pub=Lenntech&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-damph1-163"><span class="mw-cite-backlink">^ <a href="#cite_ref-damph1_163-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-damph1_163-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491568">"Dextroamphetamine Sulfate USP"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Dextroamphetamine+Sulfate+USP&amp;rft.date=2014-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww2.mallinckrodt.com%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D2147491568&amp;rft.pub=Mallinckrodt+Pharmaceuticals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-damph2-164"><span class="mw-cite-backlink">^ <a href="#cite_ref-damph2_164-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-damph2_164-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.tocris.com/dispprod.php?ItemId=5305#.VXpspvlViko">"D-amphetamine sulfate"</a>. Tocris. 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=D-amphetamine+sulfate&amp;rft.date=2015&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.tocris.com%2Fdispprod.php%3FItemId%3D5305%23.VXpspvlViko&amp;rft.pub=Tocris&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph_sulfate_mass-165"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amph_sulfate_mass_165-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amph_sulfate_mass_165-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491599">"Amphetamine Sulfate USP"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Amphetamine+Sulfate+USP&amp;rft.date=2014-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww2.mallinckrodt.com%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D2147491599&amp;rft.pub=Mallinckrodt+Pharmaceuticals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-166"><span class="mw-cite-backlink"><b><a href="#cite_ref-166">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491576">"Dextroamphetamine Saccharate"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Dextroamphetamine+Saccharate&amp;rft.date=2014-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww2.mallinckrodt.com%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D2147491576&amp;rft.pub=Mallinckrodt+Pharmaceuticals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-amph2-167"><span class="mw-cite-backlink"><b><a href="#cite_ref-amph2_167-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491591">"Amphetamine Aspartate"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Amphetamine+Aspartate&amp;rft.date=2014-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww2.mallinckrodt.com%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D2147491591&amp;rft.pub=Mallinckrodt+Pharmaceuticals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-168"><span class="mw-cite-backlink"><b><a href="#cite_ref-168">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021977s036s037lbledt.pdf">"Vyvanse Prescribing Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. January 2015. pp.&#160;12–16<span class="reference-accessdate">. Retrieved <span class="nowrap">24 February</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Vyvanse+Prescribing+Information&amp;rft.date=2015-01&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F021977s036s037lbledt.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=12-16&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-HND-170"><span class="mw-cite-backlink"><b><a href="#cite_ref-HND_170-0">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.elsevierbi.com/Publications/Health-News-Daily/1996/2/22/REGULATORY-NEWS-Richwoods-Adderall">"REGULATORY NEWS: Richwood's Adderall"</a>. <i>Health News Daily</i>. 22 February 1996<span class="reference-accessdate">. Retrieved <span class="nowrap">29 May</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=REGULATORY+NEWS%3A+Richwood%27s+Adderall&amp;rft.date=1996-02-22&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.elsevierbi.com%2FPublications%2FHealth-News-Daily%2F1996%2F2%2F22%2FREGULATORY-NEWS-Richwoods-Adderall&amp;rft.jtitle=Health+News+Daily&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-urlControlled_Drugs_and_Substances_Act-171"><span class="mw-cite-backlink"><b><a href="#cite_ref-urlControlled_Drugs_and_Substances_Act_171-0">^</a></b></span> <span class="reference-text"><cite class="citation web">The Minister and Attorney General. <a rel="nofollow" class="external text" href="http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28">"Controlled Drugs and Substances Act"</a>. <i>Justice Laws Website</i>. Government of Canada.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Controlled+Drugs+and+Substances+Act&amp;rft.au=The+Minister+and+Attorney+General&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Flaws-lois.justice.gc.ca%2Feng%2Facts%2FC-38.8%2Fpage-24.html%23h-28&amp;rft.jtitle=Justice+Laws+Website&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-url_Japan_import-172"><span class="mw-cite-backlink"><b><a href="#cite_ref-url_Japan_import_172-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mhlw.go.jp/english/topics/import/">"Importing or Bringing Medication into Japan for Personal Use"</a>. Japan Ministry of Health, Labour and Welfare.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Importing+or+Bringing+Medication+into+Japan+for+Personal+Use&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.mhlw.go.jp%2Fenglish%2Ftopics%2Fimport%2F&amp;rft.pub=Japan+Ministry+of+Health%2C+Labour+and+Welfare&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-urlMoving_to_Korea_brings_medical.2C_social_changes-173"><span class="mw-cite-backlink"><b><a href="#cite_ref-urlMoving_to_Korea_brings_medical.2C_social_changes_173-0">^</a></b></span> <span class="reference-text"><cite class="citation web">P. <a rel="nofollow" class="external text" href="http://www.koreatimes.co.kr/www/news/nation/2012/10/319_111757.html">"Moving to Korea brings medical, social changes"</a>. The Korean Times.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.au=P.&amp;rft.btitle=Moving+to+Korea+brings+medical%2C+social+changes&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.koreatimes.co.kr%2Fwww%2Fnews%2Fnation%2F2012%2F10%2F319_111757.html&amp;rft.pub=The+Korean+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-174"><span class="mw-cite-backlink"><b><a href="#cite_ref-174">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf">"Thailand Law"</a> <span style="font-size:85%;">(PDF)</span>. Government of Thailand<span class="reference-accessdate">. Retrieved <span class="nowrap">23 May</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Thailand+Law&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fnarcotic.fda.moph.go.th%2Ffaq%2Fupload%2FThai%2520Narcotic%2520Act%25202012.doc._37ef.pdf&amp;rft.pub=Government+of+Thailand&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-175"><span class="mw-cite-backlink"><b><a href="#cite_ref-175">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/">"Class A, B and C drugs"</a>. Home Office, Government of the United Kingdom. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20070804233232/http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/">Archived</a> from the original on 4 August 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">23 July</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.btitle=Class+A%2C+B+and+C+drugs&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.homeoffice.gov.uk%2Fdrugs%2Fdrugs-law%2FClass-a-b-c%2F&amp;rft.pub=Home+Office%2C+Government+of+the+United+Kingdom&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-176"><span class="mw-cite-backlink"><b><a href="#cite_ref-176">^</a></b></span> <span class="reference-text"><cite class="citation web">Substance Abuse and Mental Health Services Administration. <a rel="nofollow" class="external text" href="http://www.oas.samhsa.gov/2k6/methTX/methTX.htm">"Trends in Methamphetamine/Amphetamine Admissions to Treatment: 1993–2003"</a>. <i>The Drug and Alcohol Services Information System (DASIS) Report</i>. United States Department of Health and Human Services<span class="reference-accessdate">. Retrieved <span class="nowrap">28 February</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.atitle=Trends+in+Methamphetamine%2FAmphetamine+Admissions+to+Treatment%3A+1993%932003&amp;rft.au=Substance+Abuse+and+Mental+Health+Services+Administration&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.oas.samhsa.gov%2F2k6%2FmethTX%2FmethTX.htm&amp;rft.jtitle=The+Drug+and+Alcohol+Services+Information+System+%28DASIS%29+Report&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-isbn92-1-148223-2-177"><span class="mw-cite-backlink"><b><a href="#cite_ref-isbn92-1-148223-2_177-0">^</a></b></span> <span class="reference-text"><cite class="citation book">United Nations Office on Drugs and Crime (2007). <a rel="nofollow" class="external text" href="http://www.unodc.org/pdf/youthnet/ATS.pdf"><i>Preventing Amphetamine-type Stimulant Use Among Young People: A Policy and Programming Guide</i></a> <span style="font-size:85%;">(PDF)</span>. New York: United Nations. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/92-1-148223-2" title="Special:BookSources/92-1-148223-2">92-1-148223-2</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.au=United+Nations+Office+on+Drugs+and+Crime&amp;rft.btitle=Preventing+Amphetamine-type+Stimulant+Use+Among+Young+People%3A+A+Policy+and+Programming+Guide&amp;rft.date=2007&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.unodc.org%2Fpdf%2Fyouthnet%2FATS.pdf&amp;rft.isbn=92-1-148223-2&amp;rft.place=New+York&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-178"><span class="mw-cite-backlink"><b><a href="#cite_ref-178">^</a></b></span> <span class="reference-text"><cite class="citation web">International Narcotics Control Board. <a rel="nofollow" class="external text" href="http://www.incb.org/pdf/e/list/green.pdf">"List of psychotropic substances under international control"</a> <span style="font-size:85%;">(PDF)</span>. Vienna: United Nations. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf">Archived</a> <span style="font-size:85%;">(PDF)</span> from the original on 5 December 2005<span class="reference-accessdate">. Retrieved <span class="nowrap">19 November</span> 2005</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAdderall&amp;rft.au=International+Narcotics+Control+Board&amp;rft.btitle=List+of+psychotropic+substances+under+international+control&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.incb.org%2Fpdf%2Fe%2Flist%2Fgreen.pdf&amp;rft.place=Vienna&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Amphetamine" title="Template:Amphetamine"><abbr title="View this template" style=";;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Amphetamine" title="Template talk:Amphetamine"><abbr title="Discuss this template" style=";;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Amphetamine&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div style="font-size:114%"><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center">Main articles<br />
and<br />
pharmaceuticals</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><b><strong class="selflink">Adderall</strong></b></i></li>
<li><i>Dyanavel</i></li>
<li><i>Evekeo</i></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">N/A</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Dexedrine</i></li>
<li><i>ProCentra</i></li>
<li><i>Zenzedi</i></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Vyvanse</i></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center">Neuropharmacology</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Biomolecular_target" title="Biomolecular target" class="mw-redirect">Biomolecular targets</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/TAAR1" title="TAAR1">TAAR1</a> (<a href="/wiki/Full_agonist" title="Full agonist" class="mw-redirect">full agonist</a>)</li>
<li><a href="/wiki/Cocaine_and_amphetamine_regulated_transcript" title="Cocaine and amphetamine regulated transcript">CART</a> (<a href="/wiki/Messenger_RNA" title="Messenger RNA"><abbr title="messenger RNA">mRNA</abbr></a> inducer)</li>
<li><a href="/wiki/5-HT1A_receptor" title="5-HT1A receptor">5-HT1A receptor</a> (low affinity <a href="/wiki/Ligand_(biochemistry)" title="Ligand (biochemistry)">ligand</a>)</li>
<li><a href="/wiki/Monoamine_oxidase" title="Monoamine oxidase">MAO</a> (weak <a href="/wiki/Competitive_inhibition" title="Competitive inhibition">competitive inhibitor</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">Inhibited <a href="/wiki/Membrane_transport_protein" title="Membrane transport protein">transporters</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Dopamine_transporter" title="Dopamine transporter">DAT</a></li>
<li><a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">NET</a></li>
<li><a href="/wiki/Serotonin_transporter" title="Serotonin transporter">SERT</a></li>
<li><a href="/wiki/Vesicular_monoamine_transporter_1" title="Vesicular monoamine transporter 1">VMAT1</a></li>
<li><a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">VMAT2</a></li>
<li><a href="/wiki/Excitatory_amino_acid_transporter#EAAT3" title="Excitatory amino acid transporter">EAAT3</a></li>
<li><a href="/wiki/SLC22A3" title="SLC22A3">SLC22A3</a></li>
<li><a href="/wiki/SLC22A5" title="SLC22A5">SLC22A5</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center">Active metabolites</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine">4-Hydroxyamphetamine</a></li>
<li><a href="/wiki/P-Hydroxynorephedrine" title="P-Hydroxynorephedrine">4-Hydroxynorephedrine</a></li>
<li><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center">Related articles</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder_predominantly_inattentive" title="Attention deficit hyperactivity disorder predominantly inattentive">ADD</a></li>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">ADHD</a></li>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder_management" title="Attention deficit hyperactivity disorder management">ADHD management</a></li>
<li><a href="/wiki/Stimulant_psychosis#Substituted_amphetamines" title="Stimulant psychosis">Amphetamine psychosis</a></li>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/Doping_in_sport" title="Doping in sport">Doping in sport</a></li>
<li><a href="/wiki/Formetorex" title="Formetorex">Formetorex</a></li>
<li><a href="/wiki/FOSB#.CE.94FosB" title="FOSB">ΔFosB</a></li>
<li><a href="/wiki/History_and_culture_of_substituted_amphetamines" title="History and culture of substituted amphetamines">History and culture of substituted amphetamines</a></li>
<li><a href="/wiki/History_of_Benzedrine" title="History of Benzedrine">History of Benzedrine</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/Narcolepsy" title="Narcolepsy">Narcolepsy</a></li>
<li><a href="/wiki/Nootropic" title="Nootropic">Nootropic</a></li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Performance-enhancing_drugs" title="Performance-enhancing drugs">Performance-enhancing drugs</a></li>
<li><a href="/wiki/Pharmaceutical_drug" title="Pharmaceutical drug">Pharmaceutical drug</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="/wiki/Phenylacetone" title="Phenylacetone">Phenylacetone</a></li>
<li><a href="/wiki/Recreational_drug_use" title="Recreational drug use">Recreational drug use</a></li>
<li><a href="/wiki/Serotonin" title="Serotonin">Serotonin</a></li>
<li><a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">Substituted amphetamine</a></li>
<li><a href="/wiki/Trace_amine" title="Trace amine">Trace amine</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Phenethylamines" title="Template:Phenethylamines"><abbr title="View this template" style=";;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Phenethylamines" title="Template talk:Phenethylamines"><abbr title="Discuss this template" style=";;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Phenethylamines&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div style="font-size:114%"><a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">Phenethylamines</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">Phenethylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Psychedelics:</i> <a href="/wiki/25B-NBOMe" title="25B-NBOMe">25B-NBOMe</a></li>
<li><a href="/wiki/25C-NBOMe" title="25C-NBOMe">25C-NBOMe</a></li>
<li><a href="/wiki/25D-NBOMe" title="25D-NBOMe">25D-NBOMe</a></li>
<li><a href="/wiki/25I-NBOMe" title="25I-NBOMe">25I-NBOMe</a></li>
<li><a href="/wiki/25N-NBOMe" title="25N-NBOMe">25N-NBOMe</a></li>
<li><a href="/wiki/2C-B" title="2C-B">2C-B</a></li>
<li><a href="/w/index.php?title=2C-B-AN&amp;action=edit&amp;redlink=1" class="new" title="2C-B-AN (page does not exist)">2C-B-AN</a></li>
<li><a href="/wiki/2C-B-FLY" title="2C-B-FLY">2C-B-FLY</a></li>
<li><a href="/wiki/%CE%92k-2C-B" title="Βk-2C-B">βk-2C-B</a></li>
<li><a href="/wiki/2C-C" title="2C-C">2C-C</a></li>
<li><a href="/wiki/2C-D" title="2C-D">2C-D</a></li>
<li><a href="/wiki/2C-E" title="2C-E">2C-E</a></li>
<li><a href="/w/index.php?title=2C-EF&amp;action=edit&amp;redlink=1" class="new" title="2C-EF (page does not exist)">2C-EF</a></li>
<li><a href="/wiki/2C-F" title="2C-F">2C-F</a></li>
<li><a href="/wiki/2C-G" title="2C-G">2C-G</a></li>
<li><a href="/wiki/2C-I" title="2C-I">2C-I</a></li>
<li><a href="/wiki/2C-N" title="2C-N">2C-N</a></li>
<li><a href="/wiki/2C-P" title="2C-P">2C-P</a></li>
<li><a href="/w/index.php?title=2C-SE&amp;action=edit&amp;redlink=1" class="new" title="2C-SE (page does not exist)">2C-SE</a></li>
<li><a href="/wiki/2C-T" title="2C-T">2C-T</a></li>
<li><a href="/wiki/2C-T-2" title="2C-T-2">2C-T-2</a></li>
<li><a href="/wiki/2C-T-4" title="2C-T-4">2C-T-4</a></li>
<li><a href="/wiki/2C-T-7" title="2C-T-7">2C-T-7</a></li>
<li><a href="/wiki/2C-T-8" title="2C-T-8">2C-T-8</a></li>
<li><a href="/wiki/2C-T-9" title="2C-T-9" class="mw-redirect">2C-T-9</a></li>
<li><a href="/wiki/2C-T-13" title="2C-T-13">2C-T-13</a></li>
<li><a href="/wiki/2C-T-15" title="2C-T-15">2C-T-15</a></li>
<li><a href="/wiki/2C-T-16" title="2C-T-16">2C-T-16</a></li>
<li><a href="/wiki/2C-T-17" title="2C-T-17">2C-T-17</a></li>
<li><a href="/wiki/2C-T-21" title="2C-T-21">2C-T-21</a></li>
<li><a href="/wiki/2C-TFM" title="2C-TFM">2C-TFM</a></li>
<li><a href="/wiki/2C-YN" title="2C-YN">2C-YN</a></li>
<li><a href="/wiki/Allylescaline" title="Allylescaline">Allylescaline</a></li>
<li><a href="/wiki/DESOXY" title="DESOXY">DESOXY</a></li>
<li><a href="/wiki/Escaline" title="Escaline">Escaline</a></li>
<li><a href="/wiki/Isoproscaline" title="Isoproscaline">Isoproscaline</a></li>
<li><a href="/wiki/Jimscaline" title="Jimscaline">Jimscaline</a></li>
<li><a href="/wiki/Macromerine" title="Macromerine">Macromerine</a></li>
<li><a href="/wiki/3-Methoxy-4-ethoxyphenethylamine" title="3-Methoxy-4-ethoxyphenethylamine">MEPEA</a></li>
<li><a href="/wiki/Mescaline" title="Mescaline">Mescaline</a></li>
<li><a href="/wiki/Metaescaline" title="Metaescaline">Metaescaline</a></li>
<li><a href="/wiki/Methallylescaline" title="Methallylescaline">Methallylescaline</a></li>
<li><a href="/wiki/Proscaline" title="Proscaline">Proscaline</a></li>
<li><a href="/wiki/Psi-2C-T-4" title="Psi-2C-T-4" class="mw-redirect">Psi-2C-T-4</a></li>
<li><a href="/wiki/TCB-2" title="TCB-2">TCB-2</a><br />
<i>Stimulants:</i> <a href="/wiki/Phenylethanolamine" title="Phenylethanolamine">Phenylethanolamine</a></li>
<li><a href="/wiki/Hordenine" title="Hordenine">Hordenine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Amphetamine" title="Amphetamine">α-Methylphenethylamine</a> (amphetamine)</li>
<li><a href="/wiki/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Methylphenethylamine</a></li>
<li><a href="/wiki/M-Methylphenethylamine" title="M-Methylphenethylamine" class="mw-redirect"><i>m</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/O-Methylphenethylamine" title="O-Methylphenethylamine" class="mw-redirect"><i>o</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/P-Methylphenethylamine" title="P-Methylphenethylamine" class="mw-redirect"><i>p</i>-Methylphenethylamine</a></li>
</ul>
<ul>
<li><i>Entactogens:</i> <a href="/wiki/Lophophine" title="Lophophine">Lophophine</a></li>
<li><a href="/wiki/Methylenedioxyphenethylamine" title="Methylenedioxyphenethylamine">MDPEA</a></li>
<li><a href="/wiki/Methylenedioxymethylphenethylamine" title="Methylenedioxymethylphenethylamine">MDMPEA</a><br />
<i>Others:</i> <a href="/wiki/Benzodioxolylhydroxybutanamine" title="Benzodioxolylhydroxybutanamine" class="mw-redirect">BOH</a></li>
<li><a href="/wiki/3,4-Dimethoxyphenethylamine" title="3,4-Dimethoxyphenethylamine">DMPEA</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">Amphetamines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Psychedelics:</i> <a href="/wiki/3C-BZ" title="3C-BZ">3C-BZ</a></li>
<li><a href="/wiki/3C-E" title="3C-E">3C-E</a></li>
<li><a href="/wiki/3C-P" title="3C-P">3C-P</a></li>
<li><a href="/wiki/Aleph_(psychedelic)" title="Aleph (psychedelic)">Aleph</a></li>
<li><a href="/wiki/Beatrice_(psychedelic)" title="Beatrice (psychedelic)">Beatrice</a></li>
<li><a href="/wiki/Bromo-DragonFLY" title="Bromo-DragonFLY">Bromo-DragonFLY</a></li>
<li><a href="/wiki/D-Deprenyl" title="D-Deprenyl">D-Deprenyl</a></li>
<li><a href="/wiki/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li><a href="/w/index.php?title=4-Methyl-2,5-methoxycyclopropylamine&amp;action=edit&amp;redlink=1" class="new" title="4-Methyl-2,5-methoxycyclopropylamine (page does not exist)">DMCPA</a></li>
<li><a href="/wiki/DMMDA" title="DMMDA">DMMDA</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-bromoamphetamine" title="2,5-Dimethoxy-4-bromoamphetamine">DOB</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-chloroamphetamine" title="2,5-Dimethoxy-4-chloroamphetamine">DOC</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-fluoroethylamphetamine" title="2,5-Dimethoxy-4-fluoroethylamphetamine" class="mw-redirect">DOEF</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-ethylamphetamine" title="2,5-Dimethoxy-4-ethylamphetamine">DOET</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-iodoamphetamine" title="2,5-Dimethoxy-4-iodoamphetamine">DOI</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-methylamphetamine" title="2,5-Dimethoxy-4-methylamphetamine">DOM</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-nitroamphetamine" title="2,5-Dimethoxy-4-nitroamphetamine">DON</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-propylamphetamine" title="2,5-Dimethoxy-4-propylamphetamine">DOPR</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-trifluoromethylamphetamine" title="2,5-Dimethoxy-4-trifluoromethylamphetamine">DOTFM</a></li>
<li><a href="/wiki/Ganesha_(psychedelic)" title="Ganesha (psychedelic)">Ganesha</a></li>
<li><a href="/wiki/MMDA_(drug)" title="MMDA (drug)">MMDA</a></li>
<li><a href="/wiki/MMDA-2" title="MMDA-2">MMDA-2</a></li>
<li><a href="/wiki/Psi-DOM" title="Psi-DOM">Psi-DOM</a></li>
<li><a href="/wiki/Trimethoxyamphetamine" title="Trimethoxyamphetamine">TMA</a></li>
<li><a href="/wiki/Tetramethoxyamphetamine" title="Tetramethoxyamphetamine" class="mw-redirect">TeMA</a><br />
<i>Stimulants:</i> <a href="/wiki/2-Fluoroamphetamine" title="2-Fluoroamphetamine">2-FA</a></li>
<li><a href="/wiki/2-Fluoromethamphetamine" title="2-Fluoromethamphetamine">2-FMA</a></li>
<li><a href="/wiki/3-Fluoroamphetamine" title="3-Fluoroamphetamine">3-FA</a></li>
<li><a href="/wiki/3-Fluoromethamphetamine" title="3-Fluoromethamphetamine">3-FMA</a></li>
<li><a href="/wiki/Acridorex" title="Acridorex">Acridorex</a></li>
<li><a href="/wiki/Alfetamine" title="Alfetamine">Alfetamine</a></li>
<li><a href="/wiki/Amfecloral" title="Amfecloral">Amfecloral</a></li>
<li><a href="/wiki/Amfepentorex" title="Amfepentorex">Amfepentorex</a></li>
<li><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a> (<a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>, <a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>)</li>
<li><a href="/wiki/Amphetaminil" title="Amphetaminil">Amphetaminil</a></li>
<li><a href="/wiki/Benfluorex" title="Benfluorex">Benfluorex</a></li>
<li><a href="/wiki/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li><a href="/wiki/Cathine" title="Cathine">Cathine</a></li>
<li><a href="/wiki/Clobenzorex" title="Clobenzorex">Clobenzorex</a></li>
<li><a href="/wiki/Dimethylamphetamine" title="Dimethylamphetamine">Dimethylamphetamine</a></li>
<li><a href="/wiki/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li><a href="/wiki/Etilamfetamine" title="Etilamfetamine">Etilamfetamine</a></li>
<li><a href="/wiki/Fencamfamine" title="Fencamfamine">Fencamfamine</a></li>
<li><a href="/wiki/Fencamine" title="Fencamine">Fencamine</a></li>
<li><a href="/wiki/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="/wiki/Fenfluramine" title="Fenfluramine">Fenfluramine</a> (<a href="/wiki/Dexfenfluramine" title="Dexfenfluramine">Dexfenfluramine</a>, <a href="/wiki/Levofenfluramine" title="Levofenfluramine">Levofenfluramine</a>)</li>
<li><a href="/wiki/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li><a href="/wiki/Flucetorex" title="Flucetorex">Flucetorex</a></li>
<li><a href="/wiki/Fludorex" title="Fludorex">Fludorex</a></li>
<li><a href="/wiki/Formetorex" title="Formetorex">Formetorex</a></li>
<li><a href="/wiki/Furfenorex" title="Furfenorex">Furfenorex</a></li>
<li><a href="/wiki/Gepefrine" title="Gepefrine">Gepefrine</a></li>
<li><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine">4-Hydroxyamphetamine</a></li>
<li><a href="/wiki/Iofetamine" title="Iofetamine" class="mw-redirect">Iofetamine</a></li>
<li><a href="/wiki/Isopropylamphetamine" title="Isopropylamphetamine">Isopropylamphetamine</a></li>
<li><a href="/wiki/Lefetamine" title="Lefetamine">Lefetamine</a></li>
<li><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li><a href="/wiki/Mefenorex" title="Mefenorex">Mefenorex</a></li>
<li><a href="/wiki/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a> (Dextromethamphetamine, <a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Levomethamphetamine</a>)</li>
<li><a href="/wiki/Methoxyphenamine" title="Methoxyphenamine">Methoxyphenamine</a></li>
<li><a href="/wiki/3-Methoxy-4-methylamphetamine" title="3-Methoxy-4-methylamphetamine">MMA</a></li>
<li><a href="/wiki/Morforex" title="Morforex">Morforex</a></li>
<li><a href="/wiki/Norfenfluramine" title="Norfenfluramine">Norfenfluramine</a></li>
<li><a href="/wiki/L-Norpseudoephedrine" title="L-Norpseudoephedrine"><span style="font-size:90%;">L</span> -Norpseudoephedrine</a></li>
<li><a href="/wiki/N,alpha-Diethylphenylethylamine" title="N,alpha-Diethylphenylethylamine">N,alpha-Diethylphenylethylamine</a></li>
<li><a href="/wiki/Oxifentorex" title="Oxifentorex">Oxifentorex</a></li>
<li><a href="/wiki/Oxilofrine" title="Oxilofrine">Oxilofrine</a></li>
<li><a href="/wiki/Ortetamine" title="Ortetamine">Ortetamine</a></li>
<li><a href="/wiki/Parabromoamphetamine" title="Parabromoamphetamine" class="mw-redirect">PBA</a></li>
<li><a href="/wiki/Parachloroamphetamine" title="Parachloroamphetamine" class="mw-redirect">PCA</a></li>
<li><a href="/wiki/Phenpromethamine" title="Phenpromethamine">Phenpromethamine</a></li>
<li><a href="/wiki/4-Fluoroamphetamine" title="4-Fluoroamphetamine">PFA</a></li>
<li><a href="/wiki/4-Fluoromethamphetamine" title="4-Fluoromethamphetamine">PFMA</a></li>
<li><a href="/wiki/Paraiodoamphetamine" title="Paraiodoamphetamine" class="mw-redirect">PIA</a></li>
<li><a href="/wiki/Para-Methoxyamphetamine" title="Para-Methoxyamphetamine">PMA</a></li>
<li><a href="/wiki/Para-Methoxyethylamphetamine" title="Para-Methoxyethylamphetamine" class="mw-redirect">PMEA</a></li>
<li><a href="/wiki/Paramethoxymethamphetamine" title="Paramethoxymethamphetamine" class="mw-redirect">PMMA</a></li>
<li><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Phenylpropanolamine</a></li>
<li><a href="/wiki/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li><a href="/wiki/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li><a href="/wiki/Propylamphetamine" title="Propylamphetamine">Propylamphetamine</a></li>
<li><a href="/wiki/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li><a href="/wiki/Sibutramine" title="Sibutramine">Sibutramine</a></li>
<li><a href="/wiki/Tiflorex" title="Tiflorex">Tiflorex</a></li>
<li><a href="/wiki/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></li>
<li><a href="/wiki/Xylopropamine" title="Xylopropamine">Xylopropamine</a></li>
<li><a href="/wiki/Zylofuramine" title="Zylofuramine">Zylofuramine</a><br />
<i>Entactogens:</i> <a href="/wiki/4-Fluoroamphetamine" title="4-Fluoroamphetamine">4-FA</a></li>
<li><a href="/wiki/4-Fluoromethamphetamine" title="4-Fluoromethamphetamine">4-FMA</a></li>
<li><a href="/wiki/4-Methamphetamine" title="4-Methamphetamine" class="mw-redirect">4-MA</a></li>
<li><a href="/wiki/4-Methylmethamphetamine" title="4-Methylmethamphetamine">4-MMA</a></li>
<li><a href="/wiki/4-Methylthioamphetamine" title="4-Methylthioamphetamine">4-MTA</a></li>
<li><a href="/wiki/5-(2-Aminopropyl)indole" title="5-(2-Aminopropyl)indole" class="mw-redirect">5-IT</a></li>
<li><a href="/wiki/5-APB" title="5-APB">5-APB</a></li>
<li><a href="/wiki/5-APDB" title="5-APDB">5-APDB</a></li>
<li><a href="/wiki/5-EAPB" title="5-EAPB">5-EAPB</a></li>
<li><a href="/wiki/5-MAPB" title="5-MAPB">5-MAPB</a></li>
<li><a href="/wiki/5-MAPDB" title="5-MAPDB">5-MAPDB</a></li>
<li><a href="/wiki/6-APB" title="6-APB">6-APB</a></li>
<li><a href="/wiki/6-APDB" title="6-APDB">6-APDB</a></li>
<li><a href="/wiki/6-Chloro-MDMA" title="6-Chloro-MDMA">6-Chloro-MDMA</a></li>
<li><a href="/wiki/6-EAPB" title="6-EAPB">6-EAPB</a></li>
<li><a href="/wiki/6-MAPB" title="6-MAPB">6-MAPB</a></li>
<li><a href="/wiki/6-MAPDB" title="6-MAPDB">6-MAPDB</a></li>
<li><a href="/wiki/Ethylidenedioxyamphetamine" title="Ethylidenedioxyamphetamine" class="mw-redirect">EDA</a></li>
<li><a href="/wiki/Indanylaminopropane" title="Indanylaminopropane" class="mw-redirect">IAP</a></li>
<li><a href="/wiki/Methylenedioxyamphetamine" title="Methylenedioxyamphetamine">MDA</a></li>
<li><a href="/wiki/Methylenedioxyethylamphetamine" title="Methylenedioxyethylamphetamine">MDEA</a></li>
<li><a href="/wiki/Methylenedioxyhydroxylmethamphetamine" title="Methylenedioxyhydroxylmethamphetamine" class="mw-redirect">MDHMA</a></li>
<li><a href="/wiki/Methylenedioxymethamphetamine" title="Methylenedioxymethamphetamine" class="mw-redirect">MDMA</a></li>
<li><a href="/wiki/Methylenedioxyhydroxyamphetamine" title="Methylenedioxyhydroxyamphetamine">MDOH</a></li>
<li><a href="/wiki/Methoxymethylenedioxymethamphetamine" title="Methoxymethylenedioxymethamphetamine" class="mw-redirect">MMDMA</a></li>
<li><a href="/wiki/Naphthylaminopropane" title="Naphthylaminopropane">Naphthylaminopropane</a></li>
<li><a href="/wiki/Tetralinylaminopropane" title="Tetralinylaminopropane" class="mw-redirect">TAP</a><br />
<i>Others:</i> <a href="/wiki/3,4-Dichloroamphetamine" title="3,4-Dichloroamphetamine">3,4-DCA</a></li>
<li><a href="/wiki/Amiflamine" title="Amiflamine">Amiflamine</a></li>
<li><a href="/wiki/Difluoromethylenedioxyamphetamine" title="Difluoromethylenedioxyamphetamine" class="mw-redirect">DFMDA</a></li>
<li><a href="/wiki/Selegiline" title="Selegiline">Selegiline</a> (also <a href="/wiki/D-Deprenyl" title="D-Deprenyl"><span style="font-size:90%;">D</span> -Deprenyl</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phentermine" title="Phentermine">Phentermines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/Chlorphentermine" title="Chlorphentermine">Chlorphentermine</a></li>
<li><a href="/wiki/Cloforex" title="Cloforex">Cloforex</a></li>
<li><a href="/wiki/Clortermine" title="Clortermine">Clortermine</a></li>
<li><a href="/wiki/Etolorex" title="Etolorex">Etolorex</a></li>
<li><a href="/wiki/Mephentermine" title="Mephentermine">Mephentermine</a></li>
<li><a href="/wiki/Pentorex" title="Pentorex">Pentorex</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a><br />
<i>Entactogens:</i> <a href="/wiki/Methylenedioxyphentermine" title="Methylenedioxyphentermine">MDPH</a></li>
<li><a href="/wiki/Methylenedioxymethylphentermine" title="Methylenedioxymethylphentermine" class="mw-redirect">MDMPH</a><br />
<i>Others:</i> <a href="/wiki/Cericlamine" title="Cericlamine">Cericlamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_cathinone" title="Substituted cathinone">Cathinones</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/3-Fluoromethcathinone" title="3-Fluoromethcathinone">3-FMC</a></li>
<li><a href="/wiki/4-Methylcathinone" title="4-Methylcathinone">4-MC</a></li>
<li><a href="/wiki/4-Bromo-N-methylcathinone" title="4-Bromo-N-methylcathinone" class="mw-redirect">4-BMC</a></li>
<li><a href="/wiki/4-Chloromethcathinone" title="4-Chloromethcathinone">4-CMC</a></li>
<li><a href="/wiki/4-Ethylmethcathinone" title="4-Ethylmethcathinone">4-EMC</a></li>
<li><a href="/wiki/Flephedrone" title="Flephedrone">4-FMC</a></li>
<li><a href="/wiki/4-Methylethcathinone" title="4-Methylethcathinone">4-MEC</a></li>
<li><a href="/wiki/4-Methylbuphedrone" title="4-Methylbuphedrone">4-MeMABP</a></li>
<li><a href="/wiki/4-Methylpentedrone" title="4-Methylpentedrone">4-MPD</a></li>
<li><a href="/wiki/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li><a href="/wiki/Benzedrone" title="Benzedrone">Benzedrone</a></li>
<li><a href="/wiki/Brephedrone" title="Brephedrone" class="mw-redirect">Brephedrone</a></li>
<li><a href="/wiki/Buphedrone" title="Buphedrone">Buphedrone</a></li>
<li><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="/wiki/Cathinone" title="Cathinone">Cathinone</a></li>
<li><a href="/wiki/Dimethylcathinone" title="Dimethylcathinone" class="mw-redirect">Dimethylcathinone</a></li>
<li><a href="/wiki/Ethcathinone" title="Ethcathinone">Ethcathinone</a></li>
<li><a href="/wiki/Eutylone" title="Eutylone">Eutylone</a></li>
<li><a href="/wiki/Hydroxybupropion" title="Hydroxybupropion">Hydroxybupropion</a></li>
<li><a href="/wiki/Methcathinone" title="Methcathinone">Methcathinone</a></li>
<li><a href="/wiki/Methedrone" title="Methedrone">Methedrone</a></li>
<li><a href="/wiki/N-Ethylbuphedrone" title="N-Ethylbuphedrone">NEB</a></li>
<li><a href="/wiki/Pentedrone" title="Pentedrone">Pentedrone</a></li>
<li><a href="/wiki/Pentylone" title="Pentylone">Pentylone</a></li>
<li><a href="/wiki/Radafaxine" title="Radafaxine">Radafaxine</a><br />
<i>Entactogens:</i> <a href="/wiki/3,4-Dimethylmethcathinone" title="3,4-Dimethylmethcathinone">3,4-DMMC</a></li>
<li><a href="/wiki/3-Methylmethcathinone" title="3-Methylmethcathinone">3-MMC</a></li>
<li><a href="/wiki/Butylone" title="Butylone">Butylone</a></li>
<li><a href="/wiki/Ethylone" title="Ethylone">Ethylone</a></li>
<li><a href="/wiki/Methylone" title="Methylone">Methylone</a></li>
<li><a href="/wiki/Methylenedioxycathinone" title="Methylenedioxycathinone">Methylenedioxycathinone</a></li>
<li><a href="/wiki/Mephedrone" title="Mephedrone">Mephedrone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phenylisobutylamine" title="Phenylisobutylamine">Phenylisobutylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Entactogens:</i> <a href="/wiki/4-Chlorophenylisobutylamine" title="4-Chlorophenylisobutylamine">4-CAB</a></li>
<li><a href="/wiki/4-Methylphenylisobutylamine" title="4-Methylphenylisobutylamine">4-MAB</a></li>
<li><a href="/wiki/Ariadne_(psychedelic)" title="Ariadne (psychedelic)">Ariadne</a></li>
<li><a href="/wiki/Benzodioxolylbutanamine" title="Benzodioxolylbutanamine" class="mw-redirect">BDB</a></li>
<li><a href="/wiki/Butylone" title="Butylone">Butylone</a></li>
<li><a href="/wiki/Ethylbenzodioxolylbutanamine" title="Ethylbenzodioxolylbutanamine" class="mw-redirect">EBDB</a></li>
<li><a href="/wiki/Eutylone" title="Eutylone">Eutylone</a></li>
<li><a href="/wiki/Methylbenzodioxolylbutanamine" title="Methylbenzodioxolylbutanamine" class="mw-redirect">MBDB</a><br />
<i>Stimulants:</i> <a href="/wiki/Phenylisobutylamine" title="Phenylisobutylamine">Phenylisobutylamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phenylethylpyrrolidine" title="Phenylethylpyrrolidine">Phenylalkylpyrrolidines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/Alpha-Pyrrolidinobutiophenone" title="Alpha-Pyrrolidinobutiophenone">α-PBP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinohexiophenone" title="Alpha-Pyrrolidinohexiophenone">α-PHP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopropiophenone" title="Alpha-Pyrrolidinopropiophenone">α-PPP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopentiophenone" title="Alpha-Pyrrolidinopentiophenone">α-PVP</a></li>
<li><a href="/wiki/3%27,4%27-Methylenedioxy-%CE%B1-pyrrolidinobutiophenone" title="3',4'-Methylenedioxy-α-pyrrolidinobutiophenone">MDPBP</a></li>
<li><a href="/wiki/3%27,4%27-Methylenedioxy-%CE%B1-pyrrolidinopropiophenone" title="3',4'-Methylenedioxy-α-pyrrolidinopropiophenone">MDPPP</a></li>
<li><a href="/wiki/3,4-Methylenedioxypyrovalerone" title="3,4-Methylenedioxypyrovalerone" class="mw-redirect">MDPV</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinobutiophenone" title="4'-Methyl-α-pyrrolidinobutiophenone">4-MePBP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinohexiophenone" title="4'-Methyl-α-pyrrolidinohexiophenone">4-MePHP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone" title="4'-Methyl-α-pyrrolidinopropiophenone">4-MePPP</a></li>
<li><a href="/wiki/4%27-Methoxy-%CE%B1-pyrrolidinopropiophenone" title="4'-Methoxy-α-pyrrolidinopropiophenone">MOPPP</a></li>
<li><a href="/wiki/4%27-Methoxy-%CE%B1-Pyrrolidinopentiophenone" title="4'-Methoxy-α-Pyrrolidinopentiophenone" class="mw-redirect">MOPVP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinobutiophenone" title="4'-Methyl-α-pyrrolidinobutiophenone">MPBP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinohexiophenone" title="4'-Methyl-α-pyrrolidinohexiophenone">MPHP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone" title="4'-Methyl-α-pyrrolidinopropiophenone">MPPP</a></li>
<li><a href="/wiki/Naphyrone" title="Naphyrone">Naphyrone</a></li>
<li><a href="/wiki/Phenylethylpyrrolidine" title="Phenylethylpyrrolidine">PEP</a></li>
<li><a href="/wiki/Prolintane" title="Prolintane">Prolintane</a></li>
<li><a href="/wiki/Pyrovalerone" title="Pyrovalerone">Pyrovalerone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Catecholamine" title="Catecholamine">Catecholamines</a><br />
<span style="font-size:90%;">(and close relatives)</span></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/6-Fluoronorepinephrine" title="6-Fluoronorepinephrine">6-FNE</a></li>
<li><a href="/wiki/6-Hydroxydopamine" title="6-Hydroxydopamine" class="mw-redirect">6-OHDA</a></li>
<li><a href="/wiki/Alpha-Methyldopamine" title="Alpha-Methyldopamine">a-Me-DA</a></li>
<li><a href="/wiki/Alpha-Methyltyramine" title="Alpha-Methyltyramine" class="mw-redirect">a-Me-TRA</a></li>
<li><a href="/wiki/Adrenochrome" title="Adrenochrome">Adrenochrome</a></li>
<li><a href="/wiki/Ciladopa" title="Ciladopa">Ciladopa</a></li>
<li><a href="/wiki/D-DOPA" title="D-DOPA"><span style="font-size:90%;">D</span> -DOPA</a> (Dextrodopa)</li>
<li><a href="/wiki/Dimetofrine" title="Dimetofrine">Dimetofrine</a></li>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/Epinephrine" title="Epinephrine">Epinephrine</a></li>
<li><a href="/wiki/Epinine" title="Epinine" class="mw-redirect">Epinine</a></li>
<li><a href="/wiki/Etilefrine" title="Etilefrine">Etilefrine</a></li>
<li><a href="/wiki/Ethylnorepinephrine" title="Ethylnorepinephrine">Ethylnorepinephrine</a></li>
<li><a href="/wiki/Fenclonine" title="Fenclonine">Fenclonine</a></li>
<li><a href="/wiki/Ibopamine" title="Ibopamine">Ibopamine</a></li>
<li><a href="/wiki/Isoprenaline" title="Isoprenaline">Isoprenaline</a></li>
<li><a href="/wiki/Isoetarine" title="Isoetarine">Isoetarine</a></li>
<li><a href="/wiki/L-DOPA" title="L-DOPA"><span style="font-size:90%;">L</span> -DOPA</a> (Levodopa)</li>
<li><a href="/wiki/L-DOPS" title="L-DOPS" class="mw-redirect"><span style="font-size:90%;">L</span> -DOPS</a> (Droxidopa)</li>
<li><a href="/wiki/L-Phenylalanine" title="L-Phenylalanine" class="mw-redirect"><span style="font-size:90%;">L</span> -Phenylalanine</a></li>
<li><a href="/wiki/L-Tyrosine" title="L-Tyrosine" class="mw-redirect"><span style="font-size:90%;">L</span> -Tyrosine</a></li>
<li><a href="/wiki/Meta-Tyramine" title="Meta-Tyramine"><i>m</i>-Tyramine</a></li>
<li><a href="/wiki/Metanephrine" title="Metanephrine">Metanephrine</a></li>
<li><a href="/wiki/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="/wiki/Metaterol" title="Metaterol">Metaterol</a></li>
<li><a href="/wiki/Metirosine" title="Metirosine">Metirosine</a></li>
<li><a href="/wiki/Methyldopa" title="Methyldopa">Methyldopa</a></li>
<li><a href="/wiki/N,N-Dimethyldopamine" title="N,N-Dimethyldopamine">N,N-Dimethyldopamine</a></li>
<li><a href="/wiki/Nordefrin" title="Nordefrin" class="mw-redirect">Nordefrin</a> (<a href="/wiki/Levonordefrin" title="Levonordefrin" class="mw-redirect">Levonordefrin</a>)</li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Norfenefrine" title="Norfenefrine">Norfenefrine</a> (<i>m</i>-Octopamine)</li>
<li><a href="/wiki/Normetanephrine" title="Normetanephrine">Normetanephrine</a></li>
<li><a href="/wiki/Orciprenaline" title="Orciprenaline">Orciprenaline</a></li>
<li><a href="/wiki/Octopamine_(drug)" title="Octopamine (drug)"><i>p</i>-Octopamine</a></li>
<li><a href="/wiki/Tyramine" title="Tyramine"><i>p</i>-Tyramine</a></li>
<li><a href="/wiki/Phenylephrine" title="Phenylephrine">Phenylephrine</a></li>
<li><a href="/wiki/Synephrine" title="Synephrine">Synephrine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Miscellaneous</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/AL-LAD" title="AL-LAD">AL-LAD</a></li>
<li><a href="/wiki/Amidephrine" title="Amidephrine">Amidephrine</a></li>
<li><a href="/wiki/Arbutamine" title="Arbutamine">Arbutamine</a></li>
<li><a href="/wiki/Cafedrine" title="Cafedrine">Cafedrine</a></li>
<li><a href="/wiki/Denopamine" title="Denopamine">Denopamine</a></li>
<li><a href="/wiki/Desvenlafaxine" title="Desvenlafaxine">Desvenlafaxine</a></li>
<li><a href="/wiki/Diphenidine" title="Diphenidine">Diphenidine</a></li>
<li><a href="/wiki/Dizocilpine" title="Dizocilpine">Dizocilpine</a></li>
<li><a href="/wiki/Dobutamine" title="Dobutamine">Dobutamine</a></li>
<li><a href="/wiki/Dopexamine" title="Dopexamine">Dopexamine</a></li>
<li><a href="/wiki/Ephenidine" title="Ephenidine">Ephenidine</a></li>
<li><a href="/wiki/Etafedrine" title="Etafedrine">Etafedrine</a></li>
<li><a href="/wiki/ETH-LAD" title="ETH-LAD">ETH-LAD</a></li>
<li><a href="/wiki/Famprofazone" title="Famprofazone">Famprofazone</a></li>
<li><a href="/wiki/Fluorolintane" title="Fluorolintane">Fluorolintane</a></li>
<li><a href="/wiki/Hexapradol" title="Hexapradol">Hexapradol</a></li>
<li><a href="/wiki/IP-LAD" title="IP-LAD" class="mw-redirect">IP-LAD</a></li>
<li><a href="/wiki/Lysergic_acid_amide" title="Lysergic acid amide" class="mw-redirect">Lysergic acid amide</a></li>
<li><a href="/wiki/Lysergic_acid_2-butyl_amide" title="Lysergic acid 2-butyl amide">Lysergic acid 2-butyl amide</a></li>
<li><a href="/wiki/Lysergic_acid_2,4-dimethylazetidide" title="Lysergic acid 2,4-dimethylazetidide">Lysergic acid 2,4-dimethylazetidide</a></li>
<li><a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">Lysergic acid diethylamide</a></li>
<li><a href="/wiki/Methoxamine" title="Methoxamine">Methoxamine</a></li>
<li><a href="/wiki/Methoxphenidine" title="Methoxphenidine">Methoxphenidine</a></li>
<li><a href="/wiki/MT-45" title="MT-45">MT-45</a></li>
<li><a href="/wiki/PARGY-LAD" title="PARGY-LAD">PARGY-LAD</a></li>
<li><a href="/wiki/Phenibut" title="Phenibut">Phenibut</a></li>
<li><a href="/wiki/PRO-LAD" title="PRO-LAD">PRO-LAD</a></li>
<li><a href="/wiki/Pronethalol" title="Pronethalol">Pronethalol</a></li>
<li><a href="/wiki/Salbutamol" title="Salbutamol">Salbutamol</a> (<a href="/wiki/Levosalbutamol" title="Levosalbutamol">Levosalbutamol</a>)</li>
<li><a href="/wiki/Theodrenaline" title="Theodrenaline">Theodrenaline</a></li>
<li><a href="/wiki/Thiamphenicol" title="Thiamphenicol">Thiamphenicol</a></li>
<li><a href="/wiki/UWA-101" title="UWA-101">UWA-101</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Stimulants" title="Template:Stimulants"><abbr title="View this template" style=";;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Stimulants" title="Template talk:Stimulants"><abbr title="Discuss this template" style=";;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Stimulants&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div style="font-size:114%"><a href="/wiki/Stimulant" title="Stimulant">Stimulants</a> (<a href="/wiki/ATC_code_N06#N06B" title="ATC code N06">N06B</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Adamantane" title="Adamantane">Adamantanes</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/w/index.php?title=Adaphenoxate&amp;action=edit&amp;redlink=1" class="new" title="Adaphenoxate (page does not exist)">Adaphenoxate</a></li>
<li><a href="/wiki/Adapromine" title="Adapromine">Adapromine</a></li>
<li><a href="/wiki/Amantadine" title="Amantadine">Amantadine</a></li>
<li><a href="/wiki/Bromantane" title="Bromantane">Bromantane</a></li>
<li><a href="/w/index.php?title=Chlodantane&amp;action=edit&amp;redlink=1" class="new" title="Chlodantane (page does not exist)">Chlodantane</a></li>
<li><a href="/w/index.php?title=Gludantane&amp;action=edit&amp;redlink=1" class="new" title="Gludantane (page does not exist)">Gludantane</a></li>
<li><a href="/wiki/Memantine" title="Memantine">Memantine</a></li>
<li><a href="/wiki/Rimantadine" title="Rimantadine">Rimantadine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Adenosine_receptor" title="Adenosine receptor">Adenosine antagonists</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/8-Chlorotheophylline" title="8-Chlorotheophylline">8-Chlorotheophylline</a></li>
<li><a href="/wiki/8-Cyclopentyl-1,3-dimethylxanthine" title="8-Cyclopentyl-1,3-dimethylxanthine">8-Cyclopentyltheophylline</a></li>
<li><a href="/wiki/8-Phenyltheophylline" title="8-Phenyltheophylline">8-Phenyltheophylline</a></li>
<li><a href="/wiki/Aminophylline" title="Aminophylline">Aminophylline</a></li>
<li><a href="/wiki/Caffeine" title="Caffeine">Caffeine</a></li>
<li><a href="/wiki/CGS-15943" title="CGS-15943">CGS-15943</a></li>
<li><a href="/wiki/Dimethazan" title="Dimethazan">Dimethazan</a></li>
<li><a href="/wiki/Paraxanthine" title="Paraxanthine">Paraxanthine</a></li>
<li><a href="/wiki/SCH-58261" title="SCH-58261">SCH-58261</a></li>
<li><a href="/wiki/Theobromine" title="Theobromine">Theobromine</a></li>
<li><a href="/wiki/Theophylline" title="Theophylline">Theophylline</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Psychotropic_alkylamines" title="Psychotropic alkylamines">Alkylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Cyclopentamine" title="Cyclopentamine">Cyclopentamine</a></li>
<li><a href="/wiki/Cypenamine" title="Cypenamine">Cypenamine</a></li>
<li><a href="/wiki/Cyprodenate" title="Cyprodenate">Cyprodenate</a></li>
<li><a href="/wiki/Heptaminol" title="Heptaminol">Heptaminol</a></li>
<li><a href="/wiki/Isometheptene" title="Isometheptene">Isometheptene</a></li>
<li><a href="/wiki/Methylhexanamine" title="Methylhexanamine">Methylhexaneamine</a></li>
<li><a href="/wiki/Octodrine" title="Octodrine">Octodrine</a></li>
<li><a href="/wiki/Propylhexedrine" title="Propylhexedrine">Propylhexedrine</a></li>
<li><a href="/wiki/Tuaminoheptane" title="Tuaminoheptane">Tuaminoheptane</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Ampakine" title="Ampakine">Ampakines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/CX-516" title="CX-516">CX-516</a></li>
<li><a href="/wiki/CX-546" title="CX-546">CX-546</a></li>
<li><a href="/wiki/CX-614" title="CX-614" class="mw-redirect">CX-614</a></li>
<li><a href="/wiki/Farampator" title="Farampator">CX-691</a></li>
<li><a href="/wiki/CX717" title="CX717">CX-717</a></li>
<li><a href="/wiki/IDRA-21" title="IDRA-21">IDRA-21</a></li>
<li><a href="/wiki/LY-404,187" title="LY-404,187">LY-404,187</a></li>
<li><a href="/wiki/LY-503,430" title="LY-503,430">LY-503,430</a></li>
<li><a href="/wiki/Nooglutyl" title="Nooglutyl">Nooglutyl</a></li>
<li><a href="/wiki/Org_26576" title="Org 26576">Org 26576</a></li>
<li><a href="/wiki/PEPA_(drug)" title="PEPA (drug)">PEPA</a></li>
<li><a href="/wiki/S-18986" title="S-18986">S-18986</a></li>
<li><a href="/wiki/Sunifiram" title="Sunifiram">Sunifiram</a></li>
<li><a href="/wiki/Unifiram" title="Unifiram">Unifiram</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Arylcyclohexylamine" title="Arylcyclohexylamine">Arylcyclohexylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Benocyclidine" title="Benocyclidine">Benocyclidine</a></li>
<li><a href="/wiki/Dieticyclidine" title="Dieticyclidine">Dieticyclidine</a></li>
<li><a href="/wiki/Esketamine" title="Esketamine">Esketamine</a></li>
<li><a href="/wiki/Eticyclidine" title="Eticyclidine">Eticyclidine</a></li>
<li><a href="/wiki/Gacyclidine" title="Gacyclidine">Gacyclidine</a></li>
<li><a href="/wiki/Ketamine" title="Ketamine">Ketamine</a></li>
<li><a href="/wiki/Phencyclamine" title="Phencyclamine">Phencyclamine</a></li>
<li><a href="/wiki/Phencyclidine" title="Phencyclidine">Phencyclidine</a></li>
<li><a href="/wiki/Rolicyclidine" title="Rolicyclidine">Rolicyclidine</a></li>
<li><a href="/wiki/Tenocyclidine" title="Tenocyclidine">Tenocyclidine</a></li>
<li><a href="/wiki/Tiletamine" title="Tiletamine">Tiletamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Benzazepine" title="Benzazepine">Benzazepines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/6-Br-APB" title="6-Br-APB">6-Br-APB</a></li>
<li><a href="/wiki/SKF-77434" title="SKF-77434" class="mw-redirect">SKF-77434</a></li>
<li><a href="/wiki/SKF-81297" title="SKF-81297" class="mw-redirect">SKF-81297</a></li>
<li><a href="/wiki/SKF-82958" title="SKF-82958" class="mw-redirect">SKF-82958</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Acetylcholine" title="Acetylcholine">Cholinergics</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/A-84,543" title="A-84,543">A-84,543</a></li>
<li><a href="/wiki/A-366,833" title="A-366,833">A-366,833</a></li>
<li><a href="/wiki/ABT-202" title="ABT-202">ABT-202</a></li>
<li><a href="/wiki/ABT-418" title="ABT-418">ABT-418</a></li>
<li><a href="/wiki/AR-R17779" title="AR-R17779">AR-R17779</a></li>
<li><a href="/wiki/Altinicline" title="Altinicline">Altinicline</a></li>
<li><a href="/wiki/Anabasine" title="Anabasine">Anabasine</a></li>
<li><a href="/wiki/Arecoline" title="Arecoline">Arecoline</a></li>
<li><a href="/wiki/Bradanicline" title="Bradanicline">Bradanicline</a></li>
<li><a href="/wiki/Cotinine" title="Cotinine">Cotinine</a></li>
<li><a href="/wiki/Cytisine" title="Cytisine">Cytisine</a></li>
<li><a href="/wiki/Dianicline" title="Dianicline">Dianicline</a></li>
<li><a href="/wiki/Epibatidine" title="Epibatidine">Epibatidine</a></li>
<li><a href="/wiki/Epiboxidine" title="Epiboxidine">Epiboxidine</a></li>
<li><a href="/wiki/GTS-21" title="GTS-21">GTS-21</a></li>
<li><a href="/wiki/Ispronicline" title="Ispronicline">Ispronicline</a></li>
<li><a href="/wiki/Nicotine" title="Nicotine">Nicotine</a></li>
<li><a href="/wiki/PHA-543,613" title="PHA-543,613">PHA-543,613</a></li>
<li><a href="/wiki/PNU-120,596" title="PNU-120,596">PNU-120,596</a></li>
<li><a href="/wiki/PNU-282,987" title="PNU-282,987">PNU-282,987</a></li>
<li><a href="/wiki/Pozanicline" title="Pozanicline">Pozanicline</a></li>
<li><a href="/wiki/Rivanicline" title="Rivanicline">Rivanicline</a></li>
<li><a href="/wiki/Sazetidine_A" title="Sazetidine A">Sazetidine A</a></li>
<li><a href="/wiki/SIB-1553A" title="SIB-1553A">SIB-1553A</a></li>
<li><a href="/wiki/SSR-180,711" title="SSR-180,711">SSR-180,711</a></li>
<li><a href="/wiki/TC-1698" title="TC-1698">TC-1698</a></li>
<li><a href="/wiki/TC-1827" title="TC-1827">TC-1827</a></li>
<li><a href="/wiki/TC-2216" title="TC-2216">TC-2216</a></li>
<li><a href="/wiki/Tebanicline" title="Tebanicline">Tebanicline</a></li>
<li><a href="/wiki/UB-165" title="UB-165">UB-165</a></li>
<li><a href="/wiki/Varenicline" title="Varenicline">Varenicline</a></li>
<li><a href="/wiki/WAY-317,538" title="WAY-317,538">WAY-317,538</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Convulsion" title="Convulsion">Convulsants</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anatoxin-a" title="Anatoxin-a">Anatoxin-a</a></li>
<li><a href="/wiki/Bicuculline" title="Bicuculline">Bicuculline</a></li>
<li><a href="/wiki/DMCM" title="DMCM">DMCM</a></li>
<li><a href="/wiki/Flurothyl" title="Flurothyl">Flurothyl</a></li>
<li><a href="/wiki/Gabazine" title="Gabazine">Gabazine</a></li>
<li><a href="/wiki/Pentylenetetrazol" title="Pentylenetetrazol">Pentetrazol</a></li>
<li><a href="/wiki/Picrotoxin" title="Picrotoxin">Picrotoxin</a></li>
<li><a href="/wiki/Strychnine" title="Strychnine">Strychnine</a></li>
<li><a href="/wiki/Thujone" title="Thujone">Thujone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Eugeroic" title="Eugeroic" class="mw-redirect">Eugeroics</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Adrafinil" title="Adrafinil">Adrafinil</a></li>
<li><a href="/wiki/Armodafinil" title="Armodafinil">Armodafinil</a></li>
<li><a href="/wiki/CRL-40,940" title="CRL-40,940">CRL-40,940</a></li>
<li><a href="/wiki/CRL-40,941" title="CRL-40,941">CRL-40,941</a></li>
<li><a href="/wiki/Fluorenol" title="Fluorenol">Fluorenol</a></li>
<li><a href="/wiki/JZ-IV-10" title="JZ-IV-10">JZ-IV-10</a></li>
<li><a href="/wiki/Modafinil" title="Modafinil">Modafinil</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Oxazoline" title="Oxazoline">Oxazolines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/4-Methylaminorex" title="4-Methylaminorex">4-Methylaminorex</a></li>
<li><a href="/wiki/Aminorex" title="Aminorex">Aminorex</a></li>
<li><a href="/wiki/Clominorex" title="Clominorex">Clominorex</a></li>
<li><a href="/wiki/Cyclazodone" title="Cyclazodone">Cyclazodone</a></li>
<li><a href="/wiki/Fenozolone" title="Fenozolone">Fenozolone</a></li>
<li><a href="/wiki/Fluminorex" title="Fluminorex">Fluminorex</a></li>
<li><a href="/wiki/Pemoline" title="Pemoline">Pemoline</a></li>
<li><a href="/wiki/Thozalinone" title="Thozalinone">Thozalinone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">Phenethylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/4-Methylphenylisobutylamine" title="4-Methylphenylisobutylamine">1-(4-Methylphenyl)-2-aminobutane</a></li>
<li><a href="/w/index.php?title=1-Phenyl-2-(piperidin-1-yl)pentan-3-one&amp;action=edit&amp;redlink=1" class="new" title="1-Phenyl-2-(piperidin-1-yl)pentan-3-one (page does not exist)">1-Phenyl-2-(piperidin-1-yl)pentan-3-one</a></li>
<li><a href="/wiki/1-Methylamino-1-(3,4-methylenedioxyphenyl)propane" title="1-Methylamino-1-(3,4-methylenedioxyphenyl)propane">1-Methylamino-1-(3,4-methylenedioxyphenyl)propane</a></li>
<li><a href="/wiki/2-FA" title="2-FA" class="mw-redirect">2-Fuoroamphetamine</a></li>
<li><a href="/wiki/2-FMA" title="2-FMA" class="mw-redirect">2-Fuoromethamphetamine</a></li>
<li><a href="/wiki/2-Hydroxyphenethylamine" title="2-Hydroxyphenethylamine" class="mw-redirect">2-OH-PEA</a></li>
<li><a href="/wiki/2-Phenyl-3-aminobutane" title="2-Phenyl-3-aminobutane">2-Phenyl-3-aminobutane</a></li>
<li><a href="/w/index.php?title=2-Phenyl-3-methylaminobutane&amp;action=edit&amp;redlink=1" class="new" title="2-Phenyl-3-methylaminobutane (page does not exist)">2-Phenyl-3-methylaminobutane</a></li>
<li><a href="/wiki/2,3-Methylenedioxyamphetamine" title="2,3-Methylenedioxyamphetamine">2,3-MDA</a></li>
<li><a href="/wiki/3-FA" title="3-FA" class="mw-redirect">3-Fuoroamphetamine</a></li>
<li><a href="/wiki/3-Fluoroethamphetamine" title="3-Fluoroethamphetamine">3-Fluoroethamphetamine</a></li>
<li><a href="/wiki/3-Fluoromethcathinone" title="3-Fluoromethcathinone">3-Fluoromethcathinone</a></li>
<li><a href="/wiki/3-Methoxyamphetamine" title="3-Methoxyamphetamine">3-Methoxyamphetamine</a></li>
<li><a href="/wiki/3-Methylamphetamine" title="3-Methylamphetamine">3-Methylamphetamine</a></li>
<li><a href="/wiki/3,4-Dimethylmethcathinone" title="3,4-Dimethylmethcathinone">3,4-DMMC</a></li>
<li><a href="/wiki/4-Bromomethcathinone" title="4-Bromomethcathinone">4-BMC</a></li>
<li><a href="/wiki/4-Chloromethcathinone" title="4-Chloromethcathinone">4-CMC</a></li>
<li><a href="/wiki/4-Ethylamphetamine" title="4-Ethylamphetamine">4-Ethylamphetamine</a></li>
<li><a href="/wiki/4-FA" title="4-FA" class="mw-redirect">4-Fluoroamphetamine</a></li>
<li><a href="/wiki/4-FMA" title="4-FMA" class="mw-redirect">4-Fluoromethamphetamine</a></li>
<li><a href="/wiki/4-Methylamphetamine" title="4-Methylamphetamine">4-MA</a></li>
<li><a href="/wiki/4-Methylbuphedrone" title="4-Methylbuphedrone">4-Methylbuphedrone</a></li>
<li><a href="/wiki/4-Methylcathinone" title="4-Methylcathinone">4-Methylcathinone</a></li>
<li><a href="/wiki/4-Methylmethamphetamine" title="4-Methylmethamphetamine">4-MMA</a></li>
<li><a href="/wiki/4-Methylpentedrone" title="4-Methylpentedrone">4-Methylpentedrone</a></li>
<li><a href="/wiki/4-Methylthioamphetamine" title="4-Methylthioamphetamine">4-MTA</a></li>
<li><a href="/wiki/6-Fluoronorepinephrine" title="6-Fluoronorepinephrine">6-FNE</a></li>
<li><a href="/wiki/AL-1095" title="AL-1095">AL-1095</a></li>
<li><a href="/wiki/Alfetamine" title="Alfetamine">Alfetamine</a></li>
<li><a href="/wiki/Alpha-Ethylphenethylamine" title="Alpha-Ethylphenethylamine" class="mw-redirect">a-Ethylphenethylamine</a></li>
<li><a href="/wiki/Amfecloral" title="Amfecloral">Amfecloral</a></li>
<li><a href="/wiki/Amfepentorex" title="Amfepentorex">Amfepentorex</a></li>
<li><a href="/wiki/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li><a href="/wiki/Amidephrine" title="Amidephrine">Amidephrine</a></li>
<li><a href="/wiki/2-Amino-1,2-dihydronaphthalene" title="2-Amino-1,2-dihydronaphthalene">2-Amino-1,2-dihydronaphthalene</a></li>
<li><a href="/wiki/2-Aminoindane" title="2-Aminoindane">2-Aminoindane</a></li>
<li><a href="/wiki/5-(2-Aminopropyl)indole" title="5-(2-Aminopropyl)indole" class="mw-redirect">5-(2-Aminopropyl)indole</a></li>
<li><a href="/wiki/2-Aminotetralin" title="2-Aminotetralin">2-Aminotetralin</a></li>
<li><a href="/wiki/Acridorex" title="Acridorex">Acridorex</a></li>
<li><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a> (<a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>, <a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>)</li>
<li><a href="/wiki/Amphetaminil" title="Amphetaminil">Amphetaminil</a></li>
<li><a href="/wiki/Arbutamine" title="Arbutamine">Arbutamine</a></li>
<li><a href="/wiki/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Methylphenethylamine</a></li>
<li><a href="/wiki/%CE%92-Phenylmethamphetamine" title="Β-Phenylmethamphetamine" class="mw-redirect">β-Phenylmethamphetamine</a></li>
<li><a href="/wiki/Benfluorex" title="Benfluorex">Benfluorex</a></li>
<li><a href="/wiki/Benzedrone" title="Benzedrone">Benzedrone</a></li>
<li><a href="/wiki/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li><a href="/wiki/Benzodioxolylbutanamine" title="Benzodioxolylbutanamine" class="mw-redirect">BDB</a></li>
<li><a href="/wiki/BOH_(drug)" title="BOH (drug)">BOH</a></li>
<li><a href="/wiki/3-Benzhydrylmorpholine" title="3-Benzhydrylmorpholine">3-Benzhydrylmorpholine</a></li>
<li><a href="/wiki/Benzofuranylpropylaminopentane" title="Benzofuranylpropylaminopentane">BPAP</a></li>
<li><a href="/wiki/Buphedrone" title="Buphedrone">Buphedrone</a></li>
<li><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="/wiki/Butylone" title="Butylone">Butylone</a></li>
<li><a href="/wiki/Camfetamine" title="Camfetamine">Camfetamine</a></li>
<li><a href="/wiki/Cathine" title="Cathine">Cathine</a></li>
<li><a href="/wiki/Cathinone" title="Cathinone">Cathinone</a></li>
<li><a href="/wiki/Chlorphentermine" title="Chlorphentermine">Chlorphentermine</a></li>
<li><a href="/wiki/Cilobamine" title="Cilobamine">Cilobamine</a></li>
<li><a href="/wiki/Cinnamedrine" title="Cinnamedrine">Cinnamedrine</a></li>
<li><a href="/wiki/Clenbuterol" title="Clenbuterol">Clenbuterol</a></li>
<li><a href="/wiki/Clobenzorex" title="Clobenzorex">Clobenzorex</a></li>
<li><a href="/wiki/Cloforex" title="Cloforex">Cloforex</a></li>
<li><a href="/wiki/Clortermine" title="Clortermine">Clortermine</a></li>
<li><a href="/wiki/Cypenamine" title="Cypenamine">Cypenamine</a></li>
<li><a href="/wiki/D-Deprenyl" title="D-Deprenyl"><small>D</small>-Deprenyl</a></li>
<li><a href="/wiki/Denopamine" title="Denopamine">Denopamine</a></li>
<li><a href="/wiki/Dimethoxyamphetamine" title="Dimethoxyamphetamine">Dimethoxyamphetamine</a></li>
<li><a href="/wiki/Dimethylamphetamine" title="Dimethylamphetamine">Dimethylamphetamine</a></li>
<li><a href="/wiki/Dimethylcathinone" title="Dimethylcathinone" class="mw-redirect">Dimethylcathinone</a></li>
<li><a href="/wiki/Dobutamine" title="Dobutamine">Dobutamine</a></li>
<li><a href="/wiki/L-DOPA" title="L-DOPA">DOPA</a> (<a href="/wiki/D-DOPA" title="D-DOPA">Dextrodopa</a>, <a href="/wiki/L-DOPA" title="L-DOPA">Levodopa</a>)</li>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/Dopexamine" title="Dopexamine">Dopexamine</a></li>
<li><a href="/wiki/L-DOPS" title="L-DOPS" class="mw-redirect">Droxidopa</a></li>
<li><a href="/wiki/Ethylbenzodioxolylbutanamine" title="Ethylbenzodioxolylbutanamine" class="mw-redirect">EBDB</a></li>
<li><a href="/wiki/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li><a href="/wiki/Epinephrine" title="Epinephrine">Epinephrine</a></li>
<li><a href="/wiki/Epinine" title="Epinine" class="mw-redirect">Epinine</a></li>
<li><a href="/wiki/Etafedrine" title="Etafedrine">Etafedrine</a></li>
<li><a href="/wiki/Ethcathinone" title="Ethcathinone">Ethcathinone</a></li>
<li><a href="/wiki/Ethylnorepinephrine" title="Ethylnorepinephrine">Ethylnorepinephrine</a></li>
<li><a href="/wiki/Ethylone" title="Ethylone">Ethylone</a></li>
<li><a href="/wiki/Etilamfetamine" title="Etilamfetamine">Etilamfetamine</a></li>
<li><a href="/wiki/Etilefrine" title="Etilefrine">Etilefrine</a></li>
<li><a href="/wiki/Famprofazone" title="Famprofazone">Famprofazone</a></li>
<li><a href="/wiki/Fencamfamine" title="Fencamfamine">Fencamfamine</a></li>
<li><a href="/wiki/Fencamine" title="Fencamine">Fencamine</a></li>
<li><a href="/wiki/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="/wiki/Fenfluramine" title="Fenfluramine">Fenfluramine</a> (<a href="/wiki/Dexfenfluramine" title="Dexfenfluramine">Dexfenfluramine</a>, <a href="/wiki/Levofenfluramine" title="Levofenfluramine">Levofenfluramine</a>)</li>
<li><a href="/wiki/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li><a href="/wiki/Feprosidnine" title="Feprosidnine">Feprosidnine</a></li>
<li><a href="/wiki/Flephedrone" title="Flephedrone">Flephedrone</a></li>
<li><a href="/wiki/Fludorex" title="Fludorex">Fludorex</a></li>
<li><a href="/wiki/Formetorex" title="Formetorex">Formetorex</a></li>
<li><a href="/wiki/Furfenorex" title="Furfenorex">Furfenorex</a></li>
<li><a href="/wiki/Gepefrine" title="Gepefrine">Gepefrine</a></li>
<li><a href="/wiki/Hexapradol" title="Hexapradol">Hexapradol</a></li>
<li><a href="/wiki/4-Hydroxy-3-methoxymethamphetamine" title="4-Hydroxy-3-methoxymethamphetamine">HMMA</a></li>
<li><a href="/wiki/Hordenine" title="Hordenine">Hordenine</a></li>
<li><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine">4-Hydroxyamphetamine</a></li>
<li><a href="/wiki/5-IAI" title="5-IAI">5-Iodo-2-aminoindane</a></li>
<li><a href="/wiki/Ibopamine" title="Ibopamine">Ibopamine</a></li>
<li><a href="/wiki/Indanylmethylaminopropane" title="Indanylmethylaminopropane" class="mw-redirect">IMP</a></li>
<li><a href="/wiki/Indanylaminopropane" title="Indanylaminopropane" class="mw-redirect">Indanylamphetamine</a></li>
<li><a href="/wiki/Iofetamine" title="Iofetamine" class="mw-redirect">Iofetamine</a></li>
<li><a href="/wiki/Isoetarine" title="Isoetarine">Isoetarine</a></li>
<li><a href="/wiki/Isoethcathinone" title="Isoethcathinone">Isoethcathinone</a></li>
<li><a href="/wiki/Isoprenaline" title="Isoprenaline">Isoprenaline</a></li>
<li><a href="/wiki/Selegiline" title="Selegiline"><small>L</small>-Deprenyl</a> (Selegiline)</li>
<li><a href="/wiki/Lefetamine" title="Lefetamine">Lefetamine</a></li>
<li><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li><a href="/wiki/Lophophine" title="Lophophine">Lophophine</a></li>
<li><a href="/wiki/Methylbenzodioxolylbutanamine" title="Methylbenzodioxolylbutanamine" class="mw-redirect">MBDB</a></li>
<li><a href="/wiki/3,4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine" class="mw-redirect">MDA</a></li>
<li><a href="/wiki/Methylenedioxybutylamphetamine" title="Methylenedioxybutylamphetamine">MDBU</a></li>
<li><a href="/wiki/Methylenedioxyethylamphetamine" title="Methylenedioxyethylamphetamine">MDEA</a></li>
<li><a href="/wiki/MDMA" title="MDMA">MDMA</a></li>
<li><a href="/wiki/Methylenedioxymethylphenethylamine" title="Methylenedioxymethylphenethylamine">MDMPEA</a></li>
<li><a href="/wiki/Methylenedioxyhydroxyamphetamine" title="Methylenedioxyhydroxyamphetamine">MDOH</a></li>
<li><a href="/wiki/Methylenedioxypropylamphetamine" title="Methylenedioxypropylamphetamine" class="mw-redirect">MDPR</a></li>
<li><a href="/wiki/Methylenedioxyphenethylamine" title="Methylenedioxyphenethylamine">MDPEA</a></li>
<li><a href="/wiki/Mefenorex" title="Mefenorex">Mefenorex</a></li>
<li><a href="/wiki/Mephedrone" title="Mephedrone">Mephedrone</a></li>
<li><a href="/wiki/Mephentermine" title="Mephentermine">Mephentermine</a></li>
<li><a href="/wiki/Metanephrine" title="Metanephrine">Metanephrine</a></li>
<li><a href="/wiki/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="/wiki/Mesocarb" title="Mesocarb">Mesocarb</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a> (<a href="/wiki/Methamphetamine" title="Methamphetamine">Dextromethamphetamine</a>, <a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Levomethamphetamine</a>)</li>
<li><a href="/wiki/Methoxamine" title="Methoxamine">Methoxamine</a></li>
<li><a href="/wiki/Methoxyphenamine" title="Methoxyphenamine">Methoxyphenamine</a></li>
<li><a href="/wiki/3-Methoxy-4-methylamphetamine" title="3-Methoxy-4-methylamphetamine">MMA</a></li>
<li><a href="/wiki/Methcathinone" title="Methcathinone">Methcathinone</a></li>
<li><a href="/wiki/Methedrone" title="Methedrone">Methedrone</a></li>
<li><a href="/wiki/Methoxyphenamine" title="Methoxyphenamine">Methoxyphenamine</a></li>
<li><a href="/wiki/Methylenedioxycathinone" title="Methylenedioxycathinone">Methylenedioxycathinone</a></li>
<li><a href="/wiki/Methylone" title="Methylone">Methylone</a></li>
<li><a href="/wiki/Mexedrone" title="Mexedrone">Mexedrone</a></li>
<li><a href="/wiki/MMDA_(drug)" title="MMDA (drug)">MMDA</a></li>
<li><a href="/wiki/MMDMA_(drug)" title="MMDMA (drug)">MMDMA</a></li>
<li><a href="/wiki/3-Methoxymethamphetamine" title="3-Methoxymethamphetamine">MMMA</a></li>
<li><a href="/wiki/Morforex" title="Morforex">Morforex</a></li>
<li><a href="/wiki/N,alpha-Diethylphenylethylamine" title="N,alpha-Diethylphenylethylamine">N,alpha-Diethylphenylethylamine</a></li>
<li><a href="/w/index.php?title=N-Benzyl-1-phenethylamine&amp;action=edit&amp;redlink=1" class="new" title="N-Benzyl-1-phenethylamine (page does not exist)">N-Benzyl-1-phenethylamine</a></li>
<li><a href="/wiki/N-Ethylbuphedrone" title="N-Ethylbuphedrone">N-Ethylbuphedrone</a></li>
<li><a href="/w/index.php?title=N,N-Dimethylphenethylamine&amp;action=edit&amp;redlink=1" class="new" title="N,N-Dimethylphenethylamine (page does not exist)">N,N-Dimethylphenethylamine</a></li>
<li><a href="/wiki/Naphthylaminopropane" title="Naphthylaminopropane">Naphthylamphetamine</a></li>
<li><a href="/wiki/Nisoxetine" title="Nisoxetine">Nisoxetine</a></li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Norfenefrine" title="Norfenefrine">Norfenefrine</a></li>
<li><a href="/wiki/Norfenfluramine" title="Norfenfluramine">Norfenfluramine</a></li>
<li><a href="/wiki/Normetanephrine" title="Normetanephrine">Normetanephrine</a></li>
<li><a href="/wiki/L-Norpseudoephedrine" title="L-Norpseudoephedrine"><small>L</small>-Norpseudoephedrine</a></li>
<li><a href="/wiki/Octopamine_(drug)" title="Octopamine (drug)">Octopamine (drug)</a></li>
<li><a href="/wiki/Orciprenaline" title="Orciprenaline">Orciprenaline</a></li>
<li><a href="/wiki/Ortetamine" title="Ortetamine">Ortetamine</a></li>
<li><a href="/wiki/Oxifentorex" title="Oxifentorex">Oxifentorex</a></li>
<li><a href="/wiki/Oxilofrine" title="Oxilofrine">Oxilofrine</a></li>
<li><a href="/wiki/Para-Bromoamphetamine" title="Para-Bromoamphetamine">PBA</a></li>
<li><a href="/wiki/Para-Chloroamphetamine" title="Para-Chloroamphetamine">PCA</a></li>
<li><a href="/wiki/Para-Chloromethamphetamine" title="Para-Chloromethamphetamine">PCMA</a></li>
<li><a href="/wiki/Norpholedrine" title="Norpholedrine" class="mw-redirect">PHA</a></li>
<li><a href="/wiki/Pentorex" title="Pentorex">Pentorex</a></li>
<li><a href="/wiki/Pentedrone" title="Pentedrone">Pentedrone</a></li>
<li><a href="/wiki/Pentylone" title="Pentylone">Pentylone</a></li>
<li><a href="/wiki/Phenatine" title="Phenatine" class="mw-redirect">Phenatine</a></li>
<li><a href="/wiki/Phenpromethamine" title="Phenpromethamine">Phenpromethamine</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="/wiki/Phenylalanine" title="Phenylalanine">Phenylalanine</a></li>
<li><a href="/wiki/Phenylephrine" title="Phenylephrine">Phenylephrine</a></li>
<li><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Phenylpropanolamine</a></li>
<li><a href="/wiki/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li><a href="/wiki/Para-Iodoamphetamine" title="Para-Iodoamphetamine">PIA</a></li>
<li><a href="/wiki/Para-Methoxyamphetamine" title="Para-Methoxyamphetamine">PMA</a></li>
<li><a href="/wiki/Para-Methoxyethylamphetamine" title="Para-Methoxyethylamphetamine" class="mw-redirect">PMEA</a></li>
<li><a href="/wiki/Para-Methoxymethamphetamine" title="Para-Methoxymethamphetamine" class="mw-redirect">PMMA</a></li>
<li><a href="/wiki/Phenylpropylaminopentane" title="Phenylpropylaminopentane">PPAP</a></li>
<li><a href="/wiki/Phthalimidopropiophenone" title="Phthalimidopropiophenone">Phthalimidopropiophenone</a></li>
<li><a href="/wiki/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li><a href="/wiki/Propylamphetamine" title="Propylamphetamine">Propylamphetamine</a></li>
<li><a href="/wiki/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li><a href="/wiki/Ropinirole" title="Ropinirole">Ropinirole</a></li>
<li><a href="/wiki/Salbutamol" title="Salbutamol">Salbutamol</a> (<a href="/wiki/Levosalbutamol" title="Levosalbutamol">Levosalbutamol</a>)</li>
<li><a href="/wiki/Sibutramine" title="Sibutramine">Sibutramine</a></li>
<li><a href="/wiki/Synephrine" title="Synephrine">Synephrine</a></li>
<li><a href="/wiki/Theodrenaline" title="Theodrenaline">Theodrenaline</a></li>
<li><a href="/wiki/Tiflorex" title="Tiflorex">Tiflorex</a></li>
<li><a href="/wiki/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></li>
<li><a href="/wiki/Tyramine" title="Tyramine">Tyramine</a></li>
<li><a href="/wiki/Tyrosine" title="Tyrosine">Tyrosine</a></li>
<li><a href="/wiki/Xylopropamine" title="Xylopropamine">Xylopropamine</a></li>
<li><a href="/wiki/Zylofuramine" title="Zylofuramine">Zylofuramine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_phenylmorpholine" title="Substituted phenylmorpholine">Phenylmorpholines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/3-Fluorophenmetrazine" title="3-Fluorophenmetrazine">3-Fluorophenmetrazine</a></li>
<li><a href="/wiki/Fenbutrazate" title="Fenbutrazate">Fenbutrazate</a></li>
<li><a href="/wiki/Fenmetramide" title="Fenmetramide">Fenmetramide</a></li>
<li><a href="/wiki/G-130" title="G-130">G-130</a></li>
<li><a href="/wiki/Manifaxine" title="Manifaxine">Manifaxine</a></li>
<li><a href="/wiki/Morazone" title="Morazone">Morazone</a></li>
<li><a href="/wiki/Morforex" title="Morforex">Morforex</a></li>
<li><a href="/wiki/Oxaflozane" title="Oxaflozane">Oxaflozane</a></li>
<li><a href="/wiki/PD-128,907" title="PD-128,907">PD-128,907</a></li>
<li><a href="/wiki/Phendimetrazine" title="Phendimetrazine">Phendimetrazine</a></li>
<li><a href="/wiki/Phenmetrazine" title="Phenmetrazine">Phenmetrazine</a></li>
<li><a href="/wiki/2-Phenyl-3,6-dimethylmorpholine" title="2-Phenyl-3,6-dimethylmorpholine">2-Phenyl-3,6-dimethylmorpholine</a></li>
<li><a href="/wiki/Pseudophenmetrazine" title="Pseudophenmetrazine">Pseudophenmetrazine</a></li>
<li><a href="/wiki/Radafaxine" title="Radafaxine">Radafaxine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Piperazine" title="Piperazine">Piperazines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/2C-B-BZP" title="2C-B-BZP">2C-B-BZP</a></li>
<li><a href="/wiki/1-(3-chlorophenyl)-4-(2-phenylethyl)piperazine" title="1-(3-chlorophenyl)-4-(2-phenylethyl)piperazine" class="mw-redirect">3C-PEP</a></li>
<li><a href="/wiki/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li><a href="/w/index.php?title=CM156&amp;action=edit&amp;redlink=1" class="new" title="CM156 (page does not exist)">CM156</a></li>
<li><a href="/wiki/DBL-583" title="DBL-583">DBL-583</a></li>
<li><a href="/wiki/GBR-12783" title="GBR-12783">GBR-12783</a></li>
<li><a href="/wiki/GBR-12935" title="GBR-12935">GBR-12935</a></li>
<li><a href="/wiki/GBR-13069" title="GBR-13069">GBR-13069</a></li>
<li><a href="/wiki/GBR-13098" title="GBR-13098">GBR-13098</a></li>
<li><a href="/wiki/GBR-13119" title="GBR-13119">GBR-13119</a></li>
<li><a href="/wiki/Para-Methoxyphenylpiperazine" title="Para-Methoxyphenylpiperazine">MeOPP</a></li>
<li><a href="/wiki/Methylbenzylpiperazine" title="Methylbenzylpiperazine">MBZP</a></li>
<li><a href="/wiki/Vanoxerine" title="Vanoxerine">Vanoxerine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Piperidine" title="Piperidine">Piperidines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/1-Benzyl-4-(2-(diphenylmethoxy)ethyl)piperidine" title="1-Benzyl-4-(2-(diphenylmethoxy)ethyl)piperidine">1-Benzyl-4-(2-(diphenylmethoxy)ethyl)piperidine</a></li>
<li><a href="/w/index.php?title=1-(3,4-Dichlorophenyl)-1-(piperidin-2-yl)butane&amp;action=edit&amp;redlink=1" class="new" title="1-(3,4-Dichlorophenyl)-1-(piperidin-2-yl)butane (page does not exist)">1-(3,4-Dichlorophenyl)-1-(piperidin-2-yl)butane</a></li>
<li><a href="/wiki/2-Benzylpiperidine" title="2-Benzylpiperidine">2-Benzylpiperidine</a></li>
<li><a href="/wiki/2-Methyl-3-phenylpiperidine" title="2-Methyl-3-phenylpiperidine">2-Methyl-3-phenylpiperidine</a></li>
<li><a href="/w/index.php?title=3-Chloromethylphenidate&amp;action=edit&amp;redlink=1" class="new" title="3-Chloromethylphenidate (page does not exist)">3-Chloromethylphenidate</a></li>
<li><a href="/wiki/3,4-Dichloromethylphenidate" title="3,4-Dichloromethylphenidate">3,4-Dichloromethylphenidate</a></li>
<li><a href="/wiki/4-Benzylpiperidine" title="4-Benzylpiperidine">4-Benzylpiperidine</a></li>
<li><a href="/wiki/4-Fluoromethylphenidate" title="4-Fluoromethylphenidate">4-Fluoromethylphenidate</a></li>
<li><a href="/wiki/4-Methylmethylphenidate" title="4-Methylmethylphenidate">4-Methylmethylphenidate</a></li>
<li><a href="/wiki/Desoxypipradrol" title="Desoxypipradrol">Desoxypipradrol</a></li>
<li><a href="/wiki/Difemetorex" title="Difemetorex">Difemetorex</a></li>
<li><a href="/wiki/Diphenylpyraline" title="Diphenylpyraline">Diphenylpyraline</a></li>
<li><a href="/wiki/HDEP-28" title="HDEP-28">Ethylnaphthidate</a></li>
<li><a href="/wiki/Ethylphenidate" title="Ethylphenidate">Ethylphenidate</a></li>
<li><a href="/wiki/HDMP-28" title="HDMP-28">Methylnaphthidate</a></li>
<li><a href="/wiki/Isopropylphenidate" title="Isopropylphenidate">Isopropylphenidate</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a> (<a href="/wiki/Dexmethylphenidate" title="Dexmethylphenidate">Dexmethylphenidate</a>)</li>
<li><a href="/w/index.php?title=N-Methyl-3%CE%B2-propyl-4%CE%B2-(4-chlorophenyl)piperidine&amp;action=edit&amp;redlink=1" class="new" title="N-Methyl-3β-propyl-4β-(4-chlorophenyl)piperidine (page does not exist)">N-Methyl-3β-propyl-4β-(4-chlorophenyl)piperidine</a></li>
<li><a href="/wiki/(%2B)-CPCA" title="(+)-CPCA">Nocaine</a></li>
<li><a href="/wiki/Levophacetoperane" title="Levophacetoperane">Phacetoperane</a></li>
<li><a href="/wiki/Pipradrol" title="Pipradrol">Pipradrol</a></li>
<li><a href="/wiki/Propylphenidate" title="Propylphenidate">Propylphenidate</a></li>
<li><a href="/wiki/SCH-5472" title="SCH-5472">SCH-5472</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Pyrrolidine" title="Pyrrolidine">Pyrrolidines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/2-Diphenylmethylpyrrolidine" title="2-Diphenylmethylpyrrolidine">2-Diphenylmethylpyrrolidine</a></li>
<li><a href="/wiki/5-DBFPV" title="5-DBFPV">5-DBFPV</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopropiophenone" title="Alpha-Pyrrolidinopropiophenone">α-PPP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinobutiophenone" title="Alpha-Pyrrolidinobutiophenone">α-PBP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinohexiophenone" title="Alpha-Pyrrolidinohexiophenone">α-PHP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopentiophenone" title="Alpha-Pyrrolidinopentiophenone">α-PVP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopentiothiophenone" title="Alpha-Pyrrolidinopentiothiophenone">α-PVT</a></li>
<li><a href="/wiki/Diphenylprolinol" title="Diphenylprolinol">Diphenylprolinol</a></li>
<li><a href="/wiki/3%27,4%27-Dimethoxy-%CE%B1-Pyrrolidinopentiophenone" title="3',4'-Dimethoxy-α-Pyrrolidinopentiophenone" class="mw-redirect">DMPVP</a></li>
<li><a href="/wiki/4%27-Fluoro-%CE%B1-Pyrrolidinooctanophenone" title="4'-Fluoro-α-Pyrrolidinooctanophenone" class="mw-redirect">FPOP</a></li>
<li><a href="/wiki/4%27-Fluoro-%CE%B1-Pyrrolidinopentiophenone" title="4'-Fluoro-α-Pyrrolidinopentiophenone" class="mw-redirect">FPVP</a></li>
<li><a href="/wiki/3%27,4%27-Methylenedioxy-%CE%B1-pyrrolidinopropiophenone" title="3',4'-Methylenedioxy-α-pyrrolidinopropiophenone">MDPPP</a></li>
<li><a href="/wiki/3%27,4%27-Methylenedioxy-%CE%B1-pyrrolidinobutiophenone" title="3',4'-Methylenedioxy-α-pyrrolidinobutiophenone">MDPBP</a></li>
<li><a href="/wiki/4%27-Methyl-a-pyrrolidinobutiophenone" title="4'-Methyl-a-pyrrolidinobutiophenone" class="mw-redirect">MPBP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinohexiophenone" title="4'-Methyl-α-pyrrolidinohexiophenone">MPHP</a></li>
<li><a href="/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone" title="4'-Methyl-α-pyrrolidinopropiophenone">MPPP</a></li>
<li><a href="/wiki/4%27-Methoxy-%CE%B1-Pyrrolidinopentiophenone" title="4'-Methoxy-α-Pyrrolidinopentiophenone" class="mw-redirect">MOPVP</a></li>
<li><a href="/wiki/4%27-Methoxy-%CE%B1-pyrrolidinopropiophenone" title="4'-Methoxy-α-pyrrolidinopropiophenone">MOPPP</a></li>
<li><a href="/wiki/Indapyrophenidone" title="Indapyrophenidone">Indapyrophenidone</a></li>
<li><a href="/wiki/Methylenedioxypyrovalerone" title="Methylenedioxypyrovalerone">MDPV</a></li>
<li><a href="/wiki/Naphyrone" title="Naphyrone">Naphyrone</a></li>
<li><a href="/wiki/Phenylethylpyrrolidine" title="Phenylethylpyrrolidine">PEP</a></li>
<li><a href="/wiki/Picilorex" title="Picilorex">Picilorex</a></li>
<li><a href="/wiki/Prolintane" title="Prolintane">Prolintane</a></li>
<li><a href="/wiki/Pyrovalerone" title="Pyrovalerone">Pyrovalerone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Racetam" title="Racetam">Racetams</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Oxiracetam" title="Oxiracetam">Oxiracetam</a></li>
<li><a href="/wiki/Phenylpiracetam" title="Phenylpiracetam">Phenylpiracetam</a></li>
<li><a href="/wiki/Phenylpiracetam_hydrazide" title="Phenylpiracetam hydrazide" class="mw-redirect">Phenylpiracetam hydrazide</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Tropane" title="Tropane">Tropanes</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/w/index.php?title=3-CPMT&amp;action=edit&amp;redlink=1" class="new" title="3-CPMT (page does not exist)">3-CPMT</a></li>
<li><a href="/w/index.php?title=3%27-Chloro-3a-(diphenylmethoxy)tropane&amp;action=edit&amp;redlink=1" class="new" title="3'-Chloro-3a-(diphenylmethoxy)tropane (page does not exist)">3'-Chloro-3a-(diphenylmethoxy)tropane</a></li>
<li><a href="/wiki/4-fluorotropacocaine" title="4-fluorotropacocaine" class="mw-redirect">4-fluorotropacocaine</a></li>
<li><a href="/wiki/4%27-Fluorococaine" title="4'-Fluorococaine" class="mw-redirect">4'-Fluorococaine</a></li>
<li><a href="/w/index.php?title=AHN-1055&amp;action=edit&amp;redlink=1" class="new" title="AHN-1055 (page does not exist)">AHN-1055</a></li>
<li><a href="/wiki/Altropane" title="Altropane">Altropane (IACFT)</a></li>
<li><a href="/wiki/Brasofensine" title="Brasofensine">Brasofensine</a></li>
<li><a href="/wiki/WIN_35428" title="WIN 35428">CFT (WIN 35,428)</a></li>
<li><a href="/wiki/RTI-55" title="RTI-55">β-CIT (RTI-55)</a></li>
<li><a href="/wiki/Cocaethylene" title="Cocaethylene">Cocaethylene</a></li>
<li><a href="/wiki/Cocaine" title="Cocaine">Cocaine</a></li>
<li><a href="/wiki/Dichloropane" title="Dichloropane">Dichloropane (RTI-111)</a></li>
<li><a href="/wiki/Difluoropine" title="Difluoropine">Difluoropine</a></li>
<li><a href="/wiki/FE-%CE%B2-CPPIT" title="FE-β-CPPIT">FE-β-CPPIT</a></li>
<li><a href="/wiki/FP-%CE%B2-CPPIT" title="FP-β-CPPIT">FP-β-CPPIT</a></li>
<li><a href="/wiki/Ioflupane_(123I)" title="Ioflupane (123I)">Ioflupane (<sup>123</sup>I)</a></li>
<li><a href="/wiki/Norcocaine" title="Norcocaine">Norcocaine</a></li>
<li><a href="/wiki/2-Propanoyl-3-(4-isopropylphenyl)-tropane" title="2-Propanoyl-3-(4-isopropylphenyl)-tropane">PIT</a></li>
<li><a href="/wiki/2%CE%B2-Propanoyl-3%CE%B2-(4-tolyl)-tropane" title="2β-Propanoyl-3β-(4-tolyl)-tropane">PTT</a></li>
<li><a href="/wiki/RTI-31" title="RTI-31">RTI-31</a></li>
<li><a href="/wiki/RTI-32" title="RTI-32">RTI-32</a></li>
<li><a href="/wiki/RTI-51" title="RTI-51">RTI-51</a></li>
<li><a href="/w/index.php?title=RTI-105&amp;action=edit&amp;redlink=1" class="new" title="RTI-105 (page does not exist)">RTI-105</a></li>
<li><a href="/wiki/RTI-112" title="RTI-112">RTI-112</a></li>
<li><a href="/wiki/RTI-113" title="RTI-113">RTI-113</a></li>
<li><a href="/w/index.php?title=RTI-117&amp;action=edit&amp;redlink=1" class="new" title="RTI-117 (page does not exist)">RTI-117</a></li>
<li><a href="/wiki/RTI-120" title="RTI-120">RTI-120</a></li>
<li><a href="/wiki/RTI-121" title="RTI-121">RTI-121 (IPCIT)</a></li>
<li><a href="/wiki/(-)-2%CE%B2-(1,2,4-Oxadiazol-5-methyl)-3%CE%B2-phenyltropane" title="(-)-2β-(1,2,4-Oxadiazol-5-methyl)-3β-phenyltropane">RTI-126</a></li>
<li><a href="/wiki/RTI-150" title="RTI-150">RTI-150</a></li>
<li><a href="/w/index.php?title=RTI-154&amp;action=edit&amp;redlink=1" class="new" title="RTI-154 (page does not exist)">RTI-154</a></li>
<li><a href="/w/index.php?title=(-)-2%CE%B2-(3-methylisoxazol-5-yl)-3%CE%B2-(4-methylphenyl)tropane&amp;action=edit&amp;redlink=1" class="new" title="(-)-2β-(3-methylisoxazol-5-yl)-3β-(4-methylphenyl)tropane (page does not exist)">RTI-171</a></li>
<li><a href="/wiki/RTI-177" title="RTI-177">RTI-177</a></li>
<li><a href="/w/index.php?title=RTI-183&amp;action=edit&amp;redlink=1" class="new" title="RTI-183 (page does not exist)">RTI-183</a></li>
<li><a href="/w/index.php?title=RTI-193&amp;action=edit&amp;redlink=1" class="new" title="RTI-193 (page does not exist)">RTI-193</a></li>
<li><a href="/w/index.php?title=RTI-194&amp;action=edit&amp;redlink=1" class="new" title="RTI-194 (page does not exist)">RTI-194</a></li>
<li><a href="/w/index.php?title=RTI-199&amp;action=edit&amp;redlink=1" class="new" title="RTI-199 (page does not exist)">RTI-199</a></li>
<li><a href="/w/index.php?title=RTI-202&amp;action=edit&amp;redlink=1" class="new" title="RTI-202 (page does not exist)">RTI-202</a></li>
<li><a href="/w/index.php?title=RTI-204&amp;action=edit&amp;redlink=1" class="new" title="RTI-204 (page does not exist)">RTI-204</a></li>
<li><a href="/wiki/RTI-229" title="RTI-229">RTI-229</a></li>
<li><a href="/w/index.php?title=RTI-241&amp;action=edit&amp;redlink=1" class="new" title="RTI-241 (page does not exist)">RTI-241</a></li>
<li><a href="/wiki/(-)-2%CE%B2-(3-(4-Methylphenyl)isoxazol-5-yl)-3%CE%B2-(4-chlorophenyl)tropane" title="(-)-2β-(3-(4-Methylphenyl)isoxazol-5-yl)-3β-(4-chlorophenyl)tropane">RTI-336</a></li>
<li><a href="/wiki/RTI-354" title="RTI-354" class="mw-redirect">RTI-354</a></li>
<li><a href="/wiki/RTI-371" title="RTI-371">RTI-371</a></li>
<li><a href="/wiki/RTI-386" title="RTI-386" class="mw-redirect">RTI-386</a></li>
<li><a href="/wiki/Salicylmethylecgonine" title="Salicylmethylecgonine">Salicylmethylecgonine</a></li>
<li><a href="/wiki/Tesofensine" title="Tesofensine">Tesofensine</a></li>
<li><a href="/wiki/Troparil" title="Troparil">Troparil (β-CPT, WIN 35,065-2)</a></li>
<li><a href="/wiki/Tropoxane" title="Tropoxane">Tropoxane</a></li>
<li><a href="/wiki/2%CE%B2-Propanoyl-3%CE%B2-(2-naphthyl)-tropane" title="2β-Propanoyl-3β-(2-naphthyl)-tropane">WF-23</a></li>
<li><a href="/wiki/2%CE%B1-(Propanoyl)-3%CE%B2-(2-(6-methoxynaphthyl))-tropane" title="2α-(Propanoyl)-3β-(2-(6-methoxynaphthyl))-tropane">WF-33</a></li>
<li><a href="/w/index.php?title=2%CE%B2-Propanoyl-3%CE%B2-(2-isopropenyl)-tropane&amp;action=edit&amp;redlink=1" class="new" title="2β-Propanoyl-3β-(2-isopropenyl)-tropane (page does not exist)">WF-60</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_tryptamine" title="Substituted tryptamine">Tryptamines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/4-HO-%CE%B1MT" title="4-HO-αMT">4-HO-αMT</a></li>
<li><a href="/wiki/4-Methyl-%CE%B1ET" title="4-Methyl-αET" class="mw-redirect">4-Methyl-αET</a></li>
<li><a href="/wiki/4-Methyl-%CE%B1MT" title="4-Methyl-αMT" class="mw-redirect">4-Methyl-αMT</a></li>
<li><a href="/wiki/5-Chloro-%CE%B1MT" title="5-Chloro-αMT">5-Chloro-αMT</a></li>
<li><a href="/wiki/5-Fluoro-%CE%B1MT" title="5-Fluoro-αMT" class="mw-redirect">5-Fluoro-αMT</a></li>
<li><a href="/wiki/5-MeO-%CE%B1ET" title="5-MeO-αET" class="mw-redirect">5-MeO-αET</a></li>
<li><a href="/wiki/5-MeO-%CE%B1MT" title="5-MeO-αMT" class="mw-redirect">5-MeO-αMT</a></li>
<li><a href="/wiki/5-MeO-DIPT" title="5-MeO-DIPT" class="mw-redirect">5-MeO-DIPT</a></li>
<li><a href="/wiki/6-Fluoro-%CE%B1MT" title="6-Fluoro-αMT" class="mw-redirect">6-Fluoro-αMT</a></li>
<li><a href="/wiki/7-Methyl-%CE%B1ET" title="7-Methyl-αET" class="mw-redirect">7-Methyl-αET</a></li>
<li><a href="/wiki/%CE%91-Ethyltryptamine" title="Α-Ethyltryptamine" class="mw-redirect">αET</a></li>
<li><a href="/wiki/%CE%91-Methyltryptamine" title="Α-Methyltryptamine" class="mw-redirect">αMT</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Others</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/2-MDP" title="2-MDP">2-MDP</a></li>
<li><a href="/w/index.php?title=2-Phenylcyclohexylamine&amp;action=edit&amp;redlink=1" class="new" title="2-Phenylcyclohexylamine (page does not exist)">2-Phenylcyclohexylamine</a></li>
<li><a href="/wiki/3,3-Diphenylcyclobutanamine" title="3,3-Diphenylcyclobutanamine">3,3-Diphenylcyclobutanamine</a></li>
<li><a href="/wiki/Amfonelic_acid" title="Amfonelic acid">Amfonelic acid</a></li>
<li><a href="/wiki/Amineptine" title="Amineptine">Amineptine</a></li>
<li><a href="/wiki/Amiphenazole" title="Amiphenazole">Amiphenazole</a></li>
<li><a href="/wiki/Atipamezole" title="Atipamezole">Atipamezole</a></li>
<li><a href="/wiki/Atomoxetine" title="Atomoxetine">Atomoxetine</a></li>
<li><a href="/wiki/Bemegride" title="Bemegride">Bemegride</a></li>
<li><a href="/wiki/Benzydamine" title="Benzydamine">Benzydamine</a></li>
<li><a href="/wiki/Butyltolylquinuclidine" title="Butyltolylquinuclidine">BTQ</a></li>
<li><a href="/wiki/BTS_74,398" title="BTS 74,398">BTS 74,398</a></li>
<li><a href="/wiki/Centanafadine" title="Centanafadine">Centanafadine</a></li>
<li><a href="/wiki/Ciclazindol" title="Ciclazindol">Ciclazindol</a></li>
<li><a href="/wiki/Clofenciclan" title="Clofenciclan">Clofenciclan</a></li>
<li><a href="/wiki/Cropropamide" title="Cropropamide" class="mw-redirect">Cropropamide</a></li>
<li><a href="/wiki/Crotetamide" title="Crotetamide" class="mw-redirect">Crotetamide</a></li>
<li><a href="/wiki/D-161" title="D-161">D-161</a></li>
<li><a href="/wiki/Diclofensine" title="Diclofensine">Diclofensine</a></li>
<li><a href="/wiki/Dimethocaine" title="Dimethocaine">Dimethocaine</a></li>
<li><a href="/wiki/Efaroxan" title="Efaroxan">Efaroxan</a></li>
<li><a href="/wiki/Etamivan" title="Etamivan">Etamivan</a></li>
<li><a href="/wiki/Fenisorex" title="Fenisorex">Fenisorex</a></li>
<li><a href="/wiki/Fenpentadiol" title="Fenpentadiol">Fenpentadiol</a></li>
<li><a href="/wiki/Gamfexine" title="Gamfexine">Gamfexine</a></li>
<li><a href="/wiki/Gilutensin" title="Gilutensin">Gilutensin</a></li>
<li><a href="/wiki/GSK1360707F" title="GSK1360707F">GSK1360707F</a></li>
<li><a href="/wiki/GYKI-52895" title="GYKI-52895">GYKI-52895</a></li>
<li><a href="/wiki/Hexacyclonate" title="Hexacyclonate">Hexacyclonate</a></li>
<li><a href="/wiki/Idazoxan" title="Idazoxan">Idazoxan</a></li>
<li><a href="/wiki/Indanorex" title="Indanorex">Indanorex</a></li>
<li><a href="/wiki/Indatraline" title="Indatraline">Indatraline</a></li>
<li><a href="/wiki/JNJ-7925476" title="JNJ-7925476">JNJ-7925476</a></li>
<li><a href="/wiki/Lazabemide" title="Lazabemide">Lazabemide</a></li>
<li><a href="/wiki/Leptacline" title="Leptacline">Leptacline</a></li>
<li><a href="/wiki/Levopropylhexedrine" title="Levopropylhexedrine">Levopropylhexedrine</a></li>
<li><a href="/wiki/Lomevactone" title="Lomevactone">Lomevactone</a></li>
<li><a href="/wiki/LR-5182" title="LR-5182">LR-5182</a></li>
<li><a href="/wiki/Mazindol" title="Mazindol">Mazindol</a></li>
<li><a href="/wiki/Meclofenoxate" title="Meclofenoxate">Meclofenoxate</a></li>
<li><a href="/wiki/Medifoxamine" title="Medifoxamine">Medifoxamine</a></li>
<li><a href="/wiki/Mefexamide" title="Mefexamide">Mefexamide</a></li>
<li><a href="/wiki/Methamnetamine" title="Methamnetamine">Methamnetamine</a></li>
<li><a href="/wiki/Methastyridone" title="Methastyridone">Methastyridone</a></li>
<li><a href="/wiki/Methiopropamine" title="Methiopropamine">Methiopropamine</a></li>
<li><a href="/wiki/Naphthylaminopropane" title="Naphthylaminopropane">Naphthylaminopropane</a></li>
<li><a href="/wiki/Nefopam" title="Nefopam">Nefopam</a></li>
<li><a href="/wiki/Nikethamide" title="Nikethamide">Nikethamide</a></li>
<li><a href="/wiki/Nomifensine" title="Nomifensine">Nomifensine</a></li>
<li><a href="/wiki/O-2172" title="O-2172">O-2172</a></li>
<li><a href="/wiki/Oxaprotiline" title="Oxaprotiline">Oxaprotiline</a></li>
<li><a href="/wiki/PNU-99,194" title="PNU-99,194">PNU-99,194</a></li>
<li><a href="/wiki/Propylhexedrine" title="Propylhexedrine">Propylhexedrine</a></li>
<li><a href="/wiki/PRC200" title="PRC200">PRC200-SS</a></li>
<li><a href="/wiki/Rasagiline" title="Rasagiline">Rasagiline</a></li>
<li><a href="/wiki/Rauwolscine" title="Rauwolscine">Rauwolscine</a></li>
<li><a href="/wiki/Rubidium_chloride" title="Rubidium chloride">Rubidium chloride</a></li>
<li><a href="/wiki/Setazindol" title="Setazindol">Setazindol</a></li>
<li><a href="/wiki/Tametraline" title="Tametraline">Tametraline</a></li>
<li><a href="/wiki/Tandamine" title="Tandamine">Tandamine</a></li>
<li><a href="/wiki/Thiopropamine" title="Thiopropamine">Thiopropamine</a></li>
<li><a href="/wiki/Thiothinone" title="Thiothinone">Thiothinone</a></li>
<li><a href="/wiki/Trazium" title="Trazium">Trazium</a></li>
<li><a href="/wiki/UH-232" title="UH-232">UH-232</a></li>
<li><a href="/wiki/Yohimbine" title="Yohimbine">Yohimbine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow hlist" colspan="2" style="font-style:italic">
<div>
<ul>
<li><b><a href="/wiki/Category:Pharmacology" title="Category:Pharmacology">Category</a></b></li>
<li><b><a href="/w/index.php?title=Index_of_Pharmacology_articles&amp;action=edit&amp;redlink=1" class="new" title="Index of Pharmacology articles (page does not exist)">Index</a></b></li>
<li><b><a href="/w/index.php?title=Outline_of_Pharmacology&amp;action=edit&amp;redlink=1" class="new" title="Outline of Pharmacology (page does not exist)">Outline</a></b></li>
<li><b><a href="/wiki/Portal:Pharmacology" title="Portal:Pharmacology" class="mw-redirect">Portal</a></b></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:ADHD_pharmacotherapies" title="Template:ADHD pharmacotherapies"><abbr title="View this template" style=";;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:ADHD_pharmacotherapies" title="Template talk:ADHD pharmacotherapies"><abbr title="Discuss this template" style=";;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:ADHD_pharmacotherapies&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div style="font-size:114%"><a href="/wiki/Attention_deficit_hyperactivity_disorder_management#Medications" title="Attention deficit hyperactivity disorder management">ADHD pharmacotherapies</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a>/<a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a><br />
<a href="/wiki/Reuptake_inhibitor" title="Reuptake inhibitor">reuptake inhibitors</a>/<a href="/wiki/Releasing_agent" title="Releasing agent" class="mw-redirect">releasers</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><b><a href="/wiki/Norepinephrine_reuptake_inhibitor" title="Norepinephrine reuptake inhibitor">NRIs</a>:</b> <a href="/wiki/Atomoxetine" title="Atomoxetine">Atomoxetine</a></li>
<li><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="/wiki/Reboxetine" title="Reboxetine">Reboxetine</a>; <b><a href="/wiki/Norepinephrine-dopamine_reuptake_inhibitor" title="Norepinephrine-dopamine reuptake inhibitor" class="mw-redirect">NDRIs</a>:</b> <a href="/wiki/Dexmethylphenidate" title="Dexmethylphenidate">Dexmethylphenidate</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a>; <b><a href="/wiki/Norepinephrine-dopamine_releasing_agent" title="Norepinephrine-dopamine releasing agent">NDRAs</a>:</b> <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></li>
<li><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li><a href="/wiki/Pemoline" title="Pemoline">Pemoline</a>; <b>Others:</b> <a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a> (e.g., <a href="/wiki/Protriptyline" title="Protriptyline">protriptyline</a>, <a href="/wiki/Desipramine" title="Desipramine">desipramine</a>, <a href="/wiki/Nortriptyline" title="Nortriptyline">nortriptyline</a>, <a href="/wiki/Imipramine" title="Imipramine">imipramine</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/%CE%912-Adrenergic_receptor" title="Α2-Adrenergic receptor" class="mw-redirect">α<sub>2</sub>-Adrenergic agonists</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Clonidine" title="Clonidine">Clonidine</a></li>
<li><a href="/wiki/Guanfacine" title="Guanfacine">Guanfacine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Others</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Caffeine" title="Caffeine">Caffeine</a></li>
<li><a href="/wiki/Modafinil" title="Modafinil">Modafinil</a></li>
<li><a href="/wiki/Nicotine" title="Nicotine">Nicotine</a></li>
<li><a href="/wiki/Theophylline" title="Theophylline">Theophylline</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:TAAR_ligands" title="Template:TAAR ligands"><abbr title="View this template" style=";;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:TAAR_ligands" title="Template talk:TAAR ligands"><abbr title="Discuss this template" style=";;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:TAAR_ligands&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div style="font-size:114%"><a href="/wiki/Trace_amine-associated_receptor" title="Trace amine-associated receptor">TAAR</a> <a href="/wiki/Ligand" title="Ligand">ligands</a> in humans</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center"><a href="/wiki/TAAR1" title="TAAR1">TAAR1</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:6em">Agonists</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:5em"><a href="/wiki/Trace_amine" title="Trace amine">Endogenous</a><sup>†</sup></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;background:white">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/Histamine" title="Histamine">Histamine</a></li>
<li><a href="/wiki/3-Iodothyronamine" title="3-Iodothyronamine">3-Iodothyronamine</a></li>
<li><a href="/wiki/3-Methoxytyramine" title="3-Methoxytyramine">3-Methoxytyramine</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/N-Methyltyramine" title="N-Methyltyramine"><i>N</i>-Methyltyramine</a></li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Meta-Octopamine" title="Meta-Octopamine" class="mw-redirect"><i>m</i>-Octopamine</a></li>
<li><a href="/wiki/Para-Octopamine" title="Para-Octopamine" class="mw-redirect"><i>p</i>-Octopamine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Phenylethanolamine" title="Phenylethanolamine">Phenylethanolamine</a></li>
<li><a href="/wiki/Serotonin" title="Serotonin">Serotonin</a></li>
<li><a href="/wiki/Synephrine" title="Synephrine">Synephrine</a></li>
<li><a href="/wiki/Tryptamine" title="Tryptamine">Tryptamine</a></li>
<li><a href="/wiki/Meta-Tyramine" title="Meta-Tyramine"><i>m</i>-Tyramine</a></li>
<li><a href="/wiki/Para-Tyramine" title="Para-Tyramine" class="mw-redirect"><i>p</i>-Tyramine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:5em">Synthetic<sup>‡</sup></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;background:white">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-bromoamphetamine" title="2,5-Dimethoxy-4-bromoamphetamine">DOB</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-ethylamphetamine" title="2,5-Dimethoxy-4-ethylamphetamine">DOET</a></li>
<li><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine">4-Hydroxyamphetamine</a></li>
<li><a href="/wiki/Isoprenaline" title="Isoprenaline">Isoprenaline</a></li>
<li><a href="/wiki/3,4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine" class="mw-redirect">MDA</a></li>
<li><a href="/wiki/MDMA" title="MDMA">MDMA</a></li>
<li><a href="/wiki/2-Methylphenethylamine" title="2-Methylphenethylamine">2-Methylphenethylamine</a></li>
<li><a href="/wiki/3-Methylphenethylamine" title="3-Methylphenethylamine">3-Methylphenethylamine</a></li>
<li><a href="/wiki/4-Methylphenethylamine" title="4-Methylphenethylamine">4-Methylphenethylamine</a></li>
<li><a href="/wiki/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Methylphenethylamine</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/3-Methoxymethamphetamine" title="3-Methoxymethamphetamine">3-MMA</a></li>
<li><a href="/wiki/Norfenfluramine" title="Norfenfluramine">Norfenfluramine</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="/wiki/O-Phenyl-3-iodotyramine" title="O-Phenyl-3-iodotyramine"><i>o</i>-PIT</a></li>
<li><a href="/wiki/Propylhexedrine" title="Propylhexedrine">Propylhexedrine</a></li>
<li><a href="/wiki/RO5166017" title="RO5166017">RO5166017</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em">Antagonists</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/EPPTB" title="EPPTB">EPPTB (RO5212773)</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center"><a href="/wiki/TAAR2" title="TAAR2">TAAR2</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:6em">Agonists<sup>‡</sup></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/3-Iodothyronamine" title="3-Iodothyronamine">3-Iodothyronamine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Tyramine" title="Tyramine">Tyramine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em">Antagonists</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>&#160;</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center"><a href="/wiki/TAAR5" title="TAAR5">TAAR5</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:6em">Agonists<sup>‡</sup></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/N,N-Dimethylethylamine" title="N,N-Dimethylethylamine">Dimethylethylamine</a></li>
<li><a href="/wiki/Trimethylamine" title="Trimethylamine">Trimethylamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em">Antagonists<sup>‡</sup></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/3-Iodothyronamine" title="3-Iodothyronamine">3-Iodothyronamine</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2">
<div>
<div style="float: left;"><sup>†</sup>References for all endogenous human TAAR1 ligands are provided at <a href="/wiki/Trace_amine#list" title="Trace amine">List of trace amines</a></div>
<br />
<div style="float: left;"><sup>‡</sup>References for synthetic TAAR1 agonists can be found at <a href="/wiki/TAAR1" title="TAAR1">TAAR1</a> or in the associated compound articles. For TAAR2 and TAAR5 agonists and antagonists, see <a href="/wiki/Trace_amine-associated_receptor" title="Trace amine-associated receptor">TAAR</a> for references.</div>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1003
Cached time: 20160130034343
Cache expiry: 2592000
Dynamic content: false
CPU time usage: 3.624 seconds
Real time usage: 4.016 seconds
Preprocessor visited node count: 16228/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 647672/2097152 bytes
Template argument size: 21053/2097152 bytes
Highest expansion depth: 20/40
Expensive parser function count: 4/500
Lua time usage: 1.240/10.000 seconds
Lua memory usage: 6.12 MB/50 MB
Number of Wikibase entities loaded: 4-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00% 3227.698      1 - -total
 47.29% 1526.352      3 - Template:Reflist
 19.28%  622.305      7 - Amphetamine
 17.45%  563.174     76 - Template:Cite_journal
 12.09%  390.331      1 - Template:Infobox_drug
  7.99%  257.860     49 - Template:Cite_web
  6.89%  222.479     11 - Template:Navbox
  6.41%  206.824      1 - Template:Infobox
  3.20%  103.212     17 - Template:Cite_book
  3.17%  102.260     10 - Template:Cite_encyclopedia
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:649100-0!*!0!!en!4!* and timestamp 20160130034339 and revision id 702211477
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Adderall&amp;oldid=702211477">https://en.wikipedia.org/w/index.php?title=Adderall&amp;oldid=702211477</a>"					</div>
				<div id='catlinks' class='catlinks' data-mw='interface'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Adderall" title="Category:Adderall">Adderall</a></li><li><a href="/wiki/Category:Amphetamine" title="Category:Amphetamine">Amphetamine</a></li><li><a href="/wiki/Category:Combination_drugs" title="Category:Combination drugs">Combination drugs</a></li><li><a href="/wiki/Category:Drugs_acting_on_the_cardiovascular_system" title="Category:Drugs acting on the cardiovascular system">Drugs acting on the cardiovascular system</a></li><li><a href="/wiki/Category:Drugs_acting_on_the_nervous_system" title="Category:Drugs acting on the nervous system">Drugs acting on the nervous system</a></li><li><a href="/wiki/Category:Euphoriants" title="Category:Euphoriants">Euphoriants</a></li><li><a href="/wiki/Category:Norepinephrine-dopamine_releasing_agents" title="Category:Norepinephrine-dopamine releasing agents">Norepinephrine-dopamine releasing agents</a></li><li><a href="/wiki/Category:Phenethylamines" title="Category:Phenethylamines">Phenethylamines</a></li><li><a href="/wiki/Category:Stimulants" title="Category:Stimulants">Stimulants</a></li><li><a href="/wiki/Category:Substituted_amphetamines" title="Category:Substituted amphetamines">Substituted amphetamines</a></li><li><a href="/wiki/Category:TAAR1_agonists" title="Category:TAAR1 agonists">TAAR1 agonists</a></li><li><a href="/wiki/Category:Treatment_and_management_of_attention_deficit_hyperactivity_disorder" title="Category:Treatment and management of attention deficit hyperactivity disorder">Treatment and management of attention deficit hyperactivity disorder</a></li><li><a href="/wiki/Category:VMAT_inhibitors" title="Category:VMAT inhibitors">VMAT inhibitors</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Good_articles" title="Category:Good articles">Good articles</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_March_2014" title="Category:Use dmy dates from March 2014">Use dmy dates from March 2014</a></li><li><a href="/wiki/Category:Drugs_that_are_a_combination_of_chemicals" title="Category:Drugs that are a combination of chemicals">Drugs that are a combination of chemicals</a></li><li><a href="/wiki/Category:Infobox_drug_articles_with_contradicting_parameter_input" title="Category:Infobox drug articles with contradicting parameter input">Infobox drug articles with contradicting parameter input</a></li><li><a href="/wiki/Category:Articles_without_UNII_source" title="Category:Articles without UNII source">Articles without UNII source</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_May_2014" title="Category:Articles containing potentially dated statements from May 2014">Articles containing potentially dated statements from May 2014</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_December_2013" title="Category:Articles containing potentially dated statements from December 2013">Articles containing potentially dated statements from December 2013</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Adderall&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Adderall" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Adderall"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Adderall"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Adderall" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Adderall&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Adderall&amp;action=history"  title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Adderall" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Adderall" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Adderall&amp;oldid=702211477" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Adderall&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q935761" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Adderall&amp;id=702211477" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Adderall">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Adderall&amp;returnto=Adderall&amp;oldid=702211477&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Adderall&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%A2%D8%AF%D9%8A%D8%B1%D8%A7%D9%84" title="آديرال – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Adderall" title="Adderall – Czech" lang="cs" hreflang="cs">Čeština</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Adderall" title="Adderall – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Adderall" title="Adderall – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Adderall" title="Adderall – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Adderall" title="Adderall – Simple English" lang="simple" hreflang="simple">Simple English</a></li><li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/Amfetaminske_me%C5%A1ane_soli_(lek)" title="Amfetaminske mešane soli (lek) – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li><li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Amfetaminske_me%C5%A1ane_soli_(lek)" title="Amfetaminske mešane soli (lek) – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Adderall" title="Adderall – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Adderall" title="Adderall – Turkish" lang="tr" hreflang="tr">Türkçe</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q935761#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 29 January 2016, at 04:17.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wmf:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Adderall&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-cookiestatement"><a href="//wikimediafoundation.org/wiki/Cookie_statement">Cookie statement</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="/static/1.27.0-wmf.11/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/1.27.0-wmf.11/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /static/1.27.0-wmf.11/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>window.RLQ = window.RLQ || []; window.RLQ.push( function () {
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","user":"ready","user.groups":"ready"});mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","site","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.eventLogging.subscriber","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","mmv.bootstrap.autostart","ext.visualEditor.targetLoader","ext.wikimediaEvents","ext.navigationTiming","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"]);
} );</script><script>window.RLQ = window.RLQ || []; window.RLQ.push( function () {
mw.config.set({"wgBackendResponseTime":97,"wgHostname":"mw1174"}); /* @nomin */
} );</script>
	</body>
</html>
